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Genomic approaches to dissect innate immune pathways 
 
 
Abstract 
 
 
The innate immune system is of central importance to the early containment of infection. 
When receptors of innate immunity recognize molecular patterns on pathogens, they initiate an 
immediate immune response by inducing the expression of cytokines and other host defense 
genes. Altered expression or function of the receptors, the molecules that mediate the signal 
transduction cascade, or the cytokines themselves can predispose individuals to infectious or 
autoimmune diseases. Here we used genomic approaches to uncover novel components 
underlying the innate immune response to cytosolic DNA and to characterize variation in the 
innate immune responses of human dendritic cells to bacterial and viral ligands. 
In order to identify novel genes involved in the cytosolic DNA sensing pathway, we first 
identified candidate proteins that interact with known signaling molecules or with dsDNA in the 
cytoplasm. We then knocked down 809 proteomic, genomic, or domain-based candidates in a 
high-throughput siRNA screen and measured cytokine production after DNA stimulation. We 
identified ABCF1 as a critical protein that associates with DNA and the known DNA-sensing 
components, HMGB2 and IFI16. We also found that CDC37 regulates stability of the signaling 
molecule, TBK1, and that chemical inhibition of CDC37 as well as of several other pathway 
regulators (HSP90, PPP6C, PTPN1, and TBK1) potently modulates the innate immune response 
to DNA and to retroviral infection. These proteins represent potential therapeutics targets for 
infectious and autoimmune diseases that are associated with the cytosolic DNA response. 
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We also developed a high-throughput functional assay to assess variation in responses of 
human monocyte-derived dendritic cells to LPS (receptor: TLR4) or influenza (receptors: RIG-I 
and TLR3), with the goal to ultimately map genetic variants that influence expression levels of 
pathogen-responsive genes. We compared the variation in expression between the dendritic cells 
of 30 different individuals, and within paired samples from 9 of these individuals collected 
several months later. We found genes that have significant inter- vs. intra-individual variation in 
response to the stimuli, suggesting that there is a substantial genetic component underlying 
variation in these responses. Such variants may help to explain differences between individuals’ 
risk for infectious, autoimmune, or other inflammatory diseases.  
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INTRODUCTION 
 
The innate immune system is of central importance to the early containment of infection. When 
receptors of innate immunity recognize molecular patterns on pathogens, they initiate an 
immediate immune response by inducing the expression of cytokines and other host defense 
genes. Altered expression or function of the receptors, the molecules that mediate the signal 
transduction cascade, or the cytokines themselves can predispose individuals to infectious or 
autoimmune diseases. Here we used genomic approaches to uncover novel components of the 
innate immune system and to characterize variation in innate immune responses between 
humans. 
 
The detection of pathogens by the innate immune system 
The traditional model of the innate immune system is that it detects pathogens by discriminating 
“self” from “non-self”. In 1989, Charles Janeway wrote, “I contend that the immune system has 
evolved specifically to recognize and respond to infectious microorganisms, and that this 
involves recognition…of certain characteristic patterns common on infectious agents but absent 
from the host” (Janeway 1989). This model of host germline-encoded pattern recognition 
receptors (PRRs) detecting pathogen-associated molecular patterns (PAMP) was borne out by (i) 
identification in 1996 of the Drosophila melanogaster Toll gene which was found to control the 
synthesis of antimicrobial peptides and protect against widespread fungal infection in the insect 
(Lemaitre et al. 1996); and then (ii) identification in 1998 of human and mouse Toll-like receptor 
4 (TLR4) which was found to be the PRR for the Gram negative bacterial cell wall component 
lipopolysaccharide (LPS) (Medzhitov et al. 1997; Poltorak et al. 1998).  
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This traditional model has been modified to include not only the recognition of pathogen-
specific PAMPs but also the recognition of components shared between host and pathogen by 
recognizing these components in contexts specific to infection (e.g. DNA in the cytosol, 
discussed in further detail below); and the model has been expanded to include the recognition of 
host-derived signals of cellular stress (e.g. uric acid and ATP) referred to as danger-associated 
molecular patterns (DAMPs) (Schroder and Tschopp 2010).  
Pattern recognition receptors (Schroder and Tschopp 2010; Takeuchi and Akira 2010) are 
expressed by immune cells – such as monocytes, dendritic cells, and macrophages – that form 
the first line of defense against infection, but also by certain cells of the adaptive immune system 
(such as B cells) and certain non-hematopoietic cells depending on PRR type. The PRRs include 
the membrane-bound TLRs that scan the extracellular and endosomal spaces, the RIG-like 
receptors (RLRs) that scan the cytosol for viral RNA, the NOD-like receptors (NLRs) that scan 
the cytosol for various microbial components and DAMPs, and DNA-sensing receptors including 
AIM2 and RNA polymerase III that scan the cytosol for viral and possibly bacterial DNA. 
Several PRR types that are highlighted in the subsequent chapters are discussed in more detail 
below. 
 
Toll-like receptors (TLRs) 
TLRs are transmembrane proteins consisting of N-terminal leucine-rich repeat (LRR) domains; 
transmembrane domains; and C-terminal Toll-interleukin 1 receptor (TIR) domains (Kawai and 
Akira 2010). The LRR domains mediate PAMP recognition, while the TIR domain initiates a 
signal transduction cascade downstream of the receptor. 10 functional TLRs have been identified 
in humans and 12 in mice. They recognize a diversity of microbial PAMPs, including microbial 
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lipids/lipoproteins (TLR1/2/4/6), proteins (TLR5/11), and nucleic acids (TLR3/7/8/9) derived 
from microorganisms including bacteria, viruses, parasites, and fungi (Akira and Takeda 2004). 
TLRs regulate the expression of pro-inflammatory genes including TNFα, IL-6, and pro-IL-1β; 
as well as type I and type III interferon (IFN) genes, which themselves control the expression of 
many anti-viral genes. Certain TLRs, e.g. TLR2, primarily regulate inflammatory gene induction, 
while other TLRs, e.g. TLR3, primarily regulate the induction of anti-viral genes (Amit et al. 
2009). 
Many of the TLRs are expressed on the cell surface, but the nucleic-acid sensing TLRs 
(TLR3, TLR7, TLR8, and TLR9) are expressed on the endoplasmic reticulum (ER) and then 
translocate to endolysosomes following ligand stimulation (Latz et al. 2004; Kim et al. 2008). 
The ER-resident protein, UNC93B1, regulates this translocation event (Tabeta et al. 2006; Kim 
et al. 2008). The cell types that express TLRs vary, with some TLRs specific to immune cells 
(e.g. TLR7 and TLR9 are only expressed in plasmacytoid dendritic cells and B cells in humans) 
and some more widely expressed (e.g. TLR3 is expressed in various hematopoietic as well as 
non-hematopoietic cells (Zhang et al. 2007)).  
  
RIG-like receptors (RLRs) 
Infection by RNA viruses in a broad range of cell types elicits inflammatory gene and IFN 
production mediated by the recognition of the virus’s RNA genome in the cytosol by RIG-like 
receptors (Barbalat et al. 2011). There are three known RLRs – RIG-I, Mda5, and Lgp2 – 
characterized by a C-terminal DEAD-box (Asp-Glu-Ala-Asp) helicase domain that mediates 
RNA binding and two N-terminal caspase recruitment domains (CARDs) that mediate 
downstream signaling (though Lgp2 lacks the CARD domains) (Yoneyama et al. 2004). RIG-I is 
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believed to recognize 5’ triphosphate groups on single-stranded RNA as well as short double-
stranded RNA; MDA5 is believed to recognize long double-stranded RNA; and the function of 
LGP2 is less clear (it is believed to regulate the other RLRs, though data is conflicting) 
(Yoneyama et al. 2005; Satoh et al. 2010; Barbalat et al. 2011). The RLRs appear to be broadly 
expressed, as most hematopoietic and non-hematopoietic cell types tested respond to RLR ligand 
stimulation (with the possible exception of plasmacytoid dendritic cells (pDCs)) (Kato et al. 
2005).  
 
Cytosolic DNA sensors 
Similar to the RLR response, cytosolic DNA has been shown to induce type I IFN production, 
though the receptor(s) and components of this pathway are much less clear. This phenotype 
was first described in 1962-1963 by several groups (Isaacs et al. 1963; Jensen et al. 1963; Rotem 
et al. 1963). They had suggested that DNA viruses such as vaccinia virus stimulate the 
production of IFN through viral genomic DNA, performed initial studies showing that adding 
viral or even mammalian DNA to cells elicits IFN production, and suggested that the DNA needs 
to accumulate within the cell to be stimulatory. In 1999, Suzuki et al. demonstrated that 
transfection of herpes simplex viral DNA, mammalian DNA, or synthetic double-stranded DNA 
into a wide variety of cell types (thyrocytes, macrophages, dendritic cells, fibroblasts, and 
endothelial cells) increased expression of MHC class I and II (Suzuki et al. 1999). This effect 
was independent of sequence (e.g. the effect was not dependent on the presence of unmethylated 
CpG motifs which are recognized by TLR9). In 2006, Ishii et al. had shown that transfection of 
long stretches of double-stranded alternating AT base pairs robustly stimulates the production of 
type I IFN as well as NFκB-responsive genes in a manner independent of known TLR pathways 
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(Ishii et al. 2006). In the same year, Stetson et al. showed that transfected dsDNA of any 
sequence stimulates the production of type I IFNs in a manner independent of TLR9 (Stetson and 
Medzhitov 2006).  
 The pathway stimulated by Stetson et al. is referred to as the ISD (interferon stimulatory 
DNA) pathway (Stetson and Medzhitov 2006). While it is not yet entirely clear which pathogens 
(e.g. DNA viruses or intracellular bacteria) are sensed by the ISD pathway, perhaps the clearest 
data is that retroviral DNA (produced after reverse transcription of the genomic RNA) is sensed 
by this pathway (Yan et al. 2010). It is also not yet entirely clear what the receptor of the ISD 
pathway is. Several proteins that interact with DNA and bind to downstream signaling proteins 
have been proposed as receptors:  
(i) DAI/ZBP1. In 2008, Takaoka et al. identified DAI (also known as ZBP1) as a 
cytosolic protein that recognizes transfected DNA, interacts with downstream signaling 
components (i.e. TBK1 and IRF3, discussed below), and regulates type I IFN production 
(Takaoka et al. 2007). However, cells from DAI-deficient mice did not confirm this 
phenotype, possibly suggesting redundancy and/or cell type specificity (Ishii et al. 2008). 
Evidence is emerging, though, that DAI can indeed activate NFκB and may be involved 
in the recognition of cytomegalovirus (Kaiser et al. 2008; Rebsamen et al. 2009; 
DeFilippis et al. 2010).  
(ii) HMGB family proteins. In 2009, Yanai et al. identified the HMGB family proteins 
(HMGB2 and possibly HMGB3) as DNA interactors that regulate type I IFN production 
(Yanai et al. 2009). They found that all nucleic acid-sensing pathways of the innate 
immune system require HMGB family proteins to function, and suggested that these 
proteins act as co-receptors for nucleic acid recognition by the innate immune system.   
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(iii) LRRFIP1. In 2010, Yang et al. identified LRRFIP1 as a cytosolic protein that 
interacts with DNA and regulates type I IFN production (Yang et al. 2010). They 
suggested, though, that LRRFIP1 interacts with both DNA and RNA, and activates the 
co-activator, β-catenin, rather than known downstream components.  
(iv) IFI16. In 2010, Unterholzner et al. identified IFI16 as another cytosolic protein that 
recognizes cytosolic DNA, interacts with a downstream signaling component (i.e. STING, 
discussed below), and regulates type I IFN production (Unterholzner et al. 2010). 
However, IFI16 was found to primarily localize to the nucleus, and knockdown of Ifi16 
only gave a partial (~2-fold) phenotype.  
(v) KU70. In 2011, Zhang et al. identified KU70 as a DNA-interacting protein that 
regulates type III but not type I IFN production (Zhang et al. 2011a).  
(vi) DDX41. In 2011, Zhang et al. identified DDX41 as a cytosolic protein that 
recognizes cytosolic DNA, interacts with a downstream signaling component (i.e. 
STING), and regulates type I IFN production (Zhang et al. 2011b). Their data suggested 
that DDX41 is active in dendritic cells, but a role for DDX41 in cells outside of the 
myeloid-lineage was less clear.  
Thus, the identity of the receptor(s) of the ISD pathway is less clear than that of the other 
innate immune pathways. One possible reading of the literature is that DAI is not the ISD 
receptor because DAI-deficient cells respond normally to DNA stimulation; the HMGB proteins 
are co-receptors that aid receptor binding (perhaps through their ability to distort DNA) but are 
not sufficient as a receptor; LRRFIP1 helps regulate IFN through the alternative β-catenin arm 
but is also not sufficient; IFI16 recognizes foreign nuclear DNA in an alternative ISD pathway or 
helps regulate IFN but is also not sufficient; KU70 regulates type III but not type I IFN 
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production; and DDX41 is active in myeloid-lineage cells but not other cell types in which the 
ISD response has been observed. Such an interpretation would suggest the hypothesis that either 
the main ISD receptor has not yet been identified, or that the ISD receptor is a complex of two or 
more of the above proteins.  
In addition, the cellular compartment in which DNA recognition occurs has also been 
debated in the literature recently (Unterholzner et al. 2010; Kerur et al. 2011; Li et al. 2012; 
Orzalli et al. 2012). Groups have suggested that DNA recognition may occur in the nucleus 
rather than the cytosol. This hypothesis was borne out of results showing that IFI16 is primarily 
localized to the nucleus, and that the DNA of certain viruses such as HSV-1 co-localize with 
IFI16 in the nucleus (Li et al. 2012). Such a hypothesis is not incompatible with previous results, 
given that DNA transfection using lipid reagents likely delivers DNA to most cellular 
compartments. The data that suggests a cytosolic receptor includes: the analogous RNA 
receptors are cytosolic (Yoneyama et al. 2004); the DNA receptor of the inflammasome, AIM2 
(described below), is cytosolic (Burckstummer et al. 2009; Fernandes-Alnemri et al. 2009; 
Hornung et al. 2009); genomic DNA is nuclear and would have to be distinguished from foreign 
nuclear DNA; and the downstream components STING and TBK1 are cytosolic (Ishikawa and 
Barber 2008; Ishikawa et al. 2009) and so the signal would have to first exit the nucleus and then 
come back during IRF3 translocation. One possibility is that there are two different DNA 
receptors – one in the cytosol and one in the nucleus.  
Following the publication by Ishii et al. (Ishii et al. 2006), it was subsequently shown that 
the AT-rich ligand used by their group not only stimulates the ISD pathway, but also stimulates 
the RNA polymerase III pathway. In this pathway, AT-rich DNA as well as DNA sequences 
with specific promoter elements are recognized by RNA polymerase III, which transcribes the 
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DNA and the resulting RNA product is then able to stimulate the RIG-I receptor (Ablasser et al. 
2009; Chiu et al. 2009). While data suggests that certain viruses (e.g. HSV-1, Epstein-Barr virus, 
and adenovirus) and intracellular bacteria (e.g. Legionella pneumophila) are sensed by the RNA 
polymerase III pathway (Chiu et al. 2009), there is conflicting data in the literature (Unterholzner 
et al. 2010).  
In addition to the ISD and RNA polymerase III pathways, an alternative pathway 
mediated by the AIM2 receptor (also known as the AIM-like receptor or ALR pathway) was 
shown to bind to DNA and post-translationally regulate IL-1β maturation (Muruve et al. 2008; 
Burckstummer et al. 2009; Fernandes-Alnemri et al. 2009; Hornung et al. 2009; Roberts et al. 
2009). IFI202, which is similar in structure to AIM2 but lacks the C-terminal CARD domain, is 
believed to negatively regulate the AIM2 pathway (Roberts et al. 2009).  
 
Signal transduction cascades in the innate immune system 
Following engagement of PRRs by microbial ligands, the receptors initiate a signal transduction 
cascade that ultimately leads to transcriptional and post-translational changes in the cell. For the 
TLRs, RLRs, and certain NLRs and cytosolic DNA sensors, downstream signaling activates a 
common set of transcription factors including NFκB and AP-1 that induce the expression of 
inflammatory genes (e.g. IL-6, TNFα, IL-12); as well as IRF family members (e.g. IRF3 and 
IRF7) that induce the expression of type I and III IFNs (Akira and Takeda 2004; Barbalat et al. 
2011). For AIM2 as well as certain NLR family members termed inflammasomes, receptor 
engagement triggers post-translational maturation of caspase-1, which regulates maturation and 
secretion of inflammatory cytokines such as IL-1β, IL-18, and IL-33 (Schroder and Tschopp 
2010). The signal transduction cascades of several of these pathways are discussed in more detail 
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below. Each of these signaling cascades involves a multitude of proteins and interactions, and 
key signaling components are described.  
TLR4. The intracellular TIR domain of TLR4 recruits the TIR-domain-containing 
adaptor MYD88, which controls the expression of inflammatory genes (Akira and Takeda 2004). 
TLR4 then translocates to endosomes where it interacts with the TIR-domain-containing adaptor 
TRIF, which controls the expression of both inflammatory and anti-viral genes (Kagan et al. 
2008). The adaptor MYD88 recruits IL-1 receptor–associated kinases (IRAKs), which then 
activate the E3 ubiquitin ligase TNF receptor-associated factor 6 (TRAF6) to catalyze the 
synthesis of K63-linked polyubiquitin chains. The polyubiquitin chains then recruit the TAK1 
kinase complex as well as the IkB kinase (IKK) complex member, NEMO (NFκB essential 
modulator), to activate the IKK catalytic kinase subunits (IKKα and/or IKKβ). These subunits 
phosphorylate IκB, an inhibitor that interacts with and traps NFκB in the cytosol. 
Phosphorylation of IκB (e.g. IκBα) initiates its proteasomal degradation, allowing NFκB to 
translocate into the nucleus and turn on the expression of target genes. The TAK1 kinase 
complex also activates MAP kinases (MAPKs), which activate the transcription factor, AP-1. In 
contrast to MYD88, the adaptor TRIF recruits the kinases TANK-binding kinase 1 (TBK1) and 
IKKε, which phosphorylate the transcription factor, IRF3 (Fitzgerald et al. 2003; McWhirter et al. 
2004). Phosphorylated IRF3 dimerizes and translocates into the nucleus to induce the expression 
of IFN genes. In addition to TBK1 and IKKϵ activation, TRIF also recruits TRAF6 and the 
adaptor RIP1 to activate NFκB (Akira and Takeda 2004). 
TLR3. Following recognition of double-stranded RNA (Alexopoulou et al. 2001), TLR3 
recruits TRIF to activate downstream components as described above (Akira and Takeda 2004). 
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RIG-I. Upon binding to its RNA ligand, RIG-I is ubiquitinated by TRIM25 and 
undergoes a conformational change that exposes its CARD domains (Yoneyama et al. 2004; 
Gack et al. 2007). The CARD domains then form homotypic interactions with the CARD domain 
of the downstream adaptor, MAVS, on the mitochondrial surface and on peroxisomes (Kawai et 
al. 2005; Meylan et al. 2005; Seth et al. 2005; Dixit et al. 2010). Although the precise mechanism 
is controversial, MAVS ultimately activates NFκB and also recruits TBK1 to activate IRF3 
(Kawai et al. 2005; Meylan et al. 2005; Seth et al. 2005).  
ISD pathway. While the receptor RIG-I and the adaptor MAVS is not required for ISD 
signaling (Sun et al. 2006), the ISD pathway shares many of the downstream signaling 
components as the RIG-I pathway. The endoplasmic reticulum (ER)-membrane adaptor, STING 
(Ishikawa and Barber 2008), interacts with TBK1 and IRF3 resulting in IRF3 phosphorylation by 
TBK1 (Stetson and Medzhitov 2006; Ishikawa and Barber 2008; Ishikawa et al. 2009; Tanaka 
and Chen 2012).  
Type I IFN receptor. Following type I IFN production, the IFNs are secreted and 
interact with a heterodimeric receptor composed of IFNAR1 and IFNAR2 (Uze et al. 1990; 
Novick et al. 1994). Upon IFN binding, the Janus kinases, JAK1 (Muller et al. 1993) and TYK2 
(Velazquez et al. 1992), phosphorylate each other and the cytoplasmic domain of IFNAR1, 
allowing phosphorylation of STAT2 and then STAT1 (Fu et al. 1992; Schindler et al. 1992; 
Stark et al. 1998). The phosphorylated STAT proteins dimerize, interact with IRF9 to form the 
ISGF3 complex, and translocate into the nucleus where they induce the expression of ISGs 
(Veals et al. 1992). Type I IFNs induce an antiviral state in stimulated cells and help activate the 
adaptive immune response (Kumar et al. 2011). 
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The role of the innate immune system in host defense 
The role that these innate immune pathways play in host defense has been revealed by several 
types of experiments, including (i) forward genetic studies in humans in which the genomes of 
diseased patients are compared to those of healthy individuals, and a causative gene (in the case 
of Mendelian diseases that cause primary immunodeficiencies (PIDs)) or associated disease 
gene(s) (in the case of complex diseases) is identified; (ii) reverse genetic studies in animal 
models (e.g. Drosophila melanogaster or Mus musculus) in which a component gene is knocked 
out, the animal is infected, and various phenotypes of the pathogen (e.g. replication) and/or host 
(e.g. survival or immune correlates) are quantitated; and (iii) cellular studies in which a 
component is depleted, the cells are infected, and phenotypes of the pathogen and/or cells are 
quantitated.  
Human genetic studies of PIDs and of common infectious diseases have revealed the role 
of innate immune components in humans in vivo. As explained below, the presentation in 
knockout mice sometimes phenocopies the human disease, but the human disease often presents 
with a much more narrow spectrum of infection (Casanova et al. 2011). This may be due to lack 
of exposure to particular microorganisms that have not revealed particular infectious 
susceptibilities; environmental differences in humans (e.g. they are being studied in natura, i.e. 
with widespread use of hygienic practices, availability of antibiotics, and vaccination) (Casanova 
and Abel 2004; Quintana-Murci et al. 2007); the often unnaturally high doses of pathogens given 
to the mice; or actual physiological differences between these organisms. Furthermore, the lack 
of clinical disease in humans does not mean that the pathways do not play a role in responding to 
particular pathogens, but may suggest redundancy in the innate immune system that is 
compensated for by other pathways in vivo.   
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(i) TLR4 pathway. While no mutations in TLR4 have been identified as a cause of a PID, 
several mutations have been identified in pathway components downstream of the 
receptor (Casanova et al. 2011). However, these mutations not only affect the TLR4 
pathway but also affect one or many other pathways. Patients with mutations in MYD88 – 
affecting most TLR responses (except the TRIF-dependent branch of TLR4 and the 
TLR3 response) as well as IL-1 receptor responses – suffer from recurrent infection by 
Streptococcus pneumonia leading to meningitis or septicemia, as well as recurrent 
infection by Staphylococcus and Pseudomonas (von Bernuth et al. 2008). Patients with 
mutations in IRAK4 – affecting TLR and T-cell receptor pathways – suffer from disease 
that phenocopies MYD88 deficiency (Picard et al. 2003). Patients with hypomorphic 
mutations in NEMO or hypermorphic mutations in IκBα – affecting many NFκB-
mediated pathways – suffer from anhidrotic ectodermal dysplasia with immunodeficiency 
(EDA-ID) leading to infection by pyogenic bacteria (but also to infection by various 
mycobacteria, viruses, and fungi which are likely unrelated to TLR responses given the 
MYD88 and IRAK4 phenotypes) (Sun et al. 2006). Thus, while the relevance of certain 
downstream components in protecting against infectious disease in humans is clear, the 
relevance of the TLR4 pathway in humans is not clear.  
In mice, TLR4 deficiency has been shown to cause increased susceptibility to 
infection by Gram-negative bacteria, including Salmonella typhimurium (Vazquez-Torres 
et al. 2004; Weiss et al. 2004), and increased susceptibility to endotoxic shock (Poltorak 
et al. 1998). Myd88 deficiency has been shown to cause increased susceptibility to a wide 
range of Gram-negative bacteria, Gram-positive bacteria, viruses, fungi, and parasites, 
including but not limited to Streptococcus pneumoniae, Staphylococcus aureus, and 
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Pseudomonas aeruginosa (von Bernuth et al. 2008). Irak4 deficiency has been shown to 
increase susceptibility to infection by Staphylococcus aureus (Suzuki et al. 2002). Nemo 
deficiency results in embryonic lethality due to hepatocyte apoptosis (Rudolph et al. 
2000) [Makris et al. 2000; Schmidt-Supprian et al. 2000].  
(ii) TLR3 pathway. Unlike the TLR4 pathway, the TLR3 pathway is clearly associated 
with increased susceptibility to infectious disease in humans, though in a surprisingly 
limited way: i.e. mutations in TLR3 increase susceptibility to herpes simplex encephalitis 
(HSE) (Zhang et al. 2007; Guo et al. 2011). Even mutations in UNC93B1 or in 
downstream components – TRIF, TRAF3, NEMO, and TBK1 – which affect multiple 
pathways besides TLR3, have only been found to increase susceptibility to HSE 
(Casrouge et al. 2006; Perez de Diego et al. 2010; Audry et al. 2011; Sancho-Shimizu et 
al. 2011; Herman et al. 2012). UNC93B1 mutations abolish signaling of TLR3, TLR7, 
TLR8, and TLR9 (Casrouge et al. 2006; Tabeta et al. 2006). TRIF mutations abolish both 
TLR3 signaling as well as the IFN branch of the TLR4 pathway (Sancho-Shimizu et al. 
2011). TBK1 mutations affect many IFN-inducing pathways (Herman et al. 2012).  
In mice, Tlr3 deficiency has been shown to cause increased susceptibility to 
infection by several types of RNA viruses including mouse cytomegalovirus (MCMV) 
(Tabeta et al. 2004), but paradoxically increases resistance to West Nile virus (Wang et al. 
2004), influenza A virus (Le Goffic et al. 2006), and phlebovirus (Gowen et al. 2006). 
Unc93b1 deficiency has been shown to cause increased susceptibility to MCMV, 
Trypanosoma cruzi, and Toxoplasma gondii (Tabeta et al. 2006; Melo et al. 2010; 
Caetano et al. 2011). Trif deficiency has been shown to cause increased susceptibility to 
MCMV and vaccinia virus (VACV) (Hoebe et al. 2003). Traf3 deficiency results in early 
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postnatal lethality (Xu et al. 1996), and Tbk1 knockout mice die perinatally (Bonnard et 
al. 2000). 
(iii) Cytosolic nucleic-acid sensing pathways. No mutations specifically in the RIG-I or 
ISD pathways have yet been identified that cause Mendelian infectious disease in humans.  
In mice, RIG-I deficiency has been shown to cause increased susceptibility to 
infection by Japanese encephalitis virus (JEV; a positive-sense ssRNA virus) and 
vesicular stomatitis virus (VSV; a negative-sense ssRNA virus) (Kato et al. 2006), and 
RIG-I-deficient cells are additionally unresponsive to infection by many other ssRNA 
viruses including influenza A and hepatitis C virus (Kato et al. 2006; Loo et al. 2008). 
Mavs deficiency, which affects both the RIG-I and MDA5 pathways, has been shown to 
cause increased susceptibility to infection by VSV and EMCV; and Mavs-deficient cells 
are additionally unresponsive to infection by Sendai virus (SV) and Newcastle disease 
virus (NDV) (Kumar et al. 2006; Sun et al. 2006). Sting deficiency has been shown to 
cause increased susceptibility to infection by herpes simplex virus 1 (HSV-1) and VSV; 
and Sting-deficient cells are additionally unresponsive to infection by SV, CMV, VACV, 
baculovirus, and Listeria monocytogenes (Ishikawa and Barber 2008; Ishikawa et al. 
2009). 
(iv) Type I (and III) IFN receptor pathway. No mutations in the IFNAR1 or IFNAR2 
receptors have yet been identified that cause PIDs in humans. However, components 
downstream of the receptor have been implicated in PIDs. Mutations in STAT1 can affect 
type I, type II, and type III IFN signaling as well as signaling of other cytokines and 
growth factors including IL-6, IL-27, epidermal growth factor (EGF), and platelet-
derived growth factor (PDGF) (Casanova et al. 2012). Patients with mutations in STAT1 
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present with Mendelian susceptibility to mycobacterial diseases (MSMD) with increased 
susceptibility to salmonellosis and several other bacteria, fungi, and parasites (Dupuis et 
al. 2001), and additionally to viral infection including HSE depending on the pathways 
affected by the specific mutations in STAT1 (Dupuis et al. 2003). Mutations in TYK2 can 
affect type I and type III IFN signaling as well as signaling of other cytokine including 
IL-6, IL-10, IL-12, and IL-23 (Casanova et al. 2012). A patient with homozygous 
mutations in TYK2 was found to present with atopy, elevated serum IgE levels, and 
recurrent infection with bacteria, fungi, and viruses including herpes simplex virus 
(Casanova et al. 2012); while another patient was found to present with the infectious 
phenotypes, including herpes simplex viral and varicella zoster viral infection, but 
without atopy or elevated IgE (Kilic et al. 2012). It is not yet clear which of the 
phenotypes of these patients is due to impaired type I IFN signaling, though the increased 
infections by herpes simplex virus and varicella zoster virus seem likely given the roles in 
vitro and in animal models (Casanova et al. 2012).  
Genetic variants in IFN-stimulated genes have also been associated with increased 
susceptibility to infection in humans. For example, mutations in the ISG, ISG15, cause 
MSMD (Bogunovic et al. 2012); and rare variants in the ISG, IFITM3, have been 
associated with increased susceptibility to influenza infection (Everitt et al. 2012). Finally, 
through genome-wide association studies (GWAS) common genetic variants in the type 
III interferon IL28B, which can be induced by viral stimulation of RLR and TLR 
pathways (Coccia et al. 2004), have been associated with spontaneous clearance of HCV 
as well as response to treatment with pegylated interferon-alpha (PEG-IFN-a) and 
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ribavirin (RBV) (Ge et al. 2009; Suppiah et al. 2009; Tanaka et al. 2009; Thomas et al. 
2009). 
In mice, Ifnar1 deficiency has been shown to cause increased susceptibility to 
viruses including VSV, Semliki Forest virus (SFV), VACV, and lymphocytic 
choriomeningitis virus (LCMV) (Muller et al. 1994). Stat1 deficiency has been shown to 
cause increased susceptibility to VSV and Listeria monocytogenes (Meraz et al. 1996). 
Tyk2 deficiency has been shown to cause reduced resistance to VACV and MCMV 
(Karaghiosoff et al. 2000; Strobl et al. 2005). Jak1 knockout mice die perinatally (Rodig 
et al. 1998). 
These studies establish that variation in innate immune genes can alter the 
propensity to infectious diseases in humans. However, further studies are needed to better 
delineate the role of each innate immune pathway in host defense, especially in regards to innate 
immune genes that have pleiotropic functions in other pathways.  
 
Dysregulation of the innate immune system can lead to autoimmune/autoinflammatory 
disease 
Hyperactive innate immune responses or inappropriate responses against tissues and substances 
normally considered ‘self’ could lead to the development of autoimmune disease. While Janeway 
initially proposed that PAMPs are “characteristic patterns common on infectious agents but 
absent from the host” (Janeway 1989), it subsequently turned out that the model of PAMPs as 
foreign is sometimes a gray area, which is demonstrated by several examples below: 
1) TLR9 distinguishes bacterial from self DNA by recognizing unmethylated CpG motifs 
(Krieg et al. 1995; Hemmi et al. 2000), which are present in mammalian genomes but 
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found in much less frequency than in bacterial genomes (Krieg 2002). Barton et al. had 
shown that localization of TLR9 to endolysosomes is also important for distinguishing 
foreign from self DNA (Barton et al. 2006). When they altered TLR9 localization to the 
cell surface, the re-localized TLR9 could recognize self DNA. Barton et al. argued that 
TLR9 localization inside the cell, as well as the expression of DNases outside of the cell 
that degrade extracellular DNA, prevent self DNA recognition. 
2) Stetson et al. had shown that transfection of dsDNA of any random sequence into 
mammalian cells can stimulate the ISD pathway (Stetson and Medzhitov 2006). It is not 
yet entirely clear how the ISD pathway distinguishes foreign from self DNA, but it is 
believed that the mechanism might be receptor localization to the cytosol, where DNA is 
not normally found. This is not a perfect explanation because in certain normal cellular 
states – such as during cell division when the nuclear envelope breaks down – genomic 
DNA is exposed to the cytosol; however, the genomic DNA is coated with proteins such 
as nucleosomes which could possibly affect detection. Also others have argued that viral 
DNA recognition may occur in the nucleus (Kerur et al. 2011; Li et al. 2012; Orzalli et al. 
2012), though they have not explained how the genomic DNA evades recognition. 
3) As mentioned above, host-derived signals of cellular stress (e.g. uric acid and ATP), 
which are referred to as danger-associated molecular patterns (DAMPs), can be 
recognized by the NLR family of the innate immune system.  
Genetic variants that cause breakdown of the innate immune system’s ability to 
distinguish foreign vs. self, that decrease the function of negative regulators of the innate 
immune response, or that increase the function of positive regulators of the innate immune 
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response have been found to alter the propensity to certain autoimmune diseases, as described 
below. 
(i) TLR pathways. GWA studies have identified variants near several innate immune 
genes that associate with systemic lupus erythematosus (SLE) in humans, including 
IRAK1, TNFAIP3, and IRF5 (Graham et al. 2007; Graham et al. 2008; Jacob et al. 2009; 
Stahl et al. 2010). GWAS has also identified variants near TNFAIP3, IRF5, NFKBIE, and 
REL that associate with rheumatoid arthritis (Plenge et al. 2007; Gregersen et al. 2009; 
Stahl et al. 2010; Okada et al. 2012). TNFAIP3 is a negative regulator of TLR responses 
that controls ubiquitination of key signaling proteins including TRAF6 (Boone et al. 
2004; Wertz et al. 2004); in mice, Tnfaip3 deficiency leads to the spontaneous 
development of multiorgan inflammation and severe cachexia (Lee et al. 2000; Boone et 
al. 2004; Turer et al. 2008). IRF5 is an IRF family transcription factor; in mice, Irf5 
deficiency impairs pro-inflammatory cytokine production downstream of Myd88 
(Takaoka et al. 2005). IRAK1 is an interleukin-1 receptor associated kinase involved in 
Toll/IL-1 receptor signaling; REL is an NFκB family member; and NFKBIE (IκB-ϵ) is an 
inhibitor of NFκB as described above.  
Again, these genes are not specific to the TLR pathway and affect other pathways 
in both the innate and adaptive immune system; thus, it is difficult to determine the 
contribution of altered TLR responses to these autoimmune diseases. However, there is 
substantial evidence from mouse models that TLR responses (especially TLR7 and TLR9 
responses) play a role in the pathogenesis of autoimmune diseases such as SLE and 
psoriasis (Leadbetter et al. 2002; Pisitkun et al. 2006; Lande et al. 2007; Marshak-
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Rothstein and Rifkin 2007), suggesting that altered TLR responses caused by the human 
variants may explain at least part of the clinical associations.  
GWA studies have also identified variants near the TLR-stimulated 
immunoregulatory cytokine, IL10, that associate with type I diabetes mellitus (T1DM) 
(Barrett et al. 2009). In addition to the GWA studies, Mendelian mutations in IL10 cause 
infant colitis in humans (Glocker et al. 2010); in mice, Il10 deficiency results in a similar 
phenotype, which is rescued by knockout of Myd88, demonstrating that Toll/IL-1 
signaling is essential to the inflammatory phenotype in the animal model (Kuhn et al. 
1993; Rakoff-Nahoum et al. 2006). 
(ii) Cytosolic nucleic-acid sensing pathways. Variants in the RLR, MDA5, have been 
associated with protection from type I diabetes mellitus (T1DM) (Smyth et al. 2006; 
Nejentsev et al. 2009). Some of the MDA5 variants are believed to be deleterious to the 
function of the protein (Shigemoto et al. 2009), suggesting that the innate immune 
response to viral infection (e.g. by enteroviruses, which had previously been associated 
with T1DM (Hyoty and Taylor 2002)) may increase propensity to T1DM.  
Hyperactivation of the ISD pathway is believed to cause certain forms of 
autoimmune disease, demonstrated by mutations in a regulatory gene called TREX1. 
TREX1 is an endoplasmic reticulum (ER)-localized 3’->5’ exonuclease. This gene was 
initially discovered by linkage studies as a cause of Aicardi-Goutières syndrome (AGS), 
a family of rare monogenic disorders characterized by spontaneous (non-infectious) 
encephalitis in humans and myocarditis in mice (Crow et al. 2006). Yang et al. showed 
that AGS patients with mutations in TREX1 accumulate ssDNA in the cytoplasm (Yang 
et al. 2007). Stetson et al. hypothesized that the cytoplasmic DNA may lead to aberrant 
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activation of the ISD pathway (Stetson et al. 2008). They found that knockout of IFNAR1 
or of the ISD pathway components STING or IRF3 rescued the disease phenotype in 
Trex1-/- mice (Stetson et al. 2008; Gall et al. 2012). These results confirmed that Trex1 is 
in epistasis with ISD pathway components. Stetson et al. sequenced the ssDNA that 
accumulates in the cytoplasm, found that the DNA is enriched for retroelement DNA, and 
proposed a model that explains the pathogenesis: retroelement DNA can normally exit 
the nucleus during its life cycle, Trex1 normally degrades the DNA before recognition by 
the ISD receptor, and in the absence of TREX1 the DNA can accumulate in the 
cytoplasm and lead to constitutive activation of the ISD pathway (Stetson et al. 2008). In 
line with this hypothesis, Beck-Engeser et al. showed that treatment of Trex1-/- mice 
with reverse transcriptase inhibitors could rescue the disease phenotype (Beck-Engeser et 
al. 2011).  
Because there is a phenotypic overlap of AGS with systemic lupus erythematosus 
(SLE), Lee-Kirsch et al. sequenced the TREX1 gene in patients with SLE and found that 
variants in the TREX1 gene – some of which are the same as the AGS mutations except 
occur monoallelically – are associated with SLE (Lee-Kirsch et al. 2007a). These variants 
are found in ~2% of the SLE patients that they sequenced, suggesting that overactivation 
of the ISD pathway may occur in at least 2% of SLE cases.  
TREX1, also known as DNase III, is one of the four DNases in humans, which 
include: DNASE1, DNASE2, TREX1 (DNase III), and FEN1 (DNase IV). Mutations in 
other DNase genes are also associated with autoimmune disease. Mutations in DNASE1 
were found in patients with SLE (Yasutomo et al. 2001); in mice, knockout of Dnase1 
causes an SLE-like phenotype, including glomerulonephritis and the presence of anti-
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nuclear antibodies (Napirei et al. 2000). Knockout of Dnase2 and Fen1 also cause 
autoimmune disorders in mice (Kawane et al. 2001; Yoshida et al. 2005; Kawane et al. 
2006; Zheng et al. 2007). 
(iii) Type I IFN pathway. Genetic variants in ISGs have been found to be associated 
with autoimmune diseases. For example, in addition to TREX1 mutations, Mendelian 
mutations in the ISG, ADAR1, can also cause AGS (Rice et al. 2012). Variants near the 
ISG, STAT4, have been associated with SLE and RA in GWA studies (Remmers et al., 
2007). Additionally, signatures of IFN upregulation have been observed in several types 
of autoimmune disorders such as SLE, AGS, and spondyloenchondrodysplasia, 
suggesting a pathogenic role (Bennett et al. 2003; Crow 2011). 
 (iv) NLR pathways. Although the NLR pathways are not highlighted here, various 
Mendelian mutations in NLR components can cause autoinflammatory syndromes 
(Masters et al. 2009) including: NOD2 mutations that cause Blau syndrome; NLRP3 
mutations that cause Muckle-Wells syndrome, Familial cold urticaria, or Neonatal onset 
multisystem inflammatory disease (NOMID); MEFV (pyrin) mutations that cause 
Familial Mediterranean Fever (FMF); PSTPIP1 mutations that cause Pyogenic sterile 
arthritis, pyoderma gangrenosum, acne (PAPA); and IL1RN mutations that cause 
Deficiency of the interleukin-1–receptor antagonist (DIRA). Additionally, variants in 
NOD2 are associated with Crohn’s disease (Cho 2008), and the NLRP3 pathway is 
believed to recognize the pathologic uric acid crystals in patients with gout and 
pseudogout (Martinon et al. 2006). IL-1β antagonists such as anakinra (a soluble IL-1 
receptor) have shown promise in many of these diseases (Schroder and Tschopp 2010).  
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Taken together, these studies establish that variation in innate immune genes can 
alter propensity to autoimmune/autoinflammatory diseases in humans. Like the infectious 
diseases, in certain cases further studies are needed to understand the contribution of specific 
innate immune pathways. 
 
Characterization of variation in the human innate immune system 
The clinical phenotypes described above clearly demonstrate that innate immune responses vary 
between individuals. The Mendelian mutations demonstrate that certain rare variants in innate 
immune components cause infectious diseases or autoimmune/autoinflammatory diseases. The 
GWAS and candidate association studies demonstrate that certain common (minor allele 
frequency > 1%) variants in innate immune components associate with infectious or 
autoimmune/autoinflammatory diseases. But because the clinical phenotypes and genetic 
studies have not been comprehensive by any means, there is likely much more variation in 
the human innate immune system that affects propensity to infectious and autoimmune 
diseases.  
 Thus, in addition to forward genetic studies, researchers have more directly characterized 
variation in the innate immune system by: (1) sequencing innate immune genes in large numbers 
of individuals; and (2) stimulating cells from large numbers of individuals with innate immune 
ligands to compare their responses. Moreover, researchers have characterized genome-wide 
expression variation in immune cells – such as monocytes, monocyte-derived dendritic cells 
(MoDCs) and B cells – and associated this phenotypic variation with genome-wide genotype 
data (Barreiro et al. 2012; Fairfax et al. 2012). This has resulted in the identification of eQTLs 
(expression quantitative trait loci), which are genetic variants that associate with variation in the 
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expression of gene(s), some of which influence the expression of innate immune components 
though this has not been explicitly examined. 
(i) TLR pathways. Barreiro et al. sequenced the TLR genes in 158 healthy individuals of 
various populations (Barreiro et al. 2009). They demonstrated that the nucleic acid-
sensing TLRs (TLR3, TLR7, TLR8, TLR9) have evolved under strong purifying 
selection, suggesting that they serve essential, nonredundant functions. In contrast, they 
found that the cell surface TLRs display relatively high rates of nonsynonymous 
variations in the population, suggesting higher immunological redundancy. Fornarino et 
al. sequenced the TIR domain-containing adaptor genes (including MYD88 and TRIF) in 
183 healthy individuals of various populations (Fornarino et al. 2011). They 
demonstrated that MYD88 and TRIF have also evolved under strong purifying selection 
(suggesting that they serve essential, nonredundant functions) and have been subject to 
positive selection suggesting adaptation during human history. 
 Wurfel et al. stimulated whole blood from 102 healthy individuals with LPS, and 
then measured production of a panel of cytokines by ELISA (Wurfel et al. 2005). They 
observed substantial variation in cytokine production, though could not distinguish 
genetic from technical or biological confounders. Hedl et al. stimulated the NOD2 and 
TLR2 receptors in monocyte-derived cells from 77-102 healthy individuals, and 
measured production of cytokines by ELISA (Hedl and Abraham 2012). They also 
observed substantial variation in cytokine production, and found that genetic variants in 
IRF5 associate with part of this phenotypic variation.  
(ii) Cytosolic nucleic-acid sensing pathways. Vasseur et al. sequenced the RLR genes 
in 186 healthy individuals of various populations (Vasseur et al. 2011). They 
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demonstrated that RIG-I is the most genetically constrained RLR (i.e. low tolerance of 
amino acid-altering variation, and low levels of nucleotide diversity and population 
differentiation), suggesting an essential role in host survival. They also found that certain 
variants in MDA5 and LGP2 have been subject to positive selection, suggesting a 
selective advantage of these mutations to certain populations. 
Jin et al. genotyped the STING gene in 1074 individuals. Their data revealed a 
haplotype in STING that contains three non-synonymous single nucleotide 
polymorphisms (SNPs), R71H-G230A-R293Q, that cause a >90% reduction of STING 
function (Jin et al. 2011). ~15% of Asians and ~1.7% of Europeans are homozygous for 
this haplotype. 
(iii) Type I (and type II and III) IFN pathways. Manry et al. sequenced the types I, II, 
and III IFN genes in 186 healthy individuals of various populations (Manry et al. 2011). 
They demonstrated that IFNγ (the type II IFN) and certain IFNα subtypes (notably IFNA6, 
IFNA8, IFNA13, and IFNA14) have evolved under strong purifying selection, suggesting 
that they serve essential, nonredundant functions. They found that other type I IFNs, 
including IFNA10 and IFNE, have high frequencies of non-synonymous mutations, 
suggesting redundancy of these genes. Finally, they found that type III IFNs are the only 
IFNs to show evidence of positive selection, suggesting a selective advantage of certain 
genetic variants to certain populations.  
 These studies have characterized additional variation in innate immune genes in humans, 
some of which may affect clinical phenotypes. For example, some of the variants in the type III 
IFN genes that have been subject to positive selection overlap with variants found in GWA 
studies of viral disease (Manry et al. 2011). In addition, variation in the NOD2 and TLR2 
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responses were linked to genetic variants found in GWA studies of autoimmune disease (Hedl 
and Abraham 2012). 
 
Overview of objectives 
Aim #1: Identify novel ISD pathway components. Our first objective was to identify 
novel components of the ISD pathway, since it is one of the most poorly understood pathways in 
the innate immune system and is clearly linked to human disease. Because homology-based and 
candidate gene approaches had not been yielding further discoveries, we used an unbiased 
approach that focused on candidates from proteomic and genomic experiments. We then 
developed a high-throughput siRNA screen to functionally test our candidates for a potential role 
in the ISD pathway.  
Aim #2: Characterize variation in innate immune responses in primary dendritic 
cells in humans, and determine whether the functional variation is caused by genetic 
variation. Our second objective was to characterize variation in innate immune responses to LPS, 
influenza, and IFNβ in monocyte-derived dendritic cells of a large number of healthy individuals. 
These ligands would allow us to characterize variation in the TLR4, RIG-I and TLR3, and 
IFNAR pathways, respectively. We sought to determine whether the functional variation is 
caused by genetic variation by using serially-replicated samples to control for technical and 
biological noise, and by associating genotype data with our expression and response phenotypes.  
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ABSTRACT 
The innate immune system senses viral DNA that enters mammalian cells – or in aberrant 
situations, self DNA – and triggers type I interferon production. Here we present an integrative 
approach that combines quantitative proteomics, genomics, and small molecule perturbations to 
identify novel genes involved in this pathway. We silenced 809 candidate genes, measured the 
response to dsDNA, and connected resulting hits with the known signaling network. We 
identified ABCF1 as a critical protein that associates with dsDNA and the known DNA-sensing 
components, HMGB2 and IFI16. We also found that CDC37 regulates stability of the signaling 
molecule, TBK1, and that chemical inhibition of CDC37 and several other pathway regulators 
potently modulates the innate immune response to DNA and retroviral infection. 
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INTRODUCTION 
The innate immune system detects viral infection primarily by recognizing viral nucleic acids 
inside an infected cell (Barbalat et al. 2011). In the case of retroviruses, which are RNA viruses 
that replicate via a DNA intermediate, genomic RNA can be recognized in the endosomes of 
specialized innate immune cells using the receptor TLR7 (Altfeld et al. 2011), while the reverse 
transcribed DNA is believed to be recognized during entry into a host cell by a cytoplasmic DNA 
sensor(s) that triggers type I IFN production (Yan et al. 2010). This latter response has been 
observed in cells that lack the endoplasmic reticulum (ER)-associated 3’->5’ exonuclease, 
TREX1. When TREX1 is present, it can degrade the viral DNA before sensing occurs.  
A similar fate appears to be the case with self DNA from the host cell, as deficiency in 
Trex1 leads to the accumulation of endogenous retroelements and genomic DNA in the 
cytoplasm, causing aberrant overactivation of the DNA-sensing pathway and subsequent 
initiation of autoimmune disease (Stetson et al. 2008; Gall et al. 2012). Indeed, deleterious 
variants in Trex1 cause the Mendelian autoimmune disorders, Aicardi-Goutières syndrome (AGS) 
(Lee-Kirsch et al. 2007b) and familial chilblain lupus (Lee-Kirsch et al. 2007a) in humans, and 
are associated with a subset of systemic lupus erythematosus (SLE) (Lee-Kirsch et al. 2007b). 
Genetic ablation of DNA-sensing pathway components (i.e. Irf3 or Sting) or the type I IFN 
receptor can preclude disease onset in animal models (Stetson et al. 2008; Gall et al. 2012), 
demonstrating the key epistatic relationship between Trex1 and the interferon stimulatory DNA 
pathway and linking the recognition of DNA viral and retroviral infection to the initiation of 
autoimmune disease. Identifying components of this pathway may facilitate the identification of 
drugs that modulate the DNA-sensing response to mitigate disease. 
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The mechanism by which cytosolic DNA elicits production of type I IFNs is a long-
standing problem (Isaacs et al. 1963; Jensen et al. 1963; Rotem et al. 1963) that has gained key 
insights more recently. Several of the downstream components of this pathway are believed to be 
shared with the RIG-I pathway, which mediates an innate immune response to foreign cytosolic 
RNA (Yoneyama et al. 2004). Specific DNA sequences, e.g. AT-rich DNA, are recognized by 
cytoplasmic RNA polymerase III, which transcribes the DNA ligand, and then RIG-I recognizes 
the resulting RNA product (Ablasser et al. 2009; Chiu et al. 2009). However, the innate immune 
recognition of retroviruses or retroelements does not seem to involve this latter pathway (Yan et 
al. 2010; Gall et al. 2012). Instead, cytosolic DNA can be recognized in a sequence-independent 
manner and this latter pathway does not use the receptor RIG-I or the RIG-I adaptor, MAVS 
(Ishii et al. 2006; Stetson and Medzhitov 2006; Sun et al. 2006). Instead, it relies on the 
intracellular transmembrane protein, STING (Ishikawa and Barber 2008; Ishikawa et al. 2009), 
which binds to the kinase TBK1 and the transcription factor IRF3 to allow IRF3 phosphorylation 
(Tanaka and Chen 2012). Phosphorylated IRF3 then dimerizes and translocates into the nucleus 
to induce Ifnb1 expression. In addition, certain HMGB family proteins as well as the AIM2-like 
receptor, IFI16, are believed to play at least a partial role (Yanai et al. 2009; Unterholzner et al. 
2010). However, the mechanism is still not fully understood. 
We describe here an integrative approach for identification of novel components of this 
DNA-sensing pathway (referred to as the ‘interferon stimulatory DNA (ISD) pathway’ below) 
and the innate immune response to retroviral infection. We combined unbiased quantitative 
proteomics with curation of candidates from existing proteomic, genomic, and domain-based 
datasets, and functionally tested 809 of these candidates by high-throughput loss-of-function 
screening. We then validated hits by chemical inhibition, cDNA rescue, or targeted knockout, 
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and mined existing protein-protein interaction datasets (host-host and host-viral) to form a 
network model of the ISD pathway. 
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RESULTS 
Generation of a candidate gene set by curation and quantitative proteomics 
We generated a set of candidate genes from proteomic, genomic, and domain-based datasets that 
we hypothesized contain unidentified ISD pathway components (Fig. 1.1a). First, we used 
protein-protein interaction (PPI) datasets to nominate 36 candidate proteins that interacted with 
the known DNA-sensing signaling proteins STING (Ishikawa and Barber 2008; Ishikawa et al. 
2009), TBK1 (Ishii et al. 2006; Tanaka and Chen 2012), IKKϵ (Ishii et al. 2006), and IRF3 
(Stetson and Medzhitov 2006) from a recent mass spectrometry study (Li et al. 2011), as well as 
99 candidates from our own mass spectrometry-based list of putative STING-interacting proteins 
(Supplementary Table 1.1). Second, we selected 321 DNA- and interferon-stimulated genes 
(ISGs) from our own and existing microarray datasets (see Materials and Methods) based on 
the hypothesis that a subset of components of this pathway are feedback-regulated (Tsuchida et 
al. 2010; Unterholzner et al. 2010). Third, we focused on 126 annotated phosphatases (Gene 
Ontology (GO):0004721) and 71 deubiquitinases (GO:0004221 and ref. (Nijman et al. 2005)) as 
part of our pilot screen to identify regulators of the ISD pathway (Tsuchida et al. 2010; Tanaka 
and Chen 2012).  
Because there was no existing dataset of cytoplasmic DNA-interacting proteins, we used 
quantitative proteomics to discover such proteins. We prepared cytoplasmic extracts from mouse 
embryonic fibroblasts (MEFs) (Supplementary Fig. 1.1a), and added biotinylated 45 base pair 
double-stranded DNA (‘ISD’ sequence (Stetson and Medzhitov 2006)) coupled to streptavidin 
beads as bait. We utilized three-state SILAC (stable isotope labeling by amino acids in cell 
culture) to label and quantitate peptides using mass spectrometry (Ong et al. 2002), with medium 
isotope-labeled cells used for a negative control (beads alone), light isotope-labeled  
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Figure 1.1. Generation of a candidate gene set by curation and quantitative proteomics.  
(a) Proteomic, genomic, and domain-based gene sets that we hypothesized contain unidentified ISD 
pathway components were curated or experimentally derived. (b) Schematic of DNA-interacting SILAC 
experiment. MEFs were labeled with light (L)-, medium (M)-, or heavy (H)-isotope SILAC solutions. 
Cells were pre-treated with IFNβ or left unstimulated. Cytoplasmic extracts were prepared and incubated 
with or without biotinylated ISD. ISD was precipitated with streptavidin beads, and precipitated proteins 
were trypsinized and subjected to mass spectrometry. (c) DNA-interacting proteins. The x-axis (H/M) 
corresponds to ISD interaction, and the y-axis (H/L) corresponds to IFNβ regulation. Open circles, ISD-
interacting hit; yellow squares, non-hit; selected hits are labeled. Open circles are colored to correspond 
with pathways in (d). (d) DNA-interacting SILAC hits span several known pathways involved in sensing 
cytosolic DNA.  
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cells for bead-DNA precipitation, and heavy isotope-labeled cells for bead-DNA precipitation 
preceded by IFNβ stimulation to upregulate pathway components (Fig. 1.1b).  
While only a handful of bands were visually distinguishable by protein electrophoresis 
(Supplementary Fig. 1.1b,c), we identified 184 proteins with SILAC ratios that showed 
enrichment for DNA binding following mass spectrometry (Fig. 1.1c, Supplementary Table 1.2, 
and Supplementary Fig. 1.1d). Among the 184 proteins, 121 (64.2%) were classified by Gene 
Ontology as having nucleic acid binding function (P = 5.95x10-58; GO:0003676), and others 
were components of DNA-binding complexes.  
In total, twenty of the identified proteins (10.9%) represent the majority of known players 
involved in the immune sensing of cytosolic DNA (Fig. 1.1d). We identified known components 
of DNA sensing pathways including: the HMGB family proteins (HMGB1, HMGB2, HMGB3) 
(Yanai et al. 2009), components of the AIM2 inflammasome (IFI202B and the HMGB proteins) 
(Roberts et al. 2009; Yanai et al. 2009), and the cytosolic RNA polymerase III complex 
(POLR3A, POLR3B, POLR3C, POLR3D, POLR3E, POLR3F, POLR3G, POLR3H, POLR1C, 
POLR1D, POLR2E, POLR2H, and CRCP). We identified three members of the SET complex 
(TREX1, APEX1, and HMGB2) that regulate the ISD pathway as well as HIV-1 detection and 
infection (Stetson et al. 2008; Yan et al. 2009; Yanai et al. 2009; Yan et al. 2010). We also 
identified associated proteins responsible for the autoimmune disease, Aicardi-Goutières 
syndrome (SAMHD1 and TREX1 (Crow et al. 2006; Rice et al. 2009), which are involved in 
regulating retroviral and retroelement detection (Stetson et al. 2008; Laguette and Benkirane 
2012)). Our findings validate the utility of quantitative mass spectrometry as an approach to find 
known components of cytosolic DNA sensing pathways, and we hypothesized that the dataset 
may also contain novel DNA-sensing components.  
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High-throughput loss-of-function screening of candidates and network analysis 
In total, we generated a list of 809 proteomic, genomic, or domain-based candidates (that were 
also available in the Dharmacon SMARTpool siRNA library) to test as potential components of 
the ISD pathway. We developed a robust high-throughput siRNA (small interfering RNA) 
screening assay (Supplementary Fig. 1.2a) in which we knocked down the genes in MEFs, 
stimulated the wells with transfected dsDNA (ISD), and measured production of the IFN-
inducible protein, CXCL10, by ELISA (Fig. 1.2a). We used CXCL10 here as the representative 
of the set of IFN-inducible genes because of its high level of induction in response to nucleic 
acids, its dependence on IRF3, and the availability of robust protein and RNA assays (Okabe et 
al. 2009). We measured cell survival after knockdown to control for potential cytotoxic effects of 
the siRNAs. The averages of triplicate wells are shown in Figure 1.2b and Supplementary 
Tables 1.3a-e. Knockdown of selected hits was confirmed by qRT-PCR (Supplementary Fig. 
1.2b). 
We hypothesized positions for selected hits in the ISD pathway by bringing together 
information from our own and existing PPI datasets (Fig. 1.2c and Supplementary Methods) 
(Bouwmeester et al. 2004; Li et al. 2011). We then validated the knockdown phenotypes of 
several of the screening hits using targeted knockouts, cDNA rescue, and chemical inhibition, as 
described below. 
 
Validation by targeted knockout, cDNA rescue, and chemical inhibition 
The ISD signaling pathway can be divided broadly into three main processes: DNA sensing, 
primary signaling, and secondary (IFN) signaling (Fig. 1.2c). At the level of DNA sensing, 
several of our cytoplasmic DNA-interacting mass spectrometry hits were found to have  
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Figure 1.2. High-throughput loss-of-function screening and network analysis of hits.  
(a) Schematic of siRNA screening assay. Following siRNA knockdown, each well was stimulated with 
ISD, and CXCL10 was measured in the supernatants by ELISA. (b) siRNA screen results. Log2 CXCL10 
(pg/mL) is graphed on the y-axis. Cell viability after knockdown was measured by CellTiter-Glo; relative 
luminescence units are graphed on the x-axis. The averages of three replicate wells for each gene are 
represented as black circles; red triangles at the bottom-right of each graph represent siIRF3 positive 
controls; green triangles at the top-right of each graph represent wells with no siRNA. Selected genes are 
labeled; control genes are labeled with blue text. (c) Interaction among known and novel proteins 
involved in the ISD network, assessed using PPI datasets. Blue text, known ISD pathway components. 
Solid lines, interactions defined in other datasets; dashed lines, interactions defined in our datasets; arrows, 
transcriptional regulation. Green/gray/yellow circles, screened by siRNA and colored by log2(fold) values 
relative to no siRNA control; white circles, toxic siRNA or not screened; blue circles, viral protein; red 
circles, chemical inhibitor. 
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functional phenotypes in our siRNA screen, including Hmgb2 and Abcf1 (Supplementary Table 
1.3a). HMGB2 is a known nucleic acid sensing pathway member that interacts with DNA (Yanai 
et al. 2009). Knockout of Hmgb2 reduced ISD-induced Ifnb1 and Cxcl10 production 2-3 fold 
(Supplementary Fig. 1.3a), consistent with the role of Hmgb2 in the response to B-DNA 
(poly(dA-dT)-poly(dT-dA)) which stimulates the ISD and RNA polymerase III pathways 
(Ablasser et al. 2009; Chiu et al. 2009; Yanai et al. 2009). We validated the Abcf1 phenotype 
using additional siRNAs and cDNA rescue. Using 14 different siRNAs targeting Abcf1, we 
measured Abcf1 mRNA expression as well as CXCL10 induction in response to ISD stimulation. 
Knockdown of Abcf1 correlated with CXCL10 induction (R2 = 0.62), with the screening siRNA 
pool (si-0) and two other siRNAs (si-1 and -2) inhibiting both Abcf1 mRNA and protein 
expression and CXCL10 induction most strongly (Fig. 1.3a). We validated the strongest Abcf1 
siRNA (si-1) by cDNA rescue. We first created an siRNA-resistant cDNA (Abcf1(rescue) gene; 
Fig. 1.3b). We cloned this cDNA into a tet-on lentiviral vector (Supplementary Fig. 1.3b), 
transduced the construct into MEFs, and repeated siRNA-mediated knockdown in the presence 
of varying amounts of doxycycline to titrate the expression of the cDNA. We stimulated the cells 
with ISD and read out CXCL10 production by ELISA. Knockdown of Abcf1 reduced CXCL10 
production by 14.9-fold (P < 0.01; Fig. 1.3c). Expression of Abcf1(rescue) cDNA, but not of a 
Renilla cDNA control, significantly rescued this phenotype in a dose-dependent manner (P < 
0.001; Fig. 1.3c and Supplementary Fig. 1.3c). Abcf1 is a cytosolic and ER-localized member 
of the ATP-Binding Cassette (ABC) family of transporters with a role in translational control 
(Paytubi et al. 2009), but unlike other members of the ABC family, the Abcf subfamily genes 
lack transmembrane domains. Although a role in DNA sensing had not been previously observed, 
there is evidence that human polyomavirus 6 and 7 proteins interact with ABCF1  
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Figure 1.3. Validation of the screening hit, Abcf1. (a) Knockdown-phenotype correlation. MEFs treated 
with control siRNA (siNeg) or 14 different siRNAs targeting Abcf1 were stimulated with ISD. Abcf1 
mRNA expression was measured by qRT-PCR, and CXCL10 production was measured by ELISA. Inset: 
MEFs were treated with siNeg, siAbcf1-0, siAbcf1-1, or siAbcf1-2, and lysates were immunoblotted with 
anti-ABCF1 and anti-β-actin antibodies. (b) MEFs stably expressing Abcf1-HA or siAbcf1(si-1)-
knockdown-resistant Abcf1(rescue)-HA were treated with siAbcf1(si-1), control siRNA (siNeg), or mock 
treated (No siRNA). Lysates were immunoblotted with anti-HA and anti-β-actin antibodies. (c) 
Validation by cDNA rescue. MEFs stably expressing doxycycline-inducible Renilla-HA or Abcf1(rescue) 
cDNA were treated with siAbcf1(si-1) and doxycycline (0, 0.3, 3, 30 ug/mL). Cells were stimulated with 
ISD and CXCL10 production was measured by ELISA. * P < 0.05, *** P < 0.001 compared with 
siAbcf1-treated cells without doxycycline treatment. 
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(Rozenblatt-Rosen et al. 2012), suggesting that this DNA virus may derive a benefit from 
targeting this protein (Fig. 1.2c). 
In the primary signaling network (Fig. 2c), known components such as Sting, Tbk1, and 
Irf3 were strong hits in our screen; knockdown of these genes reduced ISD-stimulated CXCL10 
production by more than 10-fold each (Supplementary Table 1.3b,c), validating our assay. 
Several screening hits that are hypothesized to interact with these proteins were also found to 
have phenotypes in our loss-of-function screen, including Cdc37, Numa1, and Cyb5r3 (Fig. 1.2c 
and Supplementary Table 1.3c). Knockdown of Cdc37 reduced ISD-stimulated CXCL10 
production as strongly as the known components (Supplementary Table 1.3c). Consistent with 
this result, treatment of murine or human cells with celastrol, a small molecule inhibitor of the 
CDC37-HSP90 interaction (Gray et al. 2008; Zhang et al. 2008), potently reduced Ifnb1 and 
CXCL10 induction (Fig. 1.4a and Supplementary Fig. 1.4a). CDC37 is a molecular co-
chaperone that interacts with HSP90 to stabilize specific proteins, notably protein kinases (Gray 
et al. 2008), and is a putative interactor of TBK1 (Bouwmeester et al. 2004; Li et al. 2011). Thus, 
we tested whether CDC37 regulates TBK1 expression. Knockdown of Cdc37 substantially 
reduced protein levels of TBK1 (Fig. 1.4b). As expected from this result, knockdown of Cdc37 
abrogated the phosphorylation of IRF3 (serine-396) – a hallmark of the ISD pathway’s activation 
– following ISD stimulation (Fig. 1.4b). Chemical inhibition of HSP90 (by 17-DMAG) or of 
TBK1 (by BX795) had similar phenotypes as CDC37 inhibition (Fig. 1.4a and Supplementary 
Fig. 1.4a). Thus, targeting the members of this complex with small molecules can block the ISD 
response by potently inhibiting TBK1 protein stability or activity, a phenotype that may be 
applicable to the treatment of certain autoimmune disorders (see below).  
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Figure 1.4. Targeting of screening hits by small molecule inhibitors. (a) Human monocyte-derived 
dendritic cells (MoDCs) treated with small molecule inhibitors were stimulated with 0.3 ug/mL DNA 
(HIV gag-100) for 24 h and CXCL10 production was measured by ELISA. Small molecules were used at: 
500 nM celastrol, 75 nM 17-DMAG, and 500 nM BX795. * P < 0.05 compared with vehicle control. (b) 
MEFs treated with siRNAs were stimulated for 4 h with ISD, and lysates were immunoblotted with 
indicated antibodies. (c) Ptpn1-/- MEFs or Ptpn1-/- MEFs rescued with Ptpn1 cDNA were stimulated 
with ISD, and CXCL10 production was measured by ELISA. ** P < 0.01. (d) Human MoDCs treated 
with 7.5 uM PTPN1 inhibitor or 1 nM okadaic acid were stimulated with 0.3 ug/mL DNA (HIV gag-100) 
and CXCL10 production was measured by ELISA. * P < 0.05, *** P < 0.001 compared with vehicle 
control. 
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Secondary signaling downstream of the IFN receptor (Fig. 1.2c) is also important in the 
ISD response, and we identified known (e.g. Irf9 and Stat1) and candidate mediators (e.g. Ptpn1 
(Myers et al. 2001)) of the secondary signaling network (Fig. 1.2c, Supplementary Fig. 1.4b, 
and Supplementary Table 1.3b,d). Knockout of the protein tyrosine phosphatase, PTPN1, 
increased ISD-induced CXCL10 production 2.4-fold (Fig. 1.4c and Supplementary Fig. 1.4c), 
validating the screening phenotype. Consistent with this result, small molecule inhibition of 
PTPN1 increased CXCL10 production 9.1-fold in human monocyte-derived dendritic cells 
(MoDCs) stimulated with ISD (Fig. 1.4d).  
Finally, we further tested hits in which the molecular interaction partners in the ISD 
pathway remain unclear. SP110 is an IFN-regulated nuclear body protein. We found that a 
natural deleterious mutation in Sp110 (Pan et al. 2005) causes 1.5-3 fold decreased Ifnb1 
induction in response to DNA (Supplementary Fig. 1.4d). The protein serine/threonine 
phosphatase, PPP6C, is a candidate interactor of IκB-ε (Bouwmeester et al. 2004), but its target 
in the ISD pathway is unknown. Consistent with the phenotype in our siRNA screen, we found 
that small molecule inhibition of PPP6C increased ISD-stimulated CXCL10 production in 
human MoDCs 2.6-fold (Fig. 1.4d). Thus, targeting the two inhibitory phosphatases, PTPN1 and 
PPP6C, by small molecules may serve as a way to enhance the immune response to certain DNA 
viruses and retroviruses (see below), and possibly to enhance the immunogenicity of DNA 
vaccines (Ishii et al. 2008; Ishikawa et al. 2009).  
 
Quantitative proteomics analysis of the DNA-sensing network 
We sought to further understand the DNA-sensing network (Fig. 1.2c) by determining the 
interaction partners of ABCF1, a protein that we found regulates the ISD response (Fig. 1.2b and 
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Supplementary Table 1.3a) and associates with DNA (Fig. 1.1c and Supplementary Fig. 1.1d). 
We again used an unbiased quantitative mass spectrometry-based approach, in which we 
precipitated stably-expressed ABCF1-HA in MEFs with anti-HA antibody and performed 
SILAC mass spectrometry (Fig. 1.5a). We identified 53 proteins with SILAC ratios that 
demonstrated co-precipitation with ABCF1 at a P-value < 0.01 (Fig. 1.5a and Supplementary 
Table 1.5). Three of the proteins that co-precipitated with ABCF1 – SET, HMGB2, and 
ANP32A – are members of the ER-associated SET complex (Fig. 1.5b,c), of which we had 
previously isolated HMGB2 and the DNA exonucleases TREX1 and APEX1 by DNA 
precipitation (Fig. 1.1c,d). None of these interactions were seen with STING-HA pulldown 
(Supplementary Table 1.1), indicating specificity for ABCF1. Immunofluorescence suggested 
that a subset of ABCF1 colocalizes with SET and the ER-marker calreticulin, further supporting 
the interaction between ABCF1 and the SET complex (Fig. 1.5d and Supplementary Fig. 1.5a). 
The ER co-localization is consistent with another report suggesting that ABCF1 is partially 
localized to the ER and partially localized to the cytosol (Paytubi et al. 2009). 
The SET complex member, HMGB2 is hypothesized to function as a co-ligand for 
nucleic acid sensors though the precise role of HMGB2 remains unclear (Yanai et al. 2009). We 
observed that not only HMGB2, but also IFI204 – a predicted DNA sensor also known as IFI16 
(Unterholzner et al. 2010) – are candidate interactors of ABCF1 (Fig. 1.5b,c). Consistent with 
the reported functions of Hmgb2 and Ifi16 (Yanai et al. 2009; Unterholzner et al. 2010), 
knockdown of Abcf1 suppressed TBK1 and IRF3 phosphorylation in MEFs stimulated with ISD 
(Fig. 1.5e and Supplementary Fig. 1.5b,c).  
While Abcf1 knockdown significantly reduced Ifnb1 and ISG induction following dsDNA 
(HIV gag-100 sequence) stimulation or HSV-1 d109 infection (Fig. 1.5f,g and Supplementary  
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Figure 1.5. Identification of components of DNA sensing complex. (a) ABCF1 interactors. MEFs 
stably expressing Abcf1-HA or mock-transduced MEFs were stimulated with ISD or left unstimulated. 
Lysates were precipitated with anti-HA antibody. X-axis (M/L) and y-axis (H/L) correspond to co-
precipitation with ABCF1-HA in the unstimulated and stimulated states, respectively. Blue/purple circles, 
hits with P-value < 0.01; yellow squares, non-hit. (b) Interaction among proteins in DNA sensing network. 
Legend is same as in Figure 2c. (c) MEFs stably expressing doxycycline-inducible Abcf1-HA were 
treated with doxycycline for 0, 24, or 48 h. Lysates were precipitated with anti-HA antibody or IgG 
control. Precipitates were immunoblotted with indicated antibodies. (d) Immunofluorescent microscopy 
of MEFs expressing HA-tagged Abcf1, stained for DAPI, HA, and SET. Merge of images is shown.  
(e) MEFs treated with indicated siRNAs were stimulated for 4 h with ISD, and lysates were 
immunoblotted with indicated antibodies. (f) MEFs treated with indicated siRNAs were infected with 
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HSV-1 d109 for 6 h, and induction levels of Cxcl10 mRNA were determined by qRT-PCR. Data 
presented as mean and s.d. (n = 4). (g) Trex1-/- MEFs treated with indicated siRNAs were stimulated with 
4 ug/mL DNA (HIV gag-100) for 5.5 h or infected with Sendai virus for 6 h, and induction levels of Ifnb1 
mRNA were determined by qRT-PCR. Data presented as mean and s.d. (n = 3). In (f) and (g), ** P < 0.01, 
** P < 0.001 compared with cells treated with control siRNA. (h) Trex1-/- MEFs treated with indicated 
siRNAs were stimulated with 300 U/mL IFNβ for 8 h, and expression levels of Abcf1 and ISG mRNA 
were determined by qRT-PCR. Data are averages of triplicate wells. 
 
 
Fig. 1.5d,e), Abcf1 knockdown did not have a significant effect on IFN or ISG induction by 
Sendai virus (which stimulates the RIG-I pathway) or by recombinant IFNβ itself (Fig. 1.5g,h 
and Supplementary Fig. 1.5f). Taken together, these results support the hypothesis that ABCF1 
interacts with HMGB2, IFI16, and the SET complex and is a critical node in the DNA sensing 
network.  
 
Innate immune response to retroviral infection in TREX1 mutant cells 
We further examined whether our findings are relevant to Trex1-dependent autoimmunity and 
retroviral infection. While in culture Trex1-/- cells do not spontaneously produce type I IFNs or 
ISGs, retroviral infection of these cells induces IFN and ISG production in the absence of Trex1 
(Supplementary Fig. 1.6a and ref. (Yan et al. 2010)). We knocked down our major screening 
hits in Trex1-/- MEFs and infected the cells with an HIV-based retrovirus. Knockdown of 4 of 
these genes (i.e. Ptpn1, Tiparp, Mdp1, and Ppp6c) significantly enhanced the ability of retroviral 
infection to induce IFN and ISG production (P < 0.05), while knockdown of 10 of these genes 
(including Abcf1 and Cdc37) as well as 4 known signal transduction components (i.e. Trim56, 
Sting, Tbk1, and Irf3) significantly abrogated the innate immune response (P < 0.05; Fig. 1.6a-c 
and Supplementary Fig. 1.6b).  
 
  46 
 
 
Figure 1.6. Inhibition of identified regulators by RNAi or small molecules modulates the innate 
immune response to retroviral infection. (a) Trex1-/- MEFs treated with indicated siRNAs were 
infected with retrovirus for 21.5 h, and induction levels of Cxcl10 mRNA were determined by qRT-PCR. 
P-values compared with control siRNA (siNeg)-treated cells (after Benjamini-Hochberg correction for 
multiple testing) are marked as asterisks in red with P = 0.05 and P = 0.10 indicated as dotted lines. Data 
presented as mean and s.d. (n = 3). Known ISD pathway genes are colored blue. Genes whose protein 
products can be inhibited by existing small molecule inhibitors are marked with arrows. (b,c) Trex1-/- 
MEFs treated with indicated siRNAs were infected with retrovirus, and induction levels of Ifnb1 mRNA 
were determined by qRT-PCR. Data presented as mean and s.d. (n = 3). (d,e) Trex1-/- MEFs treated with 
small molecule inhibitors were infected with retrovirus, and induction levels of Ifnb1 or a panel of ISGs 
was determined by qRT-PCR. Data are averages of duplicate wells. Small molecules were used at: 400 
nM celastrol, 750 nM 17-DMAG, 500 nM BX795, 30 uM PTPN1 inhibitor, and 10 nM okadaic acid. (f) 
TREX1 mutant (AGS patient 1: R114H/D201ins; AGS patient 2: R114H/R114H) human fibroblasts and 
healthy control fibroblasts were treated with vehicle alone or small molecule inhibitors and infected with 
retrovirus. Induction levels of the ISG, MX1, was determined by qRT-PCR. Data are averages of triplicate 
wells. Small molecules were used at: 500 nM celastrol, 100 nM 17-DMAG, and 500 nM BX795. * P < 
0.05 compared with respective cells that were treated with vehicle control and infected with retrovirus. 
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Chemical inhibition of CDC37, HSP90, or TBK1 potently abrogated retroviral infection-
induced Ifnb1 induction in Trex1-/- MEFs (Fig. 1.6d,e and Supplementary Fig. 1.6c); in 
contrast, chemical inhibition of PTPN1 or PPP6C increased ISG induction in response to 
retroviral infection in a dose-dependent manner (Fig. 1.6e and Supplementary Fig. 1.6c). We 
then tested several of these small molecules in human fibroblasts derived from two healthy 
individuals and from two patients with Aicardi-Goutières syndrome that had disease-causative 
mutations in TREX1 (R114H/D201ins in one patient, and R114H/R114H in the second patient) 
(Crow et al. 2006). The R114H variant is also found in patients with SLE (Lee-Kirsch et al. 
2007b). The small molecules targeting CDC37, HSP90, and TBK1 abrogated the induction of 
ISGs (Fig. 1.6f and Supplementary Fig. 1.6d). Thus, celastrol, 17-DMAG, and BX795 may be 
therapeutic leads in TREX1-dependent autoimmune disorders, while PTPN1 inhibitor and 
okadaic acid may exacerbate the autoimmune phenotype but enhance the innate immune 
response to retroviral infection. 
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DISCUSSION 
We describe here the integration of complementary genomic and proteomic datasets to identify 
new components and physical interactions in the ISD signaling network. We generated and used 
DNA-protein interaction, protein-protein interaction, and loss-of-function screening datasets to 
identify new ISD pathway components; validated several of the newly identified components; 
demonstrated that a subset also function in the response to retroviral infection in Trex1-/- cells; 
and showed that small molecule inhibitors of several of these components can modulate the 
innate immune response to dsDNA and retroviral infection.  
In our DNA precipitation experiment, we identified 184 candidate cytoplasmic DNA-
interacting proteins that encompass most of the published components of DNA-sensing pathways 
(including ISD, RNA polymerase III, AIM2 inflammasome, and AGS proteins), with several 
exceptions (e.g. AIM2 and DDX41 which may be specific to cells of the myeloid lineage 
(Schroder and Tschopp 2010; Zhang et al. 2011b)). After screening the candidates for a potential 
role in the ISD response, we identified ABCF1 as a cytoplasmic protein that associates with 
dsDNA, IFI16, and HMGB2, and regulates the interferon response to transfected dsDNA and 
retroviral infection. These results implicate ABCF1 as a key component of the ISD pathway. It is 
still unclear whether ABCF1 interacts with DNA directly, or whether the interaction is indirect. 
Our experiments also identified SET complex members (SET, ANP32A, and HMGB2) as 
ABCF1 interactors. The SET complex contains three DNA nucleases (TREX1, APEX1, and 
NME1); the chromatin-modifying proteins SET and ANP32A; and HMGB2, which functions as 
a co-receptor for nucleic acid receptors among other roles (Chowdhury and Lieberman 2008). 
The observed interactions among dsDNA, ABCF1, HMGB2, and other SET complex members 
suggest that early steps in DNA recognition may occur at the ER-localized SET complex. 
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Consistent with this hypothesis, the complex member TREX1 can prevent HIV-1 DNA detection, 
and its absence results in accumulation of retroelement DNA at the ER which drives an ISD 
response (Yang et al. 2007; Stetson et al. 2008; Yan et al. 2010). Furthermore, the complex 
members SET and NME1 also detect HIV-1 DNA, and in turn regulate HIV-1 infectivity27. A 
recent model suggests that the SET complex may recognize viral DNA as damaged DNA, 
specifically via its base excision repair (BER) activity and/or its distorted structure (e.g. 
HMGB2) (Yan et al. 2011). Consistent with this model, we find that our ISD interactors include 
the SET and BER complex member, APEX1, as well as nearly the entire BER complex (e.g. 
PARP1, PARP2, POLB, LIG3, XRCC1, FEN1, and PCNA). Overall, these results suggest that 
the SET complex plays a central role in DNA sensing and forms a coordinated system for 
detecting, modifying, and degrading viral or retroelement DNA. 
We tested the impact of small molecule inhibitors on the DNA-sensing response and 
found that inhibition of PTPN1, PPP6C, CDC37, HSP90, or TBK1 modulates the innate immune 
response to cytosolic DNA in human dendritic cells and to retroviral infection in TREX1 mutant 
cells. Several of these small molecules have already been tested for other conditions in mice and 
humans. For example, 17-DMAG is being explored for the treatment of autoimmune disease and 
various cancers (Shimp et al. 2012), and extracts of the medicinal plant Tripterygium wilfordii, 
from which the natural product celastrol is derived, have been used as an anti-inflammatory 
(Corson and Crews 2007; Goldbach-Mansky et al. 2009). While current treatments for Trex1-
dependent autoimmune disorders (including Aicardi-Goutières syndrome, familial chilblain 
lupus, and SLE) do not target the cause of these diseases, small molecules like celastrol, 17-
DMAG, and BX795 that inhibit the ISD response may represent new therapeutics for this class 
of disorders.  
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MATERIALS AND METHODS 
Cells, viruses, and reagents. p53-/- MEFs were a gift from D.M. Sabatini and D.J. Kwiatkowski 
(Zhang et al. 2003). Trex1-/- MEFs and C57BL/6 wild type (wt) control MEFs were a gift from 
T. Lindahl. Ptpn1-/- MEFs and Ptpn1-/- MEFs rescued with Ptpn1 cDNA were a gift from B.G. 
Neel (Klaman et al. 2000). Human AGS patient (TREX1 R114H/D201ins and TREX1 
R114H/R114H) fibroblasts and healthy control cells were a gift from Y.J. Crow. 293T cells were 
obtained from ATCC. Primary murine lung fibroblasts were derived from lung tissue of 4-8 wk 
old female C57BL/6 mice as previously described (Tager et al. 2004). cDCs were prepared from 
B6.C3H-sst1 (Sp110 LoF) as previously described (Pan et al. 2005; Amit et al. 2009). Cells were 
maintained in DMEM (Mediatech) supplemented with 10% FBS (Sigma). Human monocytes 
were isolated by negative selection (Life Technologies) from peripheral blood mononuclear cells, 
and differentiated into dendritic cells by a seven day culture in GM-CSF (R&D) and IL-4 (R&D) 
in RPMI (Life Technologies) supplemented with 10% FBS (Life Technologies). Sendai virus 
was obtained from ATCC and used at an MOI of 1. HSV-1 d109 (Samaniego et al. 1998) was 
obtained as a gift from N.A. DeLuca and was used at an MOI of 10. Self-inactivating minimal 
HIV-1 virus was produced in 293T cells using the vector pLX301 (TRC, Broad Institute), the 
packaging construct psPAX2, and the envelope plasmid pCMV-VSVG. Interferon stimulatory 
DNA (ISD), HIV gag-100, and HSV60 dsDNA were annealed from oligonucleotides (IDT) as 
described previously (Stetson and Medzhitov 2006; Unterholzner et al. 2010; Yan et al. 2010). 
Sequences are listed in Supplementary Table 1.5a. In vitro transcribed RNA was synthesized as 
described previously(Hornung et al. 2006). Nucleic acids were mixed with Lipofectamine LTX 
(Life Technologies) at a ratio of 1:3 (wt/vol) in Opti-MEM (Life Technologies), and added to 
cells at a final concentration of 1 ug/mL (DNA) or 0.1 ug/mL (RNA) unless otherwise indicated. 
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Recombinant IFNβ was obtained from PBL InterferonSource; murine CXCL10 ELISA kit was 
obtained from R&D; NE-PER from Pierce; Coomassie blue (SimplyBlue SafeStain) from Life 
Technologies; EXPRESS35S Protein Labeling Mix from Perkin Elmer. Antibodies were 
obtained from the following sources: anti-P-TBK1 Ser172 (5483; Cell Signaling), anti-P-IRF3 
Ser396 (4947; Cell Signaling), anti-TBK1 (3504; Cell Signaling), anti-IRF3 (4302; Cell 
Signaling), anti-CDC37 (4793; Cell Signaling), anti-ABCF1 (SAB2106638, Sigma), anti-
HMGB2 antibody (ab67282, Abcam), anti-SET (sc25564, Santa Cruz), anti-IFI204 
(SAB2105265, Sigma), anti-α-tubulin (T5168, Sigma), anti-β-actin (ab6276, Abcam), anti-HA 
(High Affinity 3F10; Roche), anti-SMARCB1 (H-300; Santa Cruz Biotechnology), anti-
calreticulin (ab14234; Abcam), and rat IgG control (Jackson Laboratories). PTPN1 inhibitor 
(CAS 765317-72-4), okadaic acid, and celastrol were obtained from Millipore. BX795 and 17-
(Dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG) were obtained from 
Invivogen. 
 
Identification of DNA-interacting proteins by SILAC mass spectrometry. p53-/- MEFs were 
grown for six cell doublings in DMEM depleted of L-arginine and L-lysine (Caisson Labs Inc.) 
and supplemented with 10% dialyzed FBS (Sigma) and either light (L), medium (M), or heavy 
(H) isotope-labeled amino acids . The L and H cells were stimulated with 1000 U/mL IFNβ for 
18 h. The cells were pelleted and incubated in hypotonic lysis buffer (10 mM HEPES pH 7.4, 10 
mM KCl, 1 mM EDTA) containing protease inhibitors (Roche) for 10 min on ice followed by 
lysis for 1 min in hypotonic lysis buffer supplemented with 0.3% Triton X-100. Nuclei and 
insoluble proteins were removed by centrifugation. 11 mg of the H and L lysates were mixed 
with a 1:1 mix of biotinylated ISD and ISD with a tetraethylene glycol arm between the biotin 
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and the nucleic acid (IDT), and then split into two samples. No ISD was added to 11 mg of 
sample M. Equal volumes of streptavidin beads (Ultralink; Pierce) were added to all three 
samples, and samples were rotated for 2.5 h at 4°C. Beads were pelleted and washed extensively 
with wash buffer (50 mM Tris-HCl pH 7.8, 150 mM NaCl, 1 mM EDTA, 0.75% NP-40, 0.175% 
sodium deoxycholate). The three samples were mixed, cysteines were reduced by DTT and 
alkylated with iodoacetamide, and proteins were eluted by heating in SDS sample buffer (Life 
Technologies) for 10 min before separation on a 4-12% gradient gel (NuPAGE; Life 
Technologies). The resolved proteins were divided into 13 fractions and subjected to proteolysis 
with trypsin, and peptides were extracted from the gel as described (Shevchenko et al. 2006). 
Peptide extracts were cleaned up offline with C18 StageTips (Rappsilber et al. 2007) prior to 90 
min nanoESI-LCMS analyses with a gradient of 3%-35% acetonitrile/ 0.1% formic acid. Protein 
and peptide identification and quantification was performed with MaxQuant (v. 1.0.12.31) (Cox 
et al. 2011) using the IPI mouse v3.52 as the search database. Search parameters specified 
trypsin cleavage with 2 missed cleavages, peptide mass tolerance of 6 ppm and fragment mass 
tolerance of 0.5 Da; carbamidomethylated cysteines and variable modifications of oxidized 
methionine, acetylation of protein N-termini and sample-specific modifications of Arg-0,6,10 
and Lys-0,4,8 for SILAC triple labeling. Protein ratios were medians of ratios from at least two 
quantified peptides. To identify significant proteins, P-values were calculated via Gaussian 
modeling of the log(H/M) data, and a significance threshold of P < 1x10-4 was used. 
 
Identification of STING- and ABCF1-interacting proteins by SILAC mass spectrometry. 
Light (L), medium (M), and heavy (H) isotope-labeled p53-/- MEFs mock infected (L) or stably 
expressing Sting-HA (H) or Abcf1-HA (M and H) were stimulated with 1000 U/mL IFNβ for 18 
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h. H cells were transfected with ISD for 2.5 h. Cells were lysed in 50 mM Tris-HCl pH 7.8, 150 
mM NaCl, 1 mM EDTA, 0.2% NP-40, and insoluble proteins were removed by centrifugation. 
18 mg of each lysate was mixed with 1 ug/mL anti-HA antibody and Protein G beads (Pierce), 
and rotated for 2.5 h at 4°C. Beads were pelleted and washed extensively with wash buffer 
(above). The isotope-labeled samples were mixed (with Sting-HA and Abcf1-HA samples 
handled separately), cysteines were reduced by DTT and alkylated with iodoacetamide, and 
proteins were eluted by heating in SDS sample buffer for 10 min before separation on a 4-12% 
gradient gel. The whole gel lane was cut into 8 slices, proteins were digested inside the gel with 
trypsin, and peptides were extracted from the gel. Extracted peptides were purified with 
StageTips and analyzed with a 100 min acquisition method on a Thermo EASY-nLC 1000 
UHPLC coupled to a Q Exactive mass spectrometer. Raw data files were processed in MaxQuant 
(v. 1.2.2.5) using the IPI mouse v3.68 as the search database. All proteins were identified with at 
least 2 or more unique peptides and quantified with 3 or more ratios. SILAC ratios were 
normalized over the median of all protein ratios to correct for sample losses between parallel 
immunoprecipitation steps. To identify significant interactions, P-values were calculated via 
Gaussian modeling of the log(M/L) and log(H/L) data, and a significance threshold of P < 0.01 
was used. 
 
RNA interference screen. 750 p53-/- MEFs per well were seeded in 96-well plates in 60% 
DMEM and 40% Opti-MEM. 25 nM siRNA was complexed with 0.5 uL Lipofectamine 
RNAiMax (Life Technologies) in Opti-MEM, incubated for 12 min at 22°C, and added to the 
wells. 72 h later, cells were transfected with ISD. 26 h later, supernatants were collected and 
CXCL10 was quantified by ELISA. Cell viability was estimated by the CellTiter-Glo 
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Luminescent Cell Viability Assay (Promega); CellTiter-Glo values below 3.75e5 were 
considered toxic. Dharmacon siGENOME SMARTpools from Harvard ICCB were used for 
screening. ON-TARGETplus Non-targeting Pool was used as negative control (siNeg). 
Individual siRNAs were from Dharmacon, Life Technologies, Qiagen, and Sigma. siRNA 
sequences are listed in Supplementary Table 1.5b. 
 
Plasmid construction. To create the tet-on lentiviral vector (pCW57d-P2AR), the pLKO.1 
(Moffat et al. 2006) vector was modified as follows: the U6 shRNA cassette was removed from 
LKO.1 and the TRE with a MCS was inserted upstream of the PGK promoter; the rtTA was 
cloned 3' of the puroR (with a 2A multicistronic cleavage site between these two genes) along 
with a WPRE. To create the Abcf1(rescue) construct, silent mutations were made in the 
siAbcf1(si-1) targeting site using overlap extension PCR; the rescue cDNA was then cloned into 
pCW57d-P2AR. The Irf3(rescue) construct was similarly cloned, with silent mutations made in 
the siIrf3 targeting site. To generate the HA-tagged Abcf1 and HA-tagged Sting expression 
vectors, an HA tag was added to the C-terminus of the cDNAs during PCR, and the constructs 
were cloned into pLX301. Primer sequences are listed in Supplementary Table 1.5c. 
 
cDNA rescue. p53-/- MEFs stably expressing cDNA in the pCW57d-P2AR vector were 
subjected to siRNA. 72 h later, doxycycline (Sigma) at 0, 0.3, 3, or 30 ug/mL was added to the 
cells, and cells were stimulated with ISD. 26 h later, supernatants were collected and CXCL10 
was quantified by ELISA. 
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Quantitative RT-PCR. Total RNA was prepared from cells using the RNeasy Mini kit (Qiagen). 
cDNA was synthesized using the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems). Real time qPCR was performed using SYBR Green (Roche) and the LightCycler 
480 system (Roche) according to instructions provided by the manufacturer. Relative amounts of 
mRNA were normalized to Gapdh levels in each sample. The primers used for qPCR are listed 
in Supplementary Table 1.5d.  
 
Co-immunoprecipitation assays. p53-/- MEFs stably expressing doxycycline-inducible Abcf1-
HA were treated with 3 ug/mL doxycycline for 0, 24, or 48 hours, and then lysed in 10 mM Tris-
HCl, 2 mM EDTA, 0.4% NP-40 with complete EDTA-free protease inhibitors (Roche). Anti-HA 
antibody was crosslinked to Protein G beads (Roche) at a concentration of 1 ug antibody per 20 
uL beads using dimethyl pimelimidate dihydrochloride (Sigma). Cleared supernatants were 
incubated with the antibody-bound beads, and rotated overnight at 4°C. Rat IgG control bound to 
Protein G were used as IP control with the 48 h doxy-treated lysates. The beads were washed 
extensively with wash buffer (10 mM Tris-HCl, 2 mM EDTA, 1% NP-40). Immunoprecipitates 
were eluted with 100 uL 2.5 M Glycine (pH 3) and immediately buffered to pH 7.5 by adding 25 
uL of 2 M Tris. Samples were boiled in reducing Laemmli buffer for 10 min, separated by SDS-
PAGE, and immunoblotted using anti-HA, anti-SET, and anti-HMGB2 antibodies.  
 
Immunofluorescence assays. 5x104 p53-/- MEFs stably expressing doxycycline-inducible 
Abcf1-HA were grown overnight on glass coverslips in standard DMEM with 10% FBS. Abcf1-
HA expression was induced by adding 3 ug/mL doxycycline for 48 h. Cells were fixed using 4% 
PFA for 15 min and permeabilized using PBS + 0.2% Triton X-100. Cells were then treated with 
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respective primary antibodies at a concentration of 1/200 for 1 h, followed by treatment with 
respective fluorophore labeled secondary antibodies. The cells were mounted on glass sides 
using DAPI-containing VECTASHIELD (Vector Laboratories). The cells were visualized using 
503 Platform from Intelligent Imaging Innovations, under 40X and 63X oil immersion. 8 Z-
stacks were taken per image at 1 um per step and the image were deconvolved using nearest 
neighbor algorithm. The images were processed using Slidebook version 5. 
 
DNA microarray analysis. (i) 293T cells were stimulated with 1000 U/mL recombinant IFNβ 
followed by lysis 6 h later in RLT buffer (Qiagen). Total RNA was isolated using the RNeasy 
Mini kit (Qiagen). Genome-wide gene expression profiling was obtained by hybridizing the 
RNA to the Affymetrix Human U133 Plus 2.0 array. The cDNA synthesis, labeling, and 
subsequent hybridization to the microarrays were performed at the Molecular Profiling 
Laboratory, MGH Center for Cancer Research. (ii) p53-/- MEFs were treated with siRNAs for 72 
h and then transfected with ISD. 6 h later, cells were lysed in RLT buffer. Each sample was 
performed in biological duplicates. Total RNA was isolated using the RNeasy Mini kit. RNA 
quantification and quality was assessed using Agilent 2100 Bioanalyzer (Agilent Technologies). 
Genome-wide gene expression profiling was obtained by hybridizing the RNA to the Affymetrix 
GeneChip® Mouse Gene 1.0 ST Array. The cDNA synthesis, labeling, and subsequent 
hybridization to the microarrays were performed by the company Expression Analysis (Durham, 
NC).  
 
Curation of microarray data. Genes were curated as follows: (i) Top 340 upregulated genes 
(>6.1-fold upregulation after stimulation of MEFs with poly(dA-dT)-poly(dT-dA) for 4 h) from 
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GDS1773 (Ishii et al. 2006); (ii) Top 200 upregulated genes (>3.9-fold upregulation after 
stimulation of NIH3T3 cells with recombinant IFNb for 4 h), and top 300 upregulated genes 
(>6.25-fold upregulation after stimulation of L929 cells with recombinant IFNb for 4 h) from 
GSE14413 (Burckstummer et al. 2009). (iii) Top 150 upregulated genes (>1.3-fold upregulation 
after stimulation of 293T cells with recombinant IFNβ for 8 h) from above-described arrays. 
 
 
Network analysis. Network analysis was carried out using PPI data from Ingenuity, the 
STRING database (http://string.embl.de), and PPIs found experimentally in published studies 
(Bouwmeester et al. 2004; Cristea et al. 2010; Li et al. 2011; Pichlmair et al. 2012; Rozenblatt-
Rosen et al. 2012) and in above-described SILAC experiments. 
 
Statistics. Statistical significance was determined by Student’s t-test. 
  
  58 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2: A GENETICAL GENOMICS APPROACH TO UNDERSTANDING THE 
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ABSTRACT 
While naturally occurring genetic variants are known to modulate gene expression (e.g. eQTL), 
limited studies have evaluated the influence of these variants on pathogen responses using 
relevant human primary immune cells. Results from such gene-by-environment studies will be 
crucial to further understand disease etiology of a variety of disorders including infectious and 
autoimmune/autoinflammatory diseases. Here we present a systematic study evaluating variation 
of innate immune responses across a healthy cohort of individuals. We measured gene 
expression of primary monocyte-derived dendritic cells (MoDCs) activated through bacterial and 
viral receptors that mediate innate immune responses to pathogen components. We identified 
natural genetic variants that are associated with the variation in these responses, with some of the 
variants already known to be associated with disease susceptibility. 
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INTRODUCTION 
The human innate immune system is of central importance to the early containment of infection. 
When receptors of innate immunity recognize molecular patterns on pathogens, they initiate an 
immediate immune response by inducing the expression of cytokines and other host defense 
genes (Takeuchi and Akira 2010). Altered expression or function of the receptors, the signaling 
molecules activated downstream of the receptors, or the induced cytokines themselves can alter 
individuals’ propensity to acquire infectious or autoimmune diseases. 
The Toll-like receptor (TLR) and RIG-I-like receptor (RLR) pathways of the innate 
immune system play key roles in detecting infection by various microorganisms, including many 
viruses and bacteria (Akira et al. 2006). Upon activation, TLRs signal through adaptors such as 
MYD88 and TRIF to induce the expression of pro-inflammatory and anti-viral genes, while 
RLRs signal through the MAVS and/or STING adaptors to induce a similar set of host defense 
genes including the anti-viral cytokine, IFNβ (Akira and Takeda 2004; Barbalat et al. 2011). 
IFNβ stimulates the heterodimeric type I interferon receptor composed of IFNAR1 and IFNAR2, 
which activates JAK and STAT adaptors to induce the expression of interferon-stimulated genes 
(ISGs) (Stark et al. 1998).  
Genetic variation in such innate immune components has been shown to increase 
susceptibility to infectious and autoimmune diseases. For example, genetic studies of primary 
immunodeficiencies (PIDs) in humans have revealed that patients with Mendelian mutations in 
MYD88 suffer from recurrent infection by Streptococcus pneumonia leading to meningitis or 
septicemia, as well as recurrent infection by Staphylococcus and Pseudomonas (von Bernuth et 
al. 2008). Mendelian mutations in TLR3 or TRIF increase propensity to herpes simplex 
encephalitis (HSE) (Zhang et al. 2007; Guo et al. 2011; Sancho-Shimizu et al. 2011), while 
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mutations in STAT1 or the JAK kinase family member, TYK2, lead to recurrent infection by 
viruses such as varicella zoster and herpes simplex virus (Dupuis et al. 2003; Casanova et al. 
2012; Kilic et al. 2012). Mendelian mutations in the TLR-stimulated regulatory cytokine, IL10, 
cause infant colitis (Glocker et al. 2010), and variants in IL10 have also been associated with 
type 1 diabetes mellitus (Barrett et al. 2009). Through genome-wide association studies (GWAS) 
common genetic variants in the type III interferon IL28B, which can be induced by viral 
stimulation of TLR and RLR pathway (Coccia et al. 2004), have been associated with the ability 
to clear hepatitis C viral infection (Ge et al. 2009; Suppiah et al. 2009; Tanaka et al. 2009; 
Thomas et al. 2009). Common variants in the IFN-stimulated gene, IFITM3, have been 
associated with morbidity following influenza infection (Everitt et al. 2012).  
A catalog of functional variants affecting the human innate immune system would aid in 
the search for new markers of risk for infectious, autoimmune, or other inflammatory diseases, 
and may help uncover the molecular mechanism behind disease variants of unknown function 
(Cookson et al. 2009; Montgomery and Dermitzakis 2011; Dermitzakis 2012). Several studies 
have measured variation in gene expression in immune cell types such as lymphoblastoid cell 
lines (LCLs), primary B cells, and primary monocytes; and associated this variation with 
genotype data (Stranger et al. 2007; Zeller et al. 2010; Barreiro et al. 2012; Fairfax et al. 2012; 
Stranger et al. 2012). Such studies have identified genetic variants, called expression quantitative 
trait loci (eQTL), that associate with the expression levels of specific genes with statistical 
robustness (Schadt et al. 2003; Cookson et al. 2009). More recently, studies have identified 
genetic variants that associate with the change in expression in response to stimuli such as 
radiation and treatment with oxidized lipids (Smirnov et al. 2009; Romanoski et al. 2010). These 
eQTLs represent gene-by-environment interactions that are not captured by baseline expression 
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studies. Limited studies have systematically measured the capacity of individuals to mount 
innate immune responses and assessed whether underlying genetic variation explains variation in 
these responses. 
  Here we systematically assessed variation in the innate immune responses of primary 
immune cells of healthy humans. We profiled gene expression of cells: (i) at baseline; (ii) 
stimulated with the purified bacterial ligand, lipopolysaccharide (LPS) from E. coli; (iii) infected 
with the virus, influenza A ΔNS1; or (iv) stimulated with the cytokine, IFNβ. LPS stimulates the 
canonical TLR, TLR4; viral RNA from influenza stimulates the key viral sensors, RIG-I and 
TLR3, and deletion of the viral NS1 gene prevents inhibition of the RIG-I pathway (Kato et al. 
2006; Mibayashi et al. 2007; Loo et al. 2008; Gack et al. 2009); and IFNβ stimulates the type I 
interferon receptor (IFNAR1 and IFNAR2) which controls the expression of a large number of 
anti-viral genes (Uze et al. 1990; Novick et al. 1994). Because prior studies have suggested that 
many eQTL are cell type specific (Dimas et al. 2009), we measured gene expression in primary 
monocyte-derived dendritic cells (MoDCs) since DCs play a central role in detecting infection 
and link innate immune activation to activation of the adaptive immune system (Mellman and 
Steinman 2001). We assessed the robustness of these expression phenotypes by conducting a 
serial replication study and identified innate immune responses that are highly reproducible. We 
then confirmed that genetic variation underlies some of these phenotypes. 
 
  
  65 
RESULTS 
Establishment of a system to quantitatively measure innate immune responses in MoDCs 
We first established a robust, high-throughput system to quantitatively assess innate immune 
responses in primary MoDCs (Fig. 2.1a,b). To minimize batching of samples, we developed a 
method to isolate CD14+CD16lo monocytes from peripheral blood mononuclear cells (PBMCs) 
in 96-well plates that yielded a median of 93% CD14+ cells and 98% CD16lo cells.  
Next, we selected conditions to stimulate and infect the MoDCs. We stimulated MoDCs 
pooled from 5 donors with a dose curve of LPS or influenza ΔNS1 (Supplementary Fig. 2.1a). 
We read out gene expression using the Nanostring nCounter system (Geiss et al. 2008), which is 
a hybridization-based method to digitally count transcripts. For each stimulus, we selected a dose 
near the average saturation points of the dose-response curves. The doses we selected (e.g. 15 
ng/mL LPS) are consistent with standard doses used in the field. We then performed a time 
course with these stimuli in MoDCs pooled from 13 donors, and measured global gene 
expression by microarray (Supplementary Fig. 2.1b). We selected time points near the peaks of 
the kinetic curves of induced genes (5 hrs for LPS stimulation, and 10 hrs for influenza ΔNS1 
infection).  
We estimated the robustness of the technical components of the assay by performing 
separate cellular isolations from the same PBMC source, and by performing separate 
stimulations from the same MoDC source. The gene expression of LPS-stimulated MoDCs 
derived from separate cellular isolations from the same PBMC source showed a correlation of R2 
= 0.98 (Supplementary Fig. 2.1c). The gene expression of LPS-stimulated MoDCs derived 
from the same MoDC source showed a correlation of R2 = 0.99 (Supplementary Fig. 2.1d). 
These results suggested that the assay is technically robust. 
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Figure 2.1. A robust system to quantitatively assess innate immune responses in humans.  
(a) Peripheral blood from healthy donors was subjected to Ficoll centrifugation to isolate PBMCs, which 
were subjected to high-throughput magnetic sorting to isolate CD14+CD16lo monocytes. Representative 
flow cytometry graphs of PBMCs and monocytes stained with anti-CD14 and anti-CD16 antibodies is 
shown. The monocytes were then differentiated into MoDCs for 1 week with GM-CSF and IL-4. (b) 
Purified LPS, influenza A ΔNS1, and recombinant IFNβ were used to stimulate the MoDCs. The stimuli 
engage the TLR4, RIG-I and TLR3, and IFNAR pathways, respectively. 
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We then devised a two-stage design to characterize innate immune variation between 
individuals. In stage 1, we collected genome-wide expression data for 30 donors and 9 serial 
replicates. From this data, we selected genes that showed evidence of reproducible expression 
variation and response variation. In stage 2, we collected gene expression data for about 400 
selected genes in 133 donors, and performed an association study using genome-wide genotype 
data.  
 
Comparison of LPS- and influenza-stimulated gene expression among 30 donors 
First, we assessed the level of variation in gene expression of MoDCs from 30 healthy 
individuals (Fig. 2.2a) at baseline and in response to LPS and influenza ΔNS1. Following 
stimulation, we extracted RNA from the untreated and stimulated MoDCs, and then 
characterized genome-wide gene expression profiles using Affymetrix Human Gene 1.0 ST 
arrays. We normalized the expression data using RMA, and subtracted out the effect of sex and 
race using a linear mixed model. Using a pairwise t-test, we classified 837 and 1359 genes as 
significantly (P < 0.05) upregulated at log2(fold change) > 1.0 in response to LPS stimulation or 
influenza ΔNS1 infection, respectively; and 333 and 549 genes, respectively, at log2(fold change) 
> 1.5 (Fig. 2.2b). We found that the upregulated genes were enriched for Gene Ontology (GO) 
biological processes relevant to host defense such as “I-kappaB kinase/NF-kappaB cascade 
(GO:0007249)”, “JAK-STAT cascade (GO:0007259)”, and “cellular defense response 
(GO:0006968)”. We found that the downregulated genes were enriched for metabolic and other 
non-specific pathways, which may reflect morphological or metabolic changes in the cell after 
stimulation (consequently, we gave less focus to downregulated genes in subsequent 
experiments). 
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Figure 2.2. Stimulation of human MoDCs with LPS and influenza ΔNS1. (a) Flow cytometry analysis 
of monocytes isolated from 30 donors and stained with anti-CD14 and anti-CD16 antibodies. (b) Volcano 
plots showing differentially expressed genes after LPS stimulation (15 ng/mL) for 5 h, or influenza ΔNS1 
infection for 10 h. The negative log transformed P values (y-axis) test the null hypothesis of no difference 
in expression levels between untreated and stimulated DCs and are plotted against the average log fold 
changes in expression (x-axis).  
 
 
 
For each gene, we calculated the LPS and influenza ΔNS1 response values by calculating 
the difference between the log expression after stimulation and at baseline. We then calculated 
the variance of the (i) baseline expression values, (ii) LPS-induced expression values, (iii) 
influenza ΔNS1-induced expression values, (iv) LPS response values, and (v) influenza ΔNS1 
response values. While some genes showed little inter-individual variation among the 30 
individuals, other genes showed extensive variation (Fig. 2.3a).  
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Figure 2.3. Inter- versus intra-individual variation in gene expression. (a) Heatmap of selected genes 
in MoDCs of 30 donors. Each column represents a donor sample at baseline, infected with influenza, or 
stimulated with LPS. Each row represents a gene. (b) Selected genes that showed variability in the LPS 
response. The graphs show variation in LPS responses of CLEC4F and TLK2 among the individuals; 
standard deviations are marked for serial replicates. CLEC4F shows good serial reproducibility, while 
TLK2 shows poor serial reproducibility. (c) FDR enriches for known cis-eQTLs. The x-axis represents 
FDR cutoffs for baseline expression data, and the y-axis represents percent of the genes that were found 
to have statistically significant cis-eQTLs in the baseline expression data in other studies (Barreiro et al. 
2012; Fairfax et al. 2012). 
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Comparison of LPS- and influenza-stimulated gene expression within 9 serial replicates 
The observed variation in gene expression may be due to underlying genetic variation, or to non-
genetic factors such as technical noise (e.g. in the cellular isolation or stimulation) or biological 
noise (e.g. expression changes from molecules in the donor’s blood). We hypothesized that 
culturing and differentiating the cells for seven days in a defined medium may reduce biological 
noise compared to lysing cells immediately after collection.  
To directly assess the reproducibility of the expression and response values, we 
conducted a serial replication experiment. We collected fresh blood samples from 9 of the 30 
donors six to nine months after the first collection. We repeated the cellular isolations, 
stimulations, and microarrays using the same assays and conditions as the initial experiment. We 
normalized the microarray data using RMA, and again subtracted out the effects of sex and race. 
We also corrected for the batch effect using surrogate variable analysis. 
For each gene, we sought to determine whether the variation in expression and response 
within the serially replicated samples was less than the variation in expression and response 
among the different individuals. We calculated the false discovery rate (FDR) of inter- vs. intra-
individual variation using a linear mixed model. We identified genes that demonstrated 
significant (FDR < 0.1) inter- vs. intra-individual variation at baseline, after LPS stimulation, 
after influenza ΔNS1infection, in response to LPS stimulation, and in response to influenza 
ΔNS1 infection (Fig. 2.3b). These results suggested that certain innate immune responses are 
highly reproducible and that there could be a substantial genetic component underlying them. 
In order to further assess whether the genes with robust inter- vs intra-individual FDR 
scores may have an underlying genetic component, we determined whether these genes were 
enriched for known cis-eQTLs. We determined the number of genes at various FDR cutoffs that 
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were found to have cis-eQTLs in two other studies: one of monocytes (Fairfax et al. 2012) and 
one of MoDCs (Barreiro et al. 2012). We found that the genes with low inter- vs. intra-individual 
FDR scores in the baseline expression values are indeed enriched for cis-eQTLs found in other 
studies (Fig. 2.3c). These results further suggested that the genes with serially reproducible 
expression and response values (i.e. low FDR values) are likely to be associated with underlying 
genetic variants.  
Because our cohort contained three different populations – Caucasian, East Asian, and 
African-American – we also assessed the robustness of variation among the three populations. 
We calculated the FDR of inter- vs. intra-population variation using a linear mixed model, and 
identified genes that demonstrated significant (FDR < 0.1) inter- vs. intra-population variation in 
response to LPS stimulation or in response to influenza ΔNS1 infection. 
 
Selection of reporter genes 
In order to further assess variation in innate immune responses in a larger cohort of individuals, 
we first created a reporter gene codeset (Fig. 2.4a). First, we selected all genes with a log2(fold 
change) greater than 0.5 or less than -1.5, and with an inter- vs. intra-individual FDR < 0.1 in (i) 
LPS-induced expression values, (ii) influenza ΔNS1-induced expression values, (iii) LPS 
response values, and (iv) influenza ΔNS1 response values. 97 of these genes were shared 
between conditions, while 125 were unique to one condition; in total we added 222 non-
overlapping genes to the reporter gene codeset that showed evidence of serial reproducibility. 
We added 19 genes with known cis- or trans-eQTLs in monocytes or MoDCs as positive controls 
(Barreiro et al. 2012; Fairfax et al. 2012). To capture population variation, we added 21 genes  
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Figure 2.4. Selection of reporter genes for further interrogation. (a) Pie chart showing genes 
represented on Nanostring codeset. The codeset contains a total of 414 unique genes with 222 
representing inter- vs. intra-individual variation genes; 21 representing inter- vs. intra-population 
variation genes; 137 curated (expert) genes including known pathway components and key cytokines; 19 
known eQTLs and 21 known GWAS hits from infectious and autoimmune disease studies; and 35 control 
genes including low variance genes, sex-specific genes, and non-expressed genes.  
 
with a log2(fold change) greater than 0.5 or less than -1.5, and with an inter- vs. intra-population 
FDR < 0.1 in LPS response values or influenza response values. 
In addition to this set of genes, we added 137 genes that are known players in the relevant 
pathways. These included the receptors TLR4, TLR3, RIG-I, IFNAR1, and IFNAR2; adaptors 
including MYD88, TRIF, STING, MAVS, JAK1, STAT1, and TYK2; and key regulated outputs 
including IFNB1, IL28B, TNF, IL6, IL10, and IFITM3. We also added genes such as IL12B, 
ACP5, and STAT3 that are expressed in MoDCs and cause Mendelian infectious or autoimmune 
diseases when mutated.  
As controls, we added 15 genes (e.g. GAPDH) with low variance across the microarray 
data, and 8 genes that were regulated but had response values with low variance. To control for 
contaminated cell types, we added genes that are not expressed in MoDCs including CD3, CD19, 
CD56, and CD235a. To detect possible sample switching, we added sex-specific genes from the 
Y-chromosome including DDX3Y, EIF1AY, and ZFY. In total, we selected 414 unique genes for 
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our Nanostring codeset (Fig. 2.4a). We chose probes that excluded common SNPs (minor allele 
frequency > 5%) except for 11 genes for which this was not possible.  
 
Comparison of LPS-, influenza-, and IFNβ-stimulated gene expression in 133 donors 
We then collected blood samples and isolated PBMCs from 643 healthy donors with 56 
additional serial replicates (i.e. separate blood draws > 1 month later). We isolated genomic 
DNA from each sample and genotyped the DNA on the Illumina HumanOmni1-Quad BeadChip 
and Illumina Infinium HumanExome BeadChip to type about 1.1 million SNPs and 240,000 
exonic variants, respectively.  
We prepared and cultured MoDCs from 133 of the samples so far. In addition to a 
baseline sample, we stimulated the cells with LPS, influenza ΔNS1, or recombinant interferon-
beta (IFNβ), for up to 4 conditions per donor depending on available cell number. We compared 
gene expression and response values for these donors (Fig. 2.5a). Preliminary analysis suggests 
that there are significant cis-eQTLs in the baseline expression, stimulated expression, and 
response values for all stimuli (Fig. 2.5b). Several of these cis-eQTLs, including IRF5, IFITM3, 
and XBP1, have been associated with infectious or autoimmune phenotypes, including systemic 
lupus erythematosus, rheumatoid arthritis, influenza morbidity, and inflammatory bowel disease 
(Graham et al. 2006; Kaser et al. 2008; Stahl et al. 2010; Everitt et al. 2012). 
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Figure 2.5. Variation in gene expression of MoDCs from 133 donors. (a) Heatmap of 414 reporter 
genes in MoDCs of 133 donors. Each column represents a donor sample at baseline or stimulated with 
LPS, influenza, or IFNβ. Each row represents the expression of a gene. (b) Preliminary eQTL analysis of 
selected gene expression values from 133 donors (unstim, LPS, and LPS response). Q-Q plots show 
deviation of actual P-values (y-axis) from expected P-values (x-axis) for cis-eQTLs (red). The 
significance of the trans-eQTL signals (blue) are less clear.  
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DISCUSSION 
Variation in gene expression and to a more limited extent, variation in the change in expression 
in response to a stimulus has been observed in humans for a number of cell types (Storey et al. 
2007). When expression and genotype data are collected for a large number of individuals, 
studies have been able to associate individual genetic variants to the observed expression 
(Stranger et al. 2007) and response variation (Smirnov et al. 2009; Romanoski et al. 2010; 
Barreiro et al. 2012) with statistical robustness. Baseline studies comparing eQTLs in monocytes 
and B cells identified numerous genes with genetic variants associated with the expression of the 
gene in a cell type specific fashion (Fairfax et al. 2012).  
Our study differs from previous studies in that (i) multiple stimuli affecting distinct 
components of the TLR signaling pathway are used and (ii) serial replicates are collected for a 
limited number of individuals to identify the effects of short term environmental differences, 
stimulation, and genetic variation on expression variation. This work has implications for 
decomposing the proportion of variance explained by environmental and genetic factors and 
understanding the different genetic and environmental effects on TLR response components. 
We show that unlike previous work, the estimates for inter-individual gene expression is 
often inflated when only technical replicates are considered. However, both the baseline and 
response expression of a large number of genes are still remarkably reproducible between serial 
replicates collected months apart. We are able to identify key components in both the bacterial 
and viral response pathways that are both consistent within an individual and variable between 
individuals. We show that these results are highly consistent with previous results based on 
mapping studies. We further validated our results by performing a preliminary mapping study 
and identified a number of significant cis-eQTLs.  
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With further analysis, by combining detailed characterization of innate immune 
phenotypes with genotyping data, we can determine how different genotypes influence innate 
immune responses in humans. Using this collection of variants as a resource, we could ask 
whether these variants play a role in various infectious and autoimmune phenotypes in humans in 
vivo. Our results may also point to a molecular mechanism underlying GWAS hits of unknown 
function.  
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MATERIALS AND METHODS 
Reagents. LPS (ultrapure lipopolysaccharide from E. coli K12) was obtained from Invivogen. 
Influenza ΔNS1 was prepared as described (Shapira et al. 2009). Recombinant human IFNβ was 
obtained from PBL Interferon Source.  
 
Study subjects. Donors were recruited from the Boston community and gave written informed 
consent for the studies. Individuals were excluded if they had a history of inflammatory disease, 
autoimmune disease, chronic metabolic disorders, or chronic infectious disorders. For the 
microarray study, 30 healthy human donors were recruited. Donors were between 19 and 49 
years of age; 15 were male and 15 were female; 18 were Caucasian, 6 were East Asian, and 6 
were African-American. For the Nanostring study, 643 healthy human donors were recruited. 
Donors were between 18 and 56 years of age (avg. 29.9); 285 were male and 358 were female; 
363 were Caucasian, 148 were East Asian, 164 were African-American, and 24 were multi-racial.  
 
Preparation and stimulation of primary human monocyte-derived dendritic cells (MoDCs). 
35-50 mL of peripheral blood from fasting subjects was collected between 7:30 am and 8:30 am. 
The blood was drawn into sodium heparin tubes and peripheral blood mononuclear cells 
(PBMCs) were isolated by Ficoll-Paque (GE Healthcare Life Sciences) centrifugation. PBMCs 
were frozen in liquid N2 in 90% FBS (Sigma) and 10% DMSO (Sigma). Monocytes were 
isolated from PBMCs by negative selection using the Dynabeads Untouched Human Monocytes 
kit (Life Technologies) modified to increase throughput and optimize recovery and purity of 
CD14+CD16lo monocytes: the FcR Blocking Reagent was replaced with Miltenyi FcR Blocking 
Reagent (Miltenyi); per mL of Antibody Mix, an additional 333 ug biotinylated anti-CD16 (3G8), 
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167 ug biotinylated anti-CD3 (SK7), and 167 ug biotinylated anti-CD19 (HIB19) antibodies 
(Biolegend) were added; the antibody labeling was performed in 96-well plates; and Miltenyi 
MS Columns or Multi-96 Columns (Miltenyi) were used to separate the magnetically-labeled 
cells from the unlabeled cells in an OctoMACS Separator or MultiMACS M96 Separator 
(Miltenyi). The number of PBMCs and monocytes was estimated using CellTiter-Glo 
Luminescent Cell Viability Assay (Promega). A subset of the isolated monocytes was stained 
with PE-labeled anti-CD14 (M5E2; BD Biosciences) and FITC-labeled anti-CD16 (3G8; 
Biolegend), and subjected to flow cytometry analysis using an Accuri C6 Flow Cytometer (BD 
Biosciences). The remaining monocytes were cultured for seven days in RPMI (Life 
Technologies) supplemented with 10% FBS (Sigma), 100 ng/mL GM-CSF (R&D), and 40 
ng/mL IL-4 (R&D) to differentiate them into monocyte-derived dendritic cells (MoDCs). 5x104 
MoDCs were seeded in each well of a 96-well plate, and stimulated with 15 ng/mL LPS for 5 h, 
influenza ΔNS1 virus for 10 h, 100 U/mL recombinant human IFNβ for 6.5 h, or left 
unstimulated. Cells were then lysed in RLT buffer (Qiagen) supplemented with β-
mercaptoethanol (Sigma).  
 
Microarray gene expression profiling. Total RNA was isolated using the RNeasy Mini kit 
(Qiagen). RNA quantification and quality were assessed using Agilent 2100 Bioanalyzer 
(Agilent Technologies). The cDNA synthesis, labeling, and subsequent hybridization to the 
microarrays were performed by the company Expression Analysis (Durham, NC). The 
Affymetrix Human Gene 1.0 ST arrays were used to obtain genome-wide gene expression 
profiles. 
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Normalization of microarray data and adjustment for confounding effects. Outlier detection 
was first performed. The dataset was then normalized using quantile normalization as part of the 
RMA pipeline. To eliminate possible confounding affects, in particular the batch effect from 
running our array over two plates, surrogate variable analysis was used to identify a number of 
highly significant surrogate variables (SVs) identified through a permutation test and these were 
included in our follow up analysis.  
 
Mixed model estimate for proportion of variance explained by stimulation, environment 
and genetic variants. We used a linear mixed model to model the variance components for the 
expression of an individual gene: 
yi = a x LPS + b x dNS1 + c x Gender + d x Age + α x Interindividual + β x Intraindividual + s1 
x SV1 + s2 x SV2 + … sn x SVn + ε 
 
Mixed model estimates for inter-individual and inter-population variable genes. To test for 
interindividual variability, we tested the above model against the null where inter-individual 
variability is estimated to be 0 (! = 0).  
 
Reporter gene selection. Normalization controls were selected by choosing genes with low 
variance in expression in the microarray data. Additional low variance controls were selected by 
choosing genes with low variance in response to LPS or influenza ΔNS1 stimulation. Positive 
controls that represented genes with known cis-eQTLs were selected from baseline monocyte 
cis-eQTLs in Fairfax et al. (Fairfax et al. 2012) and from baseline MoDC cis-eQTLs in Barreiro 
et al. (Barreiro et al. 2012). Known pathway components were selected from KEGG, Ingenuity 
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Pathway Analysis, and references including (Akira and Takeda 2004; Barbalat et al. 2011). We 
added genes that are not expressed in MoDCs including CD3, CD19, CD56, and CD235a to 
control for contaminated cell types. We added sex-specific genes from the Y-chromosome 
including DDX3Y, EIF1AY, and ZFY to detect possible sample switching. To capture inter-
individual variation, we added genes with a log2(fold change) > 0.5 or log2(fold change) < -1.5 
(biased because downregulated genes are of less clear function by GO categories), and with an 
inter- vs. intra-individual FDR < 0.1 in (i) LPS-induced expression values, (ii) influenza ΔNS1-
induced expression values, (iii) LPS response values, and (iv) influenza ΔNS1 response values. 
To capture variation in population, we added genes with a log2(fold change) greater than 0.5 or 
less than -1.5, and with an inter- vs. intra-population FDR < 0.1 in LPS response values and 
influenza ΔNS1 response values. We did not include genes that had a maximum value of log2 > 
13 across the microarray dataset. We chose probes that excluded common SNPs (minor allele 
frequency > 5%) except for 11 genes for which this was not possible.  
 
Nanostring. The Nanostring nCounter system (Nanostring) was used to digitally count 
transcripts in a multiplex reaction as previously described (Geiss et al. 2008). Lysates in RLT 
buffer were hybridized for 12-24 hours with custom nCounter Gene Expression CodeSets. 
Quantification of hybridized RNA was performed using the nCounter Analysis System. To 
normalize the nCounter data, we first normalized each sample using the internal positive spike-in 
controls, and then normalized the data based on the average expression level of the low variance 
control genes. Surrogate variable analysis was used to eliminate possible confounding effects. 
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CONCLUSION 
 
Main findings 
Aim #1: Identify novel ISD pathway components. By precipitating DNA from a 
cytoplasmic lysate, we identified 184 candidate cytoplasmic DNA-interacting proteins. 10% of 
these proteins are known to be involved in innate immune pathways already, and the others may 
be useful as a resource for study of innate immune sensing as well as host-viral interaction. We 
silenced 809 candidate genes, measured the response to dsDNA, and connected resulting hits 
with the known signaling network. We identified many novel genes that decreased or increased 
the ISD response after knockdown; these may be useful as a resource for identification of new 
pathway members. We validated ABCF1, and demonstrated that it is a critical protein that 
associates with dsDNA and the known DNA-sensing components, HMGB2 and IFI16. We also 
found that CDC37 regulates stability of the signaling molecule, TBK1, and that chemical 
inhibition of CDC37 and several other pathway regulators (HSP90, TBK1, PTPN1, PPP6C) 
potently modulates the innate immune response to DNA and to retroviral infection in Trex1-/- 
MEFs as well as in AGS patient cells. These molecules may be therapeutic leads in TREX1-
mediated disorders such as AGS. 
Aim #2: Characterize variation in innate immune responses in primary dendritic 
cells in humans, and determine whether the functional variation is caused by genetic 
variation. We developed a high-throughput system to quantitatively measure innate immune 
responses in primary human MoDCs. We characterized variation in responses between 30 
healthy donors, and described which variants are reproducible using a serial replicate design. We 
then developed a reporter gene codeset, characterized variation in responses between 133 healthy 
donors, and performed an initial association study with corresponding genotype data. We found 
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cis-eQTLs in genes in response to the stimuli, several of which are known to be associated with 
infectious and autoimmune clinical phenotypes.  
 
The strengths and weaknesses of approaches taken 
(i) Proteomics.  
Strengths: The proteomics approach that we used to identify candidate cytoplasmic 
DNA-interacting proteins and candidate STING-interacting proteins was both unbiased 
and quantitative. The SILAC approach allowed us to find many more proteins than we 
could visualize by PAGE (the problem with cutting out bands after PAGE is low 
sensitivity; additionally, protein bands can be obscured by non-specific background 
bands).  
Weaknesses: Proteomics approaches have some false positive rate due to non-
physiological interactions that occur in vitro after lysing the whole cell and concentrating 
the lysate in buffer. This was perhaps more markedly seen with our STING pulldowns, as 
most of the hits did not have a functional effect in our siRNA screen. We also had some 
false negative rate. For example, we did not identity the interaction of TBK1 with STING. 
Some of the false negatives likely occurred because of transient interactions that are 
difficult to capture, in addition to us not capturing the correct time point after stimulation.  
Alternative approaches: In the future, crosslinking could be used to stabilize transient 
interactions. More time points can be taken after stimulation. Different amounts of 
ligands can be used. More controls can be pulled down for comparison.   
(ii) RNAi screening.  
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Strengths: The RNAi screening approach that we used was a high-throughput method that 
allowed us to test many hypotheses in parallel. 
Weaknesses: RNAi has a clear false positive rate, though it is hard to quantitate. 
Originally we wanted to estimate the false positive rate by performing a large-scale 
rescue experiment of our hits, but this was more technically difficult than we anticipated. 
RNAi also has some false negative rate, which depends on the screening library. In our 
screen, we captured expected components including Tbk1, Cxcl10, Jak1, Stat1, and Irf9. 
We also captured Irf3 but only because we used a different siRNA than was in the 
Dharmacon SMARTpool siRNA library. The SMARTpool siIRF3 was toxic; this was 
off-target toxicity, which is one source of false negatives. We captured Sting but only 
because we added the siRNA into the screen. There was no siRNA targeting Sting in the 
Dharmacon library we used; this is another source of false negatives. We missed Ifi16 
since the siRNA did not have a phenotype in our screen. Later tests using a panel of 
different siRNAs demonstrated the partial phenotype shown by the other groups.  
Alternative approaches: Two or more different siRNA libraries can be used to ameliorate 
the false negative and false positive rates seen here, though there is a cost in terms of both 
money and effort to do this. Alternative screening tools such as haplotype screening 
(Carette et al. 2011), ENU mutagenesis (Tabeta et al. 2006), overexpression screening 
(Kawai et al. 2005), and homology-based approaches (Meylan et al. 2005; Seth et al. 
2005) may have a smaller false positive rate.  
 (iii) eQTL analysis.  
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Strengths: Because genetic variants must be causal, genetic association studies have been 
a powerful method to map phenotypes. Nanostring is technically simple and highly 
reproducible.  
Weaknesses: We were limited by our readouts. The microarrays were only performed on 
30 donors, and do not capture all pertinent information about the expressed genes, such as 
isoforms. Nanostring only measured gene expression of a set of hundreds of genes. 
Genotyping only measures a fraction of genetic variants, albeit the most common ones. 
Alternative approaches: RNA sequencing and DNA sequencing captures all the 
information that we lost, albeit at higher cost. 
 
Future studies 
 ISD pathway. Our RNAi screening assay could be scaled up to test nearly the whole 
genome (i.e. the entire siRNA library). This is very practical in terms of cost and effort at this 
point, since the assay has already been set up. This would be a more unbiased approach to 
identifying novel pathway members. The downside is that, because of the false positive rate, it 
may be difficult to determine which hits are on-target. Thus, parallel to this approach, more 
datasets could be generated like the SILAC datasets described above. The STING pulldown 
could be improved as described above. Additionaly, proteins that are post-translationally 
modified (e.g. phosphorylated or ubiquitinated) could be globally measured and used to inform 
the functional data (Chevrier et al. 2011).  
 There are a number of questions that remain about the mechanism by which ABCF1 
functions in the ISD pathway. Is the interaction with DNA direct or indirect? Does ABCF1 
interact with HMGB2 and IFI16 in a single complex or in multiple complexes? Does ABCF1 
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interact with downstream signaling molecules such as STING? If not, what is the role of ABCF1 
in the DNA sensing complex? We had attempted to answer the first three questions, but were not 
able to generate convincing data to answer them at this point, and further work is needed.  
 In regards to the small molecule inhibitors, we are planning to test them in vivo in the 
Trex1-/- animal model. Trex1-/- mice develop severe autoimmune disease notably characterized 
by an inflammatory myocarditis. We will inject each of the compounds into Trex1-/- mice 
intraperitoneally, with vehicle as control. Our readouts will be Ifnb1 mRNA levels in the heart 
tissue of mice, as well as survival. We expect to see decreased Ifnb1 expression in mice treated 
with small molecules, as well as increased survival times relative to control mice. 
eQTL project. Because we did not use all the RNA from the experiment, the remaining 
RNA could be sequenced in the future. We could either wait until costs drop or we could use a 
simplified protocol to sequence only the 3’ ends. Because the design of the experiment and the 
assays are set up, more stimuli and more cell types could be used to generate similar types of 
data. Theoretically, eQTL maps should be made for every cell type x every stimulated condition 
that is relevant in vivo.  
 Similar to GWAS designs, a case-cohort design could be used to ask whether there are 
differences in innate immune responses in the cells of healthy individuals vs. individuals with 
infectious or autoimmune diseases. Given the data described in the introduction, one can 
hypothesize that individuals with certain types of diseases will have altered innate immune 
responses, which could be captured by a case-control design. The upside of a functional 
approach as described here is that it could capture any genetic variation – common, rare, or 
synergistic – in the network (without needing prior knowledge of all its components). This may 
be an advantage over genetic studies which, for example, have difficulties capturing gene x gene 
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interactions. The downside that the cells may be altered by the disease process (e.g. a pathogen) 
or by drugs that the patient is taking, and this may confound the results. 
 
Concluding remarks 
Overall, we demonstrated how high-throughput genomic approaches can be used to identify 
genes and genetic variants that are associated with human disease. Given the abundance of 
genetic data that is currently being collected to identify variants that associate with clinical 
phenotypes, there is an existing need for approaches like these to understand the molecular 
phenotypes of the disease-associating variants. Deciphering the molecular pathways and 
components that are altered in these diseases will hopefully aid in the development of 
therapeutics to target the pathways and components in patients. 
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Appendix A: Supporting information for Chapter 1 
 
 
Supplementary Figure 1.1. Generation of a candidate gene set by curation and quantitative 
proteomics. (a) Cytoplasmic extract preparation. MEFs were lysed in panel of lysis buffers. Lysates were 
immunoblotted with anti-SMARCB1 antibody (nuclear protein) and with anti-β-actin antibody (loading) 
control. Lysis buffers are described in Supplementary Methods. (b) DNA pulldown. MEFs were pre-
treated with IFNβ for 18 h or left unstimulated. Cytoplasmic extracts were prepared and incubated with 
biotinylated ISD. ISD-interacting proteins were precipitated with streptavidin beads, resolved by SDS-
PAGE, and stained with Coomassie blue. Visualizable bands near 55 kDa and 35 kDa were identified by 
mass spectrometry as IFI202B and TREX1, respectively. (c) S35 DNA pulldown. MEFs were labeled 
with S35, and incubated with IFNβ for 6 h or left unstimulated. Cytoplasmic extracts were prepared and 
incubated with or without biotinylated ISD. ISD-interacting proteins were precipitated with streptavidin 
beads, resolved by SDS-PAGE, and visualized by autoradiography. (d) DNA pulldown assays were 
performed in MEFs stably expressing HA-tagged Abcf1 with biotinylated 45-bp dsDNA of various 
sequences. Precipitates were resolved by SDS-PAGE and immunoblotted with anti-HA antibody. 
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Supplementary Figure 1.2. High-throughput loss-of-function screening and network analysis of hits. 
(a) Robustness of siRNA screening assay. Log2 CXCL10 (pg/mL) and CellTiter-Glo luminescence levels 
from representative plates from the siRNA screen were graphed (x-axis) along with their respective 
values from replicate plates (y-axis). R2 values are shown. (b) MEFs were treated with control siRNA 
(siNeg) or indicated siRNAs. Expression levels of respective genes was measured by qRT-PCR. Data is 
presented as mean and s.d. (n = 2). * P < 0.05, ** P < 0.01. 
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Supplementary Figure 1.3. Validation of screening hits. (a) Hmgb2-/- and wt MEFs were stimulated 
with DNA (ISD or HSV60 sequence) for 6 h, and Cxcl10 induction was measured by qRT-PCR. * P < 
0.05, ** P < 0.01. Data in all panels is presented as mean and s.d. (n = 3). (b) MEFs stably expressing 
doxycycline-inducible Abcf1-HA were treated with 0, 0.3, 3, or 30 ug/mL doxycycline. Lysates were 
immunoblotted with anti-HA or anti-β-actin antibody. (c) Validation by cDNA rescue. MEFs stably 
expressing doxycycline-inducible Abcf1(rescue)-HA, Abcf1(rescue), or Irf3(rescue) cDNA were treated 
with siNeg, siAbcf1, or siIrf3 along with doxycycline (0, 0.3, 3, 30 ug/mL). Cells were stimulated with 
ISD and CXCL10 production was measured by ELISA. * P < 0.05 compared with knockdown cells 
without doxycycline treatment. 
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Supplementary Figure 1.4. Targeting of screening hits by small molecule inhibitors. (a) Primary 
murine lung fibroblasts (MLFs) treated with small molecule inhibitors (500 nM celastrol, 750 nM 17-
DMAG, 500 nM BX795) were stimulated with 4 ug/mL DNA (HIV gag-100) for 5.5 h, and induction 
levels of Ifnb1 mRNA were determined by qRT-PCR. Data in all panels is presented as mean and s.d. (n 
= 3). ** P < 0.01 compared with DNA-stimulated vehicle-treated cells. (b) Trex1-/- MEFs treated with 
indicated siRNAs were stimulated with DNA (HIV gag-100) for 5.5 h, and Ifnb1 induction was measured 
by qRT-PCR. * P < 0.05. (c) Ptpn1-/- MEFs and Ptpn1-/- MEFs rescued with Ptpn1 cDNA were treated 
with indicated siRNAs and then stimulated with ISD for 26 h; CXCL10 levels were determined by 
ELISA. As expected, siPtpn1 increases CXCL10 levels in rescued MEFs, but does not have a significant 
phenotype in Ptpn1-/- MEFs. * P < 0.05. (d) B6.C3H-sst1 (Sp110 LoF) cDCs and wt control cells were 
stimulated with DNA for 6 h, and Ifnb1 and Cxcl10 induction was measured by qRT-PCR. ** P < 0.01. 
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Supplementary Figure 1.5. Identification of components of DNA sensing complex.  
(a) Immunofluorescent microscropy of MEFs expressing HA-tagged Abcf1, stained for HA, calreticulin, 
and DAPI. Merge of images as well as line intensity graph is shown. (b) MEFs treated with indicated 
siRNAs were stimulated for 3 h with ISD or in vitro transcribed RNA, and lysates were immunoblotted 
with anti-phopho-IRF3 (Ser396) antibody. (c) MEFs were stimulated for with ISD for indicated times, 
and lysates were immunoblotted with anti-phopho-TBK1 (Ser172) antibody. (d) MEFs treated with 
indicated siRNAs were stimulated with DNA (HIV gag-100) for 26 h, and CXCL10 production was 
measured by ELISA. ** P < 0.01 compared with DNA-stimulated control siRNA (siNeg)-treated cells. 
Data is presented as mean and s.d. (n = 3). (e) Microarray analysis of MEFs treated with siRNAs and 
stimulated with ISD for 5.5 h. Log2 fold changes of selected genes relative to unstimulated siNeg-treated 
cells are displayed as a heat map. Data are averages of two biological replicates. (f) Raw data from Fig. 
5h. Trex1-/- MEFs treated with indicated siRNAs were stimulated with 300 U/mL IFNβ for 8 h, and 
expression of Abcf1 mRNA as well as induction levels of ISGs were determined by qRT-PCR. ** P < 
0.01, *** P < 0.001 compared with IFNβ-stimulated siNeg-treated cells. Data is presented as mean and 
s.d. (n = 3). 
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Supplementary Figure 1.6. Inhibition of identified regulators by RNAi or small molecules 
modulates the innate immune response to retroviral infection. (a) wt or Trex1-/- MEFs were infected 
with retrovirus for 21.5 h or left uninfected, and induction levels of Cxcl10 and Ifit1 were determined by 
qRT-PCR. ** P < 0.01. Data is presented as mean and s.d. (n = 3). (b) wt or Trex1-/- MEFs treated with 
indicated siRNAs were infected with retrovirus for 21.5 h, and induction levels of Cxcl10 mRNA were 
determined by qRT-PCR. ** P < 0.01. Data presented as mean and s.d. (n = 3). (c) Trex1-/- MEFs treated 
with small molecules at various doses were infected with retrovirus for 21.5 h, and induction levels of 
Cxcl10 mRNA were determined by qRT-PCR. Data presented as mean and s.d. (n = 2). (d) TREX1 
mutant (AGS patient 1: R114H/D201ins; AGS patient 2: R114H/R114H) human fibroblasts and healthy 
control fibroblasts were treated with vehicle alone or small molecule inhibitors and infected with 
retrovirus. Induction levels of the ISGs, MX1 and IFIT1, were determined by qRT-PCR. Data are 
averages of triplicate wells. Small molecules were used at: 500 nM celastrol, 100 nM 17-DMAG, and 500 
nM BX795. * P < 0.05 compared with respective cells that were treated with vehicle control and infected 
with retrovirus. 
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Supplementary Table 1.1. STING-interacting SILAC hits 
 
!"#"$%&'" !"#"() *+,-./01 234&*5" !"#"$%&'" !"#"() *+,-./01 234&*5" !"#"$%&'" !"#"() *+,-./01 234&*5"
!"#$% &'()' '*&+, -*--./-- 012' ,'33'' -*++& 3*-,.4-5 6789) )'':' -*&)' )*),.4-'
;"1'<' ))+,: '*5(3 -*--./-- =>%<1) '+:&( -*+:' &*)(.4-5 6?1@) )((-( -*&-: )*)&.4-'
;"1)<, ','+&( '*&+: -*--./-- !<A", (,:+- -*+&( &*:).4-5 =<A? )-()5: -*&-, )*',.4-'
B@<C< '5-)&5 '*,&5 )*&:.4)( ;"D$'E ',,:&) -*+&' :*-5.4-5 ;#F1' ',):&' -*&-' )*',.4-'
!EG,+<& )5+&& '*)&5 '*+&.4), HCG5'I1< ''3&() -*+3+ :*,).4-5 ;JA)I, ))3&& -*&-) )*'(.4-'
;"1'I) 3&+&' '*-&+ ,*-).4)' KA12: )+')(+ -*+3& :*(5.4-5 !EG'(<, ):3&5 -*3++ )*'3.4-'
L)+MN%),(&O (':&5 4)*+)+ '*5'.4)) P1$) )-,+3, -*+(, +*+5.4-5 LCD(3 ('(), 4-*3', )*,5.4-'
QOF#$( ')3&33 )*+:: '*55.4)) H',--+3H)-P#J ',-:33 -*+,5 )*'5.4-, HE#$") ')3&-( -*3+) )*,3.4-'
M"<2) )-&):' )*+5) &*-&.4)) QEAD, ,-+'3 -*+,- )*'+.4-, KOE1) &('&, -*3:+ )*,+.4-'
R91'-( &-3++ )*+-5 )*(&.4)- ;IGC, )+'++ -*+'& )*,5.4-, R#?G@ 353(' -*3:& )*5).4-'
SC<G' '',,5 )*:-& )*''.4-+ =18+ ''35,' -*+), )*(3.4-, S#F '',(' 4-*3), )*53.4-'
K<A1) ))(5( )*&+( )*(&.4-+ T8U)- )&5(5 -*:+: )*:,.4-, =$2' &-5,( -*3:' )*5&.4-'
;$8)- )-'(33 )*&:3 )*:&.4-+ S<A? '',') -*:+& )*:(.4-, ?8<") '-3(' -*3(5 )*:3.4-'
K<A1)5 (5&'(, )*&&' '*(-.4-+ !"",< )35,- -*:+& )*:3.4-, 6#?")@)I (3&-' -*3(5 )*:3.4-'
VOA)E, ''3)-) )*&'5 3*5:.4-+ ;"1)I) ))+,) -*::5 '*),.4-, M<"'C ''3(3' -*3(5 )*:3.4-'
!9A25 '-+,' )*&'' 3*:,.4-+ K113A, ('-,3 -*::, '*)3.4-, H7I(A, )-+&(5 -*35& )*+&.4-'
;G<G< )-&5&3 )*335 '*-+.4-: =18& ',,&'3 -*:&3 '*,'.4-, H<?1, )',3& -*353 )*++.4-'
B81'< ')+&, )*3'( 5*,:.4-: QG$)E) ',)3(+ -*:&( '*,5.4-, !A1AI '-:): -*35) '*-&.4-'
K$1") &)&-) )*(,& '*)3.4-& PAI1) :)+)- -*:&) '*55.4-, RGJ<1)E )-(:(( -*3,+ '*-+.4-'
.#25%) '-:35, )*(): ,*--.4-& L@D,& '-:)55 -*:35 '*3).4-, WC@< )3:': -*3,5 '*)+.4-'
R8EG) &-&3+ 4)*553 ,*)).4-& H81O (+-5' -*:3, '*35.4-, B<1) '),(5 -*3,) '*',.4-'
.#2,% (,,(3 )*(-3 ,*3&.4-& K2JE ):35) -*:3' '*3&.4-, H<$D )',,- -*3': '*,-.4-'
.1A? )-&(-: )*5&( 3*',.4-& XA")5 )3335 4-*&+) '*&).4-, K2<? ',&:', -*3'3 '*,,.4-'
.CG5 ',53++ )*55+ +*35.4-& BFOF,,Y 3&:&: -*:3- '*&5.4-, RG<1% (5,+' -*3)3 '*('.4-'
T8?1C' &3&3, )*55, )*-&.4-3 LC8?" ),'-- -*:(: '*&+.4-, !FG, ),--3 -*3)' '*3-.4-'
H<C 3+&)+ )*5)' )*&&.4-3 K<A1+ :-':( -*:(( '*:&.4-, K?FC) &-'5& -*3-+ '*3&.4-'
HE"G 3&,-- )*,+& '*'&.4-3 ;A@%O25- '3:&,+ -*:53 ,*)&.4-, !OG), ))-,&+ -*3-' '*:).4-'
H@C5 )-&+,' )*,+( '*,(.4-3 TC$) )---)+ -*:,5 ,*(3.4-, V@8C) ',53:3 -*(++ '*:+.4-'
T"<15 )&&(: )*,&& ,*)'.4-3 !<A") '-''& -*:,5 ,*(&.4-, WOFC' ''535- 4-*(': '*+'.4-'
;IGI& )),-3 )*,'' &*,&.4-3 X#2)) )3(() -*:,' ,*3(.4-, Q<A" )55(- -*(+( '*+:.4-'
L$<ZG), ',((3& )*':) )*,3.4-( ;A?' :,&-) -*:'+ ,*&(.4-, RG<1C' 3:'+: -*(+5 ,*--.4-'
[18( &','' )*'35 )*&3.4-( [18& 3('53 -*:'& ,*:,.4-, !<FF(- 3:3(, 4-*(', ,*-'.4-'
!FG@C) &5,(( )*'(& )*+3.4-( =18( &-(&' -*:', 5*--.4-, T"@2C)E '&-3:( -*(:: ,*),.4-'
;?GG,E) ,'-3,' )*'(( '*--.4-( WF$< )3+-( 4-*&5, 5*5,.4-, L@D+ ),')) -*(:' ,*'&.4-'
K@I' )'-,5 )*''3 ,*-(.4-( R<<'( ',)&), -*:-) 5*+,.4-, !EG,<' )&'(5 -*(:) ,*'+.4-'
L$F") ),5,, )*''- ,*,'.4-( TGF' )&')3 -*:-) 5*+5.4-, T<"'< ','-:& -*(&: ,*,&.4-'
R9F<) )-)&-3 )*')- ,*:'.4-( R8E( ((+:+ 4-*&': (*)).4-, P<I)5 3:,3( -*(&: ,*,:.4-'
!8D' '-3&5 )*'-- 5*5).4-( 6?1<5 )(('( -*&+3 (*''.4-, T"@2C' )&&3: -*(&: ,*,+.4-'
QU#$) &5((: )*):+ (*-+.4-( TF?)+ &')++ -*&:5 (*:'.4-, !OG,)< 3+)3' -*(&& ,*5).4-'
;"1)<) ))+': )*)&& 3*-5.4-( SC<G, '',,( -*&:, (*+-.4-, SC<G) '',,, -*(&5 ,*5+.4-'
!?A) )-&(), )*)5: +*-).4-( 012,I 3:),5 -*&:- 3*-(.4-, W<?)E &3),- -*(3+ ,*3-.4-'
RF# 353:( )*)5) +*:3.4-( =FF" &33)5 4-*&-( 3*,+.4-, ;GE7 )-5))' -*(3( ,*&).4-'
B2AG ''-5' )*)') )*'&.4-5 012) )+&-5 -*&(3 &*3,.4-, !O1"+ (,:3- -*(3, ,*&:.4-'
K#%? '&3:53 )*)-& )*(,.4-5 K$J1 (+-5& -*&(, &*:-.4-, R8F8) '))(5: -*((: ,*+).4-'
W#%, )3::' )*)-, )*3).4-5 W<A1) &,)(: -*&5: :*''.4-, 0F1? '''5& -*((3 ,*+:.4-'
H$8") ',5(+5 )*-+( )*:-.4-5 L"D,E '-+'-- -*&53 :*,-.4-, W<A? )-&-5( -*((3 ,*+:.4-'
;AI1 )):,& )*-+) )*:+.4-5 !)--<5 '-)+: -*&,& +*-3.4-, W#%) )3::) -*,,, 5*)+.4-'
V<A) 3&5'- )*-:: )*+&.4-5 ;?GG, &&+:& -*&,( +*').4-, ;EC8< ))3&5 -*(5& 5*'5.4-'
T<$'<) )&)(: )*-35 '*3(.4-5 PA1)' )-&-+5 -*&': +*:-.4-, \CA&& &-53( -*(55 5*,'.4-'
=2#,( &-))- )*-3) '*&&.4-5 B@A<1, ',-&(, -*&'& +*+'.4-, 0?1)( )55&+ -*(5) 5*5,.4-'
.AE#$' '55,&, )*-,+ ,*3(.4-5 H,,--'&H-+P#J ''5)&) -*&'& +*+5.4-, LCD(: ',--&, -*(,3 5*(&.4-'
!OG3)<) (,5') )*-'& 5*)+.4-5 0I<1'E &5,:, -*&'5 )*-).4-' T<"A, )&):5 -*(,3 5*(+.4-'
="1A#1 5)5:-) )*-)( 5*:5.4-5 P1$' '--)5 -*&'' )*-5.4-' HG<A) 3&(-- -*(,) 5*&(.4-'
!<GF)E :,5+, )*-)( 5*:5.4-5 !FG' )5')) -*&'' )*-5.4-' PIF)5 (3'&( -*(': 5*:(.4-'
!GA#I )-(&:' )*--+ (*',.4-5 [18) )-,(&, -*&)+ )*-&.4-' !E2$+ ',&::3 -*('3 5*+,.4-'  
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Supplementary Table 1.2. DNA-interacting SILAC hits. 
 
!"#"$%&'" !"#"() *+,-./01 *+,-./21 !"#"$%&'" !"#"() *+,-./01 *+,-./21 !"#"$%&'" !"#"() *+,-./01 *+,-./21
!!!"""#$!%&'( )#)"* "+,-. /"+",0 1234! !%-!0 !+"** /"+!%% &5260 %)%!) !+*.- "+"%!
!.!""0,7!)&'( ))0.0 "+%,% /"+!"* 14849:" ##!-* !+"." /"+"". &526- 0"#!.! !+!". /"+!%#
0.!"*-0;",&'( ),,)! "+),. /"+!%* 14849:- 00,0#, !+-*) /"+"-) &59< !,))* !+%0- /"+"#)
.*-"*")="#&'( #*%0. !+"*" /"+"). 14849> !!,,! !+-!) /"+"-, &?@AB !,),! "+,## /"+".!
.*-"*!"C!#&'( 0-00!" !+"., /"+!%0 14849D %!.!" !+".- /"+".0 &??9- 0.!,- !+0!! /"+!*-
C)-""%%E"-&'( 00-,#" !+-", "+"%* 1489:5 !%-.* !+*#. /"+"-% &??9* #0%*, !+"*! /"+",.
C5@F! 00*#*0 "+.#, /"+"#) =F'0"05 0)-.. !+0)# !+!#! &F@! !,).# !+"-% /"+",#
CB(5G0 0-!)*0 "+.0) /"+"## =F'H! !%,%# "+%0" !+--* &F@0 !,#!. "+,)) /"+".0
C49-05 )#)0. !+*"% /"+")# I'F00 !!""-- !+-0# /"+"%, &F@- ),0)- "+.#- /"+!""
C4J:* !!#*) !+!-* /"+""% I'F0: !)%)- "+*** /"+"#% &F@* !")-** !+!%" /"+"..
C4J:% !!#*# !+-!# /"+"%. $>G: !).0. !+%%, /"+"-. &F@% #0!%! !+""" /"+"##
C9?J! !!#,0 !+!*, /"+"%. $>G5 !).-0 !+*". /"+!*% &9:! ).0#% !+0!* /"+"#"
C9BF #0!"- "+.,* /"+")* $'3- !)..0 "+,"" /"+!"" &9:0 !,.,! "+,.% /"+"))
C9HJ ))*". !+0.. /"+!"" $KL!"""**"). !"""**"). !+0-0 !+!"% &9:- ).0*" "+#", /"+"##
C6@@! ),"," "+,#, /"+",% M>G! !#**, !+)*! /"+!!" &99-. 00#%00 "+*.) /"+!-%
C6@@0 #%*%0 !+0*- "+!)" M>G0 !#**. !+*-% /"+"%* &859! .!,!" !+!-- /"+"%-
C6@@- ##,.# !+!." "+!## MN8F*B0 %)-,# "+)#* /"+"), &6B!>! ))*", "+%%) /"+0*%
C6F!: ))*"- "+,%, /"+",! M93 0).-,% !+".0 /"+"") O:2G>! %)"*% "+)*! "+",0
C6F!5 )),0, !+0-0 /"+!*, M6G0 !#).% "+*.) /"+",* O?859! )).#" "+#!) /"+"*,
76H0 ),%%" "+-00 !+!.) M6G- !#).) "+.*. /"+".# OF860 0"-.0 "+%-* /"+"%)
L@>@!0* 0-*-.. "+)!) /"+!0. M6G) !#).. !+"*# /"+0-- OF86- 0"-.- "+%-" /"+"))
L?9!#" %*%-., "+%*# /"+-"0 M6'0 #))0) "+.0! "+"0) OF86# 00%"0# "+*,* "+"0!
L3359! !")!*- "+%%- /"+!-* MH:9!5 !##%% !+!!. /"+!!% O(9!: 0!*"0 "+*0. /"+".0
L'859 !0),) !+"!) /"+"#- MH:9* !##%. !+"0% /"+"** O2:8@:B! %*-." "+.." /"+".%
L440 !0#,. !+-.- /"+"0% MP559!: !.*-0 !+!"" /"+"), O489: %-)"# "+."% /"+",!
L8@9 !0,", "+,). /"+""! Q:3( %)!#* !+!-) /"+"), O4J, )))!) "+#%% /"+")#
L8?5! !0,!0 !+"#. "+"0- Q?'B! #0##* !+!-! /"+!)% O82 0".!" "+*#% /"+!!*
L8?5-B! 0)*0# !+0-* /"+"!, QF'5 !."0. "+..% /"+00. O659! -.!#)" "+,", /"+"0,
L8?5-B0 0".)*# "+%%, /"+!,- QHGB! !.0"# "+.0* /"+"#. OD5! 0""0* !+)%! /"+"%0
L6>: %)**, "+%*" /"+!%0 QD:(0 #*!-# !+!%! /"+!"% R59 0!-#* !+0", /"+"%*
;:S:9! #"0*. !+!*# "+"-! K5F@! !".)., "+##" /"+!"! R@F?- 0",**) !+%!- /"+"%#
;>5! !-!,* "+.)* /"+"#- K33! !.0,* !+-*! /"+".# R@F?5 0!*0% !+,"" /"+"#0
;>50 !"#,.) !+".% /"+"0) T:89! !!%*% !+!.* /"+!-* R>3 0!))% !+*-# /"+!#.
;>J*# )##%% "+-0# /"+!*, T:890 !!%*) !+0#" /"+".0 R>9! !"*..* !+""# /"+",%
;>J*, 0-*-#* "+*%" /"+"## T:89- 0-%%.# !+0** "+0"- R?:>! 0!)#) "+*,- /"+""%
;?( !!""%0 !+"," /"+"-. T@4: !.%-. "+#%, /"+"0# RF:2 0!#." !+-0- /"+"-!
;GJ-) #0!)0 "+*#) /"+""% T>':- !*.0# "+*#! /"+"0, RG?J! )#0#) "+)!) /"+".0
;4:<@, !".)#! !+*.! /"+")) TGF) #",,. !+"". /"+".. RGN@* 0!).! "+%*) /"+"%-
;8! !-*.) !+*)! /"+"0# T(20 !.#*) !+0!) /"+"%" RGP4! ##.)0 !+*". /"+".,
;8:9! ))%%) !+)%! /"+"0. T4(9 %,"*# !+-0" /"+"#0 RN9! 0!,), !+0!" /"+"#0
;83! !-*,* "+*0) /"+"-# TNB5 !.,#" !+!*, /"+!"* RN90: 0!,#- !+0,. /"+""*
U*-"""*Q"*&'( 0!"#%# "+*)# /!+)%- TNB>0 !.,#0 "+#-. "+"-, R8?J! 00"*" !+,-0 "+,-0
U?F!> )))%) !+!"# /"+"-, TNB?- %,""! !+!%% /"+".! R8'9* %)*"* !+-#% "+!0*
U'F06! !-))% "+%!! /"+".# TNB8!@ 0""!) !+#*. /"+"%0 R82H) )),0) "+.-! /"+""*
U'F060 )#0"* "+%!. /"+"## TNB8!> 0""!. "+.", /"+"%# R82H)!: -0.!)0 !+--* /"+!!*
U'F06-J 0),"% "+%-, /"+".0 TNB80? ))*0" !+)%0 /"+"-- R64:J %-*0* !+%0. /"+"#0
U'F%5 00),.0 "+.%% /"+")) TNB80G 0*%.*! "+,-* /"+")" RHF0 #*"** !+)0# "+"0)
V:2*,5 00-)"! "+*0! "+""0 TNB8-: 0!..-0 !+"*- /"+"#! W5HF 0!*0, "+,,, /"+".*
V5JN!. %"#%% "+%0* /"+"#) TNB8-5 #"*0. "+##, /"+")% W69-, 0."-% "+)#) /"+".!
V?4! !*!%) !+0*! /"+"*# TNB8-@ #**!* !+%.0 /"+"%- X8(! 00-)# !+"*0 /"+"*!
V83! !*-"" "+)), /"+!!# TNB8-> )#")% "+."% /"+")- Y>8#) 0*!)0# "+)!. "+""-
E:H:* !**)- "+))! "+"-0 TNB8-? 0),-, "+.-) /"+")# Y84 00*0# !+*#! "+"!0
E450B! !*),* !+0,! /"+"-" TNB8-F #"*". !+%%. /"+"." Z59! 00*-- !+0*! /"+!%)
1!FJ 0*-%0, "+)") /"+!-, TNB8-3 )#*.) "+,)* /"+",. Z9: 00%," !+*-, /"+!*%
1'6H!G!: .".-. !+%)! /"+",) TNB8-G #.,0, "+##) /"+!-" Z8@@! 00%,* !+-,) /"+!*.
1'6H!G!5 %)#"0 !+%." /"+".% T8(:805 !,".. "+*-! /"+"%# Z8@@% 00%,) !+!!- /"+!"-
1'6H!G!@ %"#". !+*)" /"+"#, T88J! !.,-- !+*#, "+",0 Z8@@) !*-#% !+0#) /"+!""
1'6H!G!? %"#", !+"". /"+"#- T6'9! !"!#-, !+!,- /"+"#- [5J! 00)". "+0%" /"+".-
123:! !%-)! !+*** /"+"-- TP@80 ),"%! !+"%* /"+!-0 \@-G!% ),".0 "+)!" /"+"%-
123:0 !%-)* !+)"- /"+"0, &:533H5 !,-%0 !+-%, /"+")% \4FJ! ,.,,, !+.-% "+*"*
1235! !%0., !+*"- /"+".! &520. ).0#0 "+.!) /"+"0" \8:45- 00)*", !+0#* /"+!0)
12350 ,#!)% !+%%" /"+")# &52-, !#"#,! "+),! /"+"0,
1235- !%-%* !+--# /"+!-0 &526! %).#. !+!"" /"+"".  
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Supplementary Table 1.3a. siRNA screen (DNA SILAC). 
 
!"#"$%&'" !"#"() *"++,-."/0!+1 +1234*5*6789$:2;'6< !"#"$%&'" !"#"() *"++,-."/0!+1 +1234*5*6789$:2;'6< !"#"$%&'" !"#"() *"++,-."/0!+1 +1234*5*6789$:2;'6<
!"#$%&!' 945520 11.86 ()*+, -.,./ 0,1222 -342, &556/ 73./8 ,82311 24.3
9:;, ./-,- 886771 8.66 ()*<- -.,-3 .7.788 --428 &;=- -8207 -813- .40/
-0-1138>-2&%? 22303 080..1 --482 (<:<6@ .-0-1 /3,1/ .4.- &;=/ -12,// 8/-103 --488
30-1/,3A18&%? 2882- 332801 84./ (<:6B, 338378 80,78. -343. &6B- 2037. -112- .41.
0/,1/12917&%? 7/.30 ,3/,-8 -14,2 (<:6B+ -.,0/ .,3./. -34-7 &6B3 -808- 383,1 2433
0/,1/-1'-7&%? 3,33-1 -2/317 -143/ (<:6C --88- 31,,.. 24,- &6B, 203/1 71,7. 2483
'+=;- 33/7/3 /,2,-0 24-7 9;%313+ 32,00 -1-221 8438 &:+6- 0-8-1 22--2, -14,3
'D?+E3 3,-2/3 70-3/8 -1407 9;%F- -.8.7 0-,7-8 -34-3 &$D-C- 22/18 30,170 8413
'<6,3+ 27230 08-312 -3472 G%;33 --11,, 238728 --4.3 HB)EC- .21/. 3.,3.1 7401
'<IB/ --7/2 .8/317 -1433 G%;3B -2.2, 073.8, -14,0 H5:+6- 22071 87-//- -34-0
'<IB. --7/7 2/3880 -141- JCE- -7//8 /10/23 --40, H;:$3 31,03 0-.1- 24-8
'65I- --783 2/002, -3430 JCE3 -7//0 78371- -347/ H;:$, 31,0, 7-087 2411
'6D; 73-1, 2-3-8- 84,3 J":;/D3 .2,87 020833 -3427 H;:$7 33.137 /18-13 -142-
'6FI 22/10 0/,.8. -3478 J6* 320,8. ,0.1.- 8402 H)B:=BD- ./,01 30.111 -14,3
'$==- 28181 0880-. -34-. J$E3 -720. 0,1070 -3411 H<:6B .,217 /083.0 8400
'$==3 7./.3 8,,11. -34/1 J$E, -7202 777.-- -34,- H<I8 222-2 8.3,3/ -3483
'$==, 77807 831208 --40. J$E2 -7200 7-1020 -34-7 H@+- 3113/ 837.1. -14-0
'$;-B 22/1, 7302,7 84-, J$%3 72232 0,--.7 -340, K+6 3-,7/ -.//-7 8417
'$;-+ 22838 .2-781 84.8 JFB6-+ -77.. ,/322/ 8402 K=;5, 318//2 032,1, --42,
L**+6- -12-/, 383/80 742- JFB6/ -77.0 .27-3- --478 K=;5+ 3-/3. 7/.288 -3431
L%:+6 -3282 /--28. --478 JM++6-B -0/,3 -17,8- 04,, KC* 3-22. /..,1. --47-
L<<3 -3780 -2-/01 0403 !B*? .2-7/ 73312/ -343, KC6- -1/00/ /381-, 04,1
L:=6 -3818 71/021 -14/0 !5%D- 7377/ 28038/ -1437 K5BC- 3-272 7,012, -34.0
L:5+- -38-3 .2-0/7 841. !;%+ -0130 07-.20 --402 K;B) 3-701 72-8,2 -3407
L:5+,D- 32/37 /--0,0 -14./ !FED- -0317 7.8,,. --40. KE5)%$ 3-17.7 2732-0 -343-
L:5+,D3 3102/7 88...- -14// !@B?3 7/-,7 2123,2 -347/ KE5I- 27372 ,-0.,. 8400
ABNB6- 713/0 /780.3 -1403 O+;=- -10208 00381. --42/ KE"=/ 3-20- 38../. --4-/
AC+- -,-8/ -00-,2 8427 O**- -038/ //170- -147. KEM<- 77023 -8307, 84.2
AC+3 -17802 72//,/ -3431 PB:6- --./. 282//. -34,0 K"6- 3-828 .03311 -143/
A5? --11.3 031080 -341. PB:63 --./2 /8.3.3 --427 K"63B 3-87, ..2201 --40-
AEI,2 73-23 3..382 -14.7 PB:6, 3,..07 /31,/7 -14.. K:5I- 331/1 ..8220 -3431
A<BQ=8 -1027- 783301 --4-8 P=<B -0.,0 32.1,2 -1420 K:%6/ .2/1/ 2182-2 -1470
A:- -,/02 017030 --477 PC%B, -/037 -8.310 -14-, K:)F2 22832 72727, --4/2
A:B6- 22..2 288,30 -14.. PE;2 71880 28,/2- -34.1 K:)F2-B ,30-23 2-,332 -3478
A:*- -,/8/ 82308 048. P?)3 -07/2 ,.-80, --4// K$<BI .,/3/ .3,021 -3472
R5;-C 222.2 21-.2, -,411 P<?6 .81/7 0381-/ -1478 KF;3 7/1// 7132.. -340,
R%;3$- -,22. ,7,., .41- P"D+ -0871 81.0,2 -1402 S+F; 3-/38 3--7,- -14-2
R%;3$3 2731/ 332,, /421 P"DC3 -0873 ,,/-- 8411 S$6,8 301,. ,3-7,. -1488
R%;3$,I 3281. 2,1,3 2432 P"D5, .811- 72281/ --401 T:?- 33,27 7/2012 -341-
R%;.+ 332803 088-/ 74-3 P"D:,B 3-00,3 2,3/0 .423 UC:72 3/-237 /.--1/ 8480
V+I"-0 .17.. ./23,3 --487 P"D:,+ 71/30 322./1 0487 U:< 33/37 /32,1. -14.3
V5<- -/-.2 ..73,0 --48/ P"D:,; 71/10 .,7-1 24/0 W+6- 33/,, ,8,810 -14,3
V:*- -/,11 2.782, -14/0 P:?B:3+ -8100 77./3 24.2 W6B 33.81 731/,2 --42/
XBFB/ -//2, 0.1828 --43, P::I- -08,, 8270,, --408 W:==- 33.8/ .07/20 -143/
X5F/ 2721/ 7.33,8 -34.0 P$%6- -1-7,8 /,-,72 847/ W:==. 33.82 7-088- --42-
X<+3D- -/28/ -33808 -1413 PM=:3 281.- 7/78,1 -342, W:==2 -/,7. .,008/ -14/2
(-;I 3/,.38 ,1080 .4-1 &B+**F+ -8,.3 7/,-1/ --4.2 Y=,E-. 28103 70,2,2 -347-
(%$F-E-B 010,0 3-738, --41, &+)30 20373 .-,313 8471 Y<;I- 80888 07280/ --478
(%$F-E-+ .2713 773/72 -3487 &+),8 -7178- 3.-,3 .438
(%$F-E-= .1710 .10128 -347- &+)$- .2070 227.,- --4/1
(%$F-E-5 .1718 7..3/0 -34,1 &+)$3 .2.-2 .1,823 --47/
()*B- -.,2- .1-007 840. &+)$, 317-0- 03/-7/ --401
()*B3 -.,2/ 0-.2.3 --40- &+6Q -822/ 772.87 --488
()*+- -.308 72733. --4.0 &5=ZD -828- 70312, --427
()*+3 87-2. 2.2,73 74,- &556, 30-8, 7.3,// -3480  
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Supplementary Table 1.3b. siRNA screen (Microarray). 
 
!"#"$%&'" !"#"() *"++,-."/0!+1 +1234*5*6789$:2;'6< !"#"$%&'" !"#"() *"++,-."/0!+1 +1234*5*6789$:2;'6< !"#"$%&'" !"#"() *"++,-."/0!+1 +1234*5*6789$:2;'6<
!"#$%&!' ()**+, --./0 12$3%- -,/04, 05,040 --.,+ !6,7- --0-) (,/54) --.0)
8695 *)-5- //044- /.00 :;<407 4+/+0 /+5))* -+.(+ !63= -/-// **5+(4 -,.,/
>7?- *0)/, /4*5*0 /.+* :;$ -)-,+ 0,+/+, -+.4+ !3=@+ -4--4- 44/5-( -+.5/
ABC)- 4+(5* +)4,)- -,.)0 :7CD+- +-55-- *5/)(+ -+.,5 !EF?$- (/)-* /+),(/ --.,0
1G;) -),*- /,+*,,.* -+.)* :"C;- -*54* 44,+0, -+.-) !EB3-5 044+* //5*00 -+.-/
H;I$ ++/0,4 4*04,,.- -,.*) J;D=3D* 04(,( +,(+0( --.*0 !E<7 -/+++ /+0550 -+.00
8?7?K *0)/( +4+-*,.( (.44 J;$4 -))*4 )(+)(/ (.0) L;$-; +)045, /)-5+, --.0/
8?7?7 -0-*, 4))450.- -,.), J72- -))0/ 40(-0+ --.)* L;$-7 +5(0- 0-,05, --.,/
>;=? +-5*5 **5(0*.) -5.-/ J72+ -))0( 504-,/ /.*4 L;$-F --)0)5 0)5()4 -+.)0
&%2?- -(400 )0+,50.- -5.0+ J725 **(5+ 40+(-( -,./) L;$-@ +5(0, /4*)-4 --.0*
Jak1 -0)*- /(/5/0.- -,.,+ J72) -4)4+ 0,++)( -,.(4 L;$+ +)04+/ 404)/ 0.(-
Myd88 17874 *)*004.4 -+.*) J72* ++(/(/ (5*)+0 -+.// L;$5 +)04+4 -((/-4 -,.5)
Trif 106759 +*5/+0.* (.(/ J720 ++((,, 4,+-+4 --.(( L;$D- +5-0** 0+(+55 --.0/
Nod2 257632 /+/(0(.5 --./, J72( +50*45 /00-0 0.0+ L;$D+ +5(0+ +/454/ (.-0
---,,,51,-&%? 0/**+ 0++(4- --.,* JF; ++4(0, 55)*)- -,.-* L@96 4+,4* 004-4) -+.)0
---,,)(:-+&%? 00-(5 555**, --.*0 JFM- -)*+/ *--550 (./) LD9<5 ++(4*( )/(+(4 (.5/
-4,,,-,8-)&%? 00(5- +*)+-4 -,.(* JB;2-, -)*)0 0/-55+ -+.*) L"@- -(55++ ()/+5* -+.5)
-4,,,-(J-4&%? 4**)- )/(-,- -,.5( J%<;2) -,4*+0 +**0)5 (.*- L2D;M 4*)4* (04,5( -+.*5
)(5,*)4N-,&%? 0/+4) 0+(040 --.,- JDEB- -)00- 4*(*,0 -+./- O;=?+ 4))*, 0+0,** --./)
)(55)--P+,&%? 004*0 +,/)5, (./) J=@3- -)0(( (4(,5* -+.,( O;62-- -,--/4 )-*4), -,./+
((5,---Q+-&%? +)*+), 0(**-) -,.(+ J26-547 /5(+) 4-554* -5.5) O;62-+ +)544- (*(0* /.-4
'+5,,*,O+,&%? 5-(+4/ (*+(*- --.() J265) +5/(, 04-,-+ /.0- O;62-) *)4+*5 /(/--0 -,.*)
'7MB-- 0/4*/ ++4*00 0.+4 JI%=- 4)**/ 44)54) --./( O;62( /,+/* 0+*4-/ -+.4(
'7MB5 -,0/0- /*4/*5 --.0, R;2- -*--) 45/5/0 -+.)* O;C0 -/*,/ 004/*4 /./4
'737+ ((5/+ 50))(* -+.,- RK6F* 04-5/ *,()+0 --./( OF72+ -/*+- 5/+40/ (.0+
'B;6 *0)-4 (04(-- -+.)5 R%@B-7 4*0/( 454(40 -,./( O7DB+ 045,4 /5-55+ -+.0)
'@6= --0,5 40+0*4 -,./4 R<@+,; 00/04 4*-4+, --.+, OBD%<* *0540 0-,*5/ -,.)-
'@36D- +54(0 440*)) -+.,+ R<C5 -*545 /,05/) -5.-5 OBC- -/0,( ),04)* -,.0(
'8)*-0-4 +,(5/4 /0,44/ -,.,) R"2C 4)5-/ +4+4(+ (.(- OKD%- 04+)* )5+,*- (.(-
'%<- --05, 0(-+-( -,.05 R"6<;B- 04(/- -()-// -,.,( OKC-5 4+-+( 4,4)0- --.+)
'?35 +54(4 0*-(+( --.0- R"CB-5 -*)55 /+,+/, --.*4 OMF5 +)-(-* 00))*) -,.,)
'D2?+ ++*05/ 45)544 --.04 R$2(,7- ++,+4 ),/,,, --.4+ OMKC -/04* 0+4/(* -+.(,
'2"7KF- --/-, 000-0- -+.4+ 89%+,5 -*(*, 5*(5/0 /.** OM9-- +-(-5- )+-**4 -,.5*
'2"7KF5 /,+/4 *4***) -,.-4 89%+,) -*(*- 4)4+4+ -+.*- OM%2 /5()0 40)0-( --.(+
'6M@;2( +-0))* /0-()) --.)) 89%+,* ++00(* (-)-4, --.(- OMGM%2D 4,(-- 5//,)5 --.(,
'6%B*; +-)/** */54*) -+.)/ 89%+4 40(55 5+-,+0 -,.** O%@7 **(/- -,-*0,- -+.*4
'$7-5 -)+0// 4-+50) (.+* 89%5* 4,--, -/(*+/ (.(5 O%?5F+@ -/4,* +-4)(/ --.5(
'$7-) -)+0/4 -4(/() /.)- 89%)) ((/(( 0000,/ --.)4 OD;+@-7 -/44/ )05--5 -5.,/
'32-7) 04/+- 0**/(- -,.+( 89%)4 -*(*5 -/0)(0 4.04 OD;F/ +5-*,4 /4(005 --.*0
'S,50--/ -4,4(/ */(5-, --.,/ 89%M- 4-*/0 /0-,+/ -+.++ OD;@D- ++05) 5,,450 *.((
T+< -+,-, /,/+/, --.,5 89%3+ -*(*/ -555(/ -,.-, ODKF- -//-, */++4/ --.*,
T;39+ 4))/- 5*/5(, -+.,, 89%35 -*(*( 0+/,4( -+.0) ODK?M;) 0(+-4 5555+, --.-0
T;U+; --0/)/ +5/5*- (.(/ 89%3<- 0/4-5 */+)-4 0.+0 OD?+ +,0+, --4() 5.4,
TN,,044( ++(,,5 *-5)4/ -+.(5 89%3<+ /,/40 0+-(++ -+.++ OD$F6- ++,5/ *504,4 -+.5(
T239 +,4-0* 44(/,, -+.-( 89%3<5 00-)- +,,4() -,.4, OD$F6+ -//+/ *(/0-/ -+.(,
T6B) *4+0- )/-(*- -,.5+ 8@32 -0-)* 5/)(4+ (.*5 O<D -//*) ))+0+5 -+.)0
T$3+ 0(**, 0-/+/5 -+.0- 8M2?- +45(( (-0-+, --.*) O=2 -/(*, *++,54 --.4*
T3=-;- -++5- 4(/-,5 -+.5- 8%@2- 0,)), *055,0 -+.5/ O=2D;+ 00/*5 */40+0 --.+-
N;72- +(/04 05++++ --.*- 8%@2+ *)5(0 /)0-/5 -+.0( O=23- 4-4,- 4-*-+4 -+.50
N;6M$2- *+*,+ 5),)/, -,.-+ 8D0 -0-(5 4*0/)- -,./+ O=6F- -,/404 4*-/(( --.*4
N;$24 -+50( 4-++5/ -+.)+ 8=$D0 +45*0 4)*0(, -,.+) O"BCD +4+,* /*4+, /.4+
NF=75 +,(,(- /-+(54 -+.++ 8=$<- *50+0 5+5+/( -,.*+ O"E)95 -/((/ +/,((( -,.-,
NB+4) 0,*55 050/), --./, 869+ -0505 5))*** /./5 O2<-; -(,)+ 5(/,0, --.04
NB), +-(5( *(0+55 (.05 8694 *)-+5 044+// --.4, O2<-? +)55/+ 4,)++/ -+.+5
NB;BF- 4-/(- /)4*,* --.00 869( -05(- (*4,), -,.0, O6@+ -(,4) -,,,/55 -+.4/
NK=2V +-(-,5 4,4-)( -,.*( 86@< -*()) 0)*/00 -,.45 O$<7( -0(-+ 4/5),( --.04
NMK?- -+0)( */(,/( --.54 8$@+, *4))) ))5)(4 --.(0 O$<K- -(-/0 **-*/) -+.(4
NM<2)F 0054- (*()0) -,.0/ Q;<+ 0454) 4/0-/( -+.45 O$6F- *04)+ *,)/)5 --.5(
NM<2* 40(*( 5*4(40 -+.,- Q;6%B+ -0)0/ /,))0, -+.(4 OI6 *+--/ 40+)/0 -+.5+
NM=+ 0(((5 (,(-/0 --.0) PF=K5 *4))+ 4*54-) -+.(0 OGM%=- +505-+ 40+5+/ -+.4-
NDKF+B (50() /0,,5) -+.), PDMD-, 004+, (,4(-( --.(, W? -(5-4 *4)/4/ -+.5)
N=3=5 -/)// )/,054 -+.,5 PD?-7-0 -00-* /05-,4 --.05 &;7+4; --/(- /(/(54 -+.,4
N"2@+ *)-0, *-0/+) --.4( PD?-7* -00++ *-((// /.)0 &;75F 04+(* *404(5 /./0
N"2$* +04*) +)0)+5 0.4/ PD6;-0 +4)+) 4)-0*+ -,./( &;%+ +),,) (50/4 (.0+
N2K75 +,/(++ 4)(-(( -+.*0 PD6;/ -005( ),--*+ (.5) &;$@K9-7 5+,+(+ /)/0*0 -,.)+
N2MC -,**() 0/4,+/ --.-* X;<25 +5(45( ((--55 -+.)+ &7F?- +)-,* )-,((+ 4.(-
N$9- -+(44 /(+5)+ --.4- X%<;- 0*(4, 0+/-5+ -+.** &7<)5 4-0/) /(/,/( -+.-(
N$26$ --)*0) -4*-(/ (.(4 X%=47 ++5)+ 44/)*) --.45 &=9-*- 04*,) )/0/(* (.(,
NCFD-, -*()* /+)*,* 4./) HFD- -4+-, -5++/- /.5* &=95- +0/4)( *+)/(0 --.**
A-)163B00/K +-(-5+ 54+4/- -,.)0 HK9+F -4+0, -/0)(0 (.+5 &$- +,-)4 )-4+,* (.0-
A-O;$- --,(*4 5,45,- -,.,/ HKD; -4+40 )405*0 -,.)- &$;B+ */-/* 4),)04 -+.)+
A;7- -5-5- /,,4-4 -+.(5 H"I-, -4)*) *,0,4) -+.)+ &$MD- /5)5) 0(0-4/ -+.0+
A;9+ -5-54 40)454 --.)+ H2;+D -,,4,+ /+)**+ -5.55 &$6F- 00//, *0/++( (.+(
A;CC -5-05 4--)45 -+.-) H2UD+ -),-+ /**,() --.(( &32) 0444* 054-/* --.*(
AF22- -5-/) +)-(-+ 4.5, H62$-* 00),4 ***,(/ -,.0/ Y;<B(D +,(,/0 /5(++- --.0-
ABC5G +0(,, +)(-/5 -,.0- H$);)B 000,4 (/))-) --.(+ Y;25,D *,4+) ++*,55 /.+*
ABC) -5+,0 *-5,*5 -,.*0 HE2) -4/)5 -,5(/*0 --./4 YF"3%= 00(), 5+/4+5 /.54
ABC*/ +5,,45 -00(,) /.04 HC- -4/*4 /-/)0) --.), YKF- *0*)0 /,)0*- -+.+/
AMC*/ /,/0- 54/0+* -+.+0 HC+ -4/*/ +((+(( --.,/ YK62%=;5< +,4-4 *450, ).((
ABC0, +5)5-- /0+(,) -+.5/ HGFD- -0(-/ )*0//5 -+.), YK62%=;0 -+),- /(0+(/ -+.,/
A=;$K-D5 -5)+- 55,*-( --.+0 HGB// -4/4) *)*00/ -+.*) YK62%=7( +,4+5 4,4+44 -+.(5
1;6* *)-*( ++4*5) (.(0 HGK9+ -4/40 -,-0(5- -+.-, YK62%=%- +,4-5 /)/*+5 --.+-
J</((* 00/-5( )5+,// -,.-, HG3- -4(5+ 4004-0 -,.() YMM +,)+5 *,554- --.*,
1@972+ -50)4 /0-4(+ -+.(- !)72- /,4*, )*-,-4 (.(* YDF-;5 +,*-+ 40/+5, -+./*
1%9+;?+ -(-,0 -///(0 (.,+ !9CD- -,,(4/ 0-0-5/ (./+ YDF+*;++ 0/+04 +4-(*0 -,.-*
1D9- -54,( /(500, --.4, !D@=+ +-0/*0 *-)0,/ --.(- YDF+*;+/ +)00(0 +/-+4- -,.-)
J<)/50 ++*+0 55/)+/ --.0* !<% 0)0/* /005** --.0) YDF5;- +,*5+ 05*)+* --.,5
12<+;%2- 444/- 4(**/5 -+.*+ !2M25 4),+* /4(00) -+.)- YDF0;-) *044) +((45( (./+  
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Supplementary Table 1.3b. siRNA screen (Microarray, continued). 
 
!"#"$%&'" !"#"() *"++,-."/0!+1 +1234*5*6789$:2;'6<
!"#$%& ''()* $'(+,( *(-$'
!"#.*%, /&/0+ +(+))& **-(0
!"12*( /)'&&' *+(&$, &-0,
!"12/ /(00, ,'*0/( **-$$
!"12) /(00' &(*/+( **-/0
!"12+ /(00& *((($$ ,-$/
!"120 )/'$'& 0&$)+$ */-)/
!"12& /',$0( &,+&*( **-+'
!"12$ /)'&&, *//$&/ ,-**
!.#3/ /*,/)) &*/&(+ *(-*'
!4*(( /(,&+ &*0(,/ **-&'
!4**( *($()/ ,','$) *(-+)
!56 *($00/ $&&++, **-,/
!7%7* /(&+, $0/)', *(-0*
!7%7/ /(&+' /,'$0& $-,)
!78)* ''+&0 ,0))&$ $-+$
!78)/# 0''+( &*/')( */-)&
!78+ 0&/)* +)(&0' **-/'
9/:4 /**00( +)&*($ &-'+
9%4* /*)0+ 0$'(/' **-&(
9%4/ /*)00 ,0($*0 *(-'/
9%4:4 /*)0, '+&/&( **-//
9:#*;*(% *()'/+ ,+*,)$ **-,(
9#/2 '++*) '')')* **-))
9#65<* /'(,( &$'&$0 **-'&
9#7=) /*,+' ,'*)// **-((
9;5;) /*$/+$ )(&$&& **-,+
9;5;' *((*/* 0'$,&) **-)+
9<74 /*&// $*(',& */-,*
9>534 /*&)0 ))/)'+ *(-+'
964%54 $$$/$ '+$0,+ *)-$)
9"5) *+/$&( */(*), '-&0
9?=?*(,% /*'/() /)*+$/ ,-/*
9?=?*+( ,&+&' $/&)++ */-*+
9?=?*0(# /)*0() '//+&0 **-&/
9?=?//$: /,&0,' ,0*0&( *(-/&
9?=?'$ '*$*) &)&&(, */-)'
92# /*$/) *'$$0, **-'0
921%64) /*$/$ &&0((+ **-&'
924* /*$0& ,+,*** **-)(
9.5*%64* /(&/,) 0&)$$, **-+$
9.5*%64/ /+(&)/ ',0/)$ *(-+)
9.5)% )($)0 $0,(*+ */-)&
95%/% *(*/*+ ,)/*&) **-/+
95%1;* /)*'*/ +$(+/' *(-+$
956?*/# )*$/), '+'+0( **-(&
956?*+ '+')0 $$*((* **-,*
956?/* /(&/* )(&'$& **-/,
956?/0 /*'(,$ +0&'*& **-''
956?/, //,'( ''$$(( **-*0
956?/' *$'/( &(+$0, */-+)
956?)( /(*/& )'0+/, *(-((
956?)+ $+($+ &)+/$$ */-,/
956?0, )&+)($ $+/*'' $-&(
956?,$ '($/& ,*'/0& $-&+
9@1* *$/)( *,&$// 0-0'
9A2;#*( ,'$&& ,*+,,, *(-)*
9B86 //*,$ $')''& *)-0'
C:=*" '+*0) ,&'&/' */-$*
C:=/", 0,'$* ,/0(+0 **-$*
C2#$):* 0+++0 $,$&&+ **-$0
C34*& /+**( )/&$0/ '-+(
C34/0 )($+( )+&&0+ &-$+
D*5;/ &*(*, $++,00 **-+0
D;%#* //))) ,0*/)0 **-0)
D22* //),* *&'(0+ &-&,
D7#2* /+/*// )()*'( **-*+
E;5'& /+/0&+ ,$0$&& */-)$
F:4* 0&/() ',++)$ **-0,
F#)>%G* '&'&* &,&0,$ **-&*
F14)*) &*(*& *+*//' **-*'
F83#%2*+ ,'/)0 &$$*+' *)-0)   
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Supplementary Table 1.3c. siRNA screen (Protein-protein interactions). 
 
!"#"$%&'" !"#"() *"++,-."/0!+1 +1234*5*6789$:2;'6< =1>/?" !"#"$%&'" !"#"() *"++,-."/0!+1 +1234*5*6789$:2;'6< =1>/?"
!"#$%&!' ()*+,)- ((.(+ &/( (-0*1 -+1*-+ ().20 3&45#36#78%#!"#$%.9
3:;5 1*(5( -*5+)5 0.)1 &//<1 2(5*0* ((02,2 ,.+1 #=>?(#36#78%#!"#$%.9
@A%BC +21(2 **-2++ *.,+ &/D( (-01) ,0(05+ ().+, 3&45#36#78%#!"#$%.9
'/E/+ ((5)0 2,11+2 ().-2 @=3!F#@38'G &/D2 (-01( 01(-)( ().,- 3&45#36#78%#!"#$%.9
'/EE( (+21) ,(5-(( -.-+ #@=3!F#36#78%#!"#$%.9 &/H(* 102+1 (+*15) ,.1* @=3!F#@38'G
'/EI5 (-2-- -(0,5( ((.(5 @=3!F#@38'G &<B( ()5-05 (-(*,( ,.,( @=3!F#@38'G
'EJEJ ()+*+0 2221-0 ((.(- @=3!F#@38'G &<B2 2))(* 12-,)( -.,5 @=3!F#@38'G
'EDK ()*((2 +1(-+0 ().(1 @=3!F#@38'G &:<(2 ()+)-* 05(+2( ().-0 @=3!F#@38'G
'E$D5 +*2)1 ,215*5 ((.)* #@=3!F#36#78%#!"#$%.9 @())J* 2)(-, -5*,(5 ((.0) @=3!F#@38'G
'L:(/5 ((0++ *,--21 ().++ @=3!F#@38'G @JEH(D ,5*-5 -((-(1 ().,+ @=3!F#@38'G
'DI"J ((0+* 0211( 0.-1 @=3!F#@38'G @JHH1) 0,015 (255-( 0.,5 @=3!F#@38'G
':/< ((,5+ (5)(0- +.0, @=3!F#@38'G @J<$5 12)50 10(,5+ ((.2( @=3!F#@38'G
':$2 ,5+)( (51(2, ,.12 @=3!F#@38'G @J:A( 2)22+ (*2-(+ +.+- @=3!F#@38'G
'A<(J( ((-2, 2(0*+5 -.05 @=3!F#@38'G @E:%/ ()1+,2 50)-)- ,.+0 @=3!F#@38'G
'A<(J5 252-+1 ,,*0,0 ((.*0 @=3!F#@38'G @ME(5 (()5+- 5)-01* -.++ @=3!F#@38'G
'A<(/( ((-5( ())+5-) ().+0 @=3!F#@38'G @ME0(J( 15*2( *52*( *.+( #@=3!F#36#78%#!"#$%.9
'A<2J2 ((-5, (,(0*( ().-) @=3!F#@38'G @M<A- 15,0) **1*15 ().5+ @=3!F#@38'G
'ANB2D 255,+( 2))+01 ().5* @=3!F#@38'G @C<D( 2)5-+ 15),-5 ().05 #@=3!F#36#78%#!"#$%.9
'O%2 2+2(1 2(())+ ,.-) #=>?(#36#78%#!"#$%.9 @DE21J5 (,0+* **+2*2 -.)0 @=3!F#@38'G
G25))-0G()&%L 25),00 1*+)+1 ().,* @=3!F#@38'G @DE5-J(* 2(5)15 ((*1),, ().-+ #@=3!F#36#78%#!"#$%.9
G55))2+G)-&%L 22*(+( 001+(, ((.5+ @=3!F#@38'G @DE5-J+ (*-++ *5+0)+ ().(2 @=3!F#@38'G
GJBN (255) 51212) ((.(1 @=3!F#@38'G @DE5J2 (+21* -(*,)5 ().-* @=3!F#@38'G
GJ$<5 (250+ 22*0)) -.,* @=3!F#@38'G @HE2 (*2(( 22),,5 ().(( @=3!F#@38'G
GEJ:( 0+1)) (11+)2 ,.*0 @=3!F#@38'G @HE5 (5))0 5--(10 -.*- @=3!F#@38'G
GEIE*+ 0+(05 (0(,+1 -.-1 #@=3!F#36#78%#!"#$%.9 @HEPI( +*511 (1-+2( -.50 @=3!F#@38'G
GIE5+ (215- 1-(20- 0.** #3??%#36#78%#!"#$%.9 @"JA( 2)012 -+2(+( ((.)) @=3!F#@38'G
GIE*2/<C 2*)1)1 01())) ((.(0 #=>?(#36#78%#!"#$%.9 @:<:/ 2),(, +2)+0( ().25 @=3!F#@38'G
GD<AH(D 2(,551 (1*1+2 +.2, #@=3!F#36#78%#!"#$%.9 @$:( ()+1(5 ,*151- ().55 @=3!F#@38'G
GBBH5 -*2(, 0)*2)0 ().2, #@=3!F#36#78%#!"#$%.9 @AA5J (0*5) 5,*-5- ().(, #@=3!F#36#78%#!"#$%.9
G"<M 1-)*2 (*0((, ,.(5 @=3!F#@38'G @Q:;* 2)-52 +0(-1( ().55 #@=3!F#36#78%#!"#$%.9
G:M//< (2-(* -2015+ ((.(0 3&45#36#78%#!"#$%.9 =/L/<( +5(+* 20(((+ ().22 #=>?(#36#78%#!"#$%.9
GK/1:5 ()-+1* ,),,+* ,.22 @=3!F#@38'G =;:E 22)*2 2*,*1, ().5* @=3!F#@38'G
R(->SC(51+M 12,+* *20-+0 ().0) @=3!F#@38'G =PJIJ 2*)(+* ,,+22) ((.(- @=3!F#@38'G
RI"$A (52)) ,*,1* 0.+2 #@=3!F#36#78%#!"#$%.9 =P:J<5 25)+15 +*)+)) ((.(5 @=3!F#@38'G
RBHA( (5*55 ++11-- ((.1, @=3!F#@38'G =HMH(0L ()2100 0022*5 ().)2 @=3!F#@38'G
TIE* 25*0-- +**1) *.*, @=3!F#@38'G =HMH55 0+,+, (++))1 +.+1 @=3!F#@38'G
T%;2E2 25-12, -505*5 ().)* #=>?(#36#78%#!"#$%.9 =NDBJ ()-01, *-(-0( ((.(( #=>?(#36#78%#!"#$%.9
T%;5C 15510 25(1)5 -.02 @=3!F#@38'G =NDBC 515(+) (,+5*5 -.11 #=>?(#36#78%#!"#$%.9
T<5)) 52,1+2 512(+* -.5, 3&45#36#78%#!"#$%.9 U/J<2D +*5,5 *,-0,2 ().)) @=3!F#@38'G
T<:$ ()+1), 2200,, -.+0 @=3!F#@38'G UH<$ 222*+ 51++*1 ().(5 @=3!F#@38'G
T:D%B2 2**5+5 *,5+,+ -.22 @=3!F#@38'G VJ:$ 2252( 2+22)5 -.,, @=3!F#@38'G
4P"I( 25*0,0 (+()*5 1.*- @=3!F#@38'G VIJE2 2255* 2-)),1 -.02 @=3!F#@38'G
4H:( (*201 -+,,)+ ((.)- #=>?(#36#78%#!"#$%.9 VIJE5 22551 05)*10 ().5- @=3!F#@38'G
4N:2 25,+- ,+5)-+ -.0* #=>?(#36#78%#!"#$%.9 V%H 22512 +((((5 ().5- @=3!F#@38'G
FJ:A (**1) 2+12++ ().25 @=3!F#@38'G WI:++ +)*01 **2((5 +.*2 @=3!F#@38'G
FMH%B1 2(0+00 ()+(2)- -.,) @=3!F#@38'G X<"( ()51+5 55(*1( ().,( @=3!F#@38'G
FDHB (+),25 +2,+1- ().*2 #@=3!F#36#78%#!"#$%.9 X<"1 +2522 -))21, ((.55 @=3!F#@38'G
FD:N5 5)-20 *)(+-5 -.+1 @=3!F#@38'G X<"+ 012*0 +0-+5) ().*+ @=3!F#@38'G
Y(5 (*-1) 1)0-5( ().,* #@=3!F#36#78%#!"#$%.9 Z%<;1 0+(,) 25)-+5 ().2) #@=3!F#36#78%#!"#$%.9
YHH: (1500 ,22551 ().+( #=>?(#36#78%#!"#$%.9
Y$<(() (11)1 *5-,25 ((.(0 @=3!F#@38'G
Y$<J* (1121 2+05)2 ().*1 @=3!F#@38'G
YK"Q( (22,2 ,)++)( ().,+ @=3!F#@38'G
3J:$ ()1(*, -((** 1.-5 @=3!F#@38'G
3HHA +00(* 0,)0-( ().-0 @=3!F#@38'G
3B;2 +)*51 22(25- ((.)* @=3!F#@38'G
3<"+ 255+20 0+)555 ().(, @=3!F#@38'G
3[CJ<( 2-,+1 *0+,5* ().+, @=3!F#@38'G
?%;(( (011( ((215- ,.0, @=3!F#@38'G
?:A(* (000* ,,-50) ((.2+ @=3!F#@38'G
8J$(D +0(5) (5-*)0 0.02 @=3!F#@38'G
8MHI2 22*0*) 551(+1 -.02 @=3!F#@38'G
8MBC* ++1,2 -((+)0 ((.2( #@=3!F#36#78%#!"#$%.9
8MAH( 105,* 20++0+ ().)1 #=>?(#36#78%#!"#$%.9
\JA2J 252),+ 21(,,( -.0- @=3!F#@38'G
\IB( ()))(- 22,()5 -.-) @=3!F#@38'G
\%/( 221(0* ,-+(5( ().0, #=>?(#36#78%#!"#$%.9
\D$AI2 0+*2) ,*0-22 ((.*5 @=3!F#@38'G
\H$(- +2(-- -1,0(, ().+- @=3!F#@38'G
\AP;I(D 2+)0,1 +)1-,1 ((.)* @=3!F#@38'G
\AP;I2 (++0, ()+-2+, ().-2 @=3!F#@38'G
!JJ21 25(+(5 (2+505 0.01 @=3!F#@38'G
!EJ<I2 0,2-, 2)1-2+ ().0( @=3!F#@38'G
!ELJ<(D ()1,11 ,1,),( ().)+ @=3!F#@38'G
!%$EP 0*012 0*5502 ().*1 @=3!F#@38'G
!"D1 11-,- *1,(-5 ,.,) @=3!F#@38'G
!"DE( +)+0- 112--+ -.-( @=3!F#@38'G
!"H"( 2((1*, (),((2) ().,+ @=3!F#@38'G
!<E( (,(*1 2,0000 ().-5 #@=3!F#36#78%#!"#$%.9
!QHJ( ()(+)0 +)*-5) ,.-- @=3!F#@38'G
]<AB +(0*, **1)-+ ((.*+ #=>?(#36#78%#!"#$%.9
6J<I( 0+**) 11*1+- ().-( #=>?(#36#78%#!"#$%.9
6MD<( +12+5 -0,--- ((.0+ @=3!F#@38'G
6;LD (,0*( *1,*-) -.-+ @=3!F#@38'G
6P/2 (2)5* ()(01, 0.,- @=3!F#@38'G
6%C$ 2+0,*0 +5,*,+ ().2, @=3!F#@38'G
&J/(* 0,501 +11**- ((.)- @=3!F#@38'G
&JB/<1 +)1+2 5)*,0( ((.5( @=3!F#@38'G  
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Supplementary Table 1.3d. siRNA screen (Phosphatases). 
 
!"#"$%&'" !"#"() *"++,-."/0!+1 +1234*5*6789$:2;'6< !"#"$%&'" !"#"() *"++,-."/0!+1 +1234*5*6789$:2;'6<
!"#$%&!' 1252393 12.47 ()*+, ,-./0 ,,1,/22 ,/3,0
4567 8/,7, 1152920 8.69 ()*+,, ,-./1 1-/8.2 ,,392
/-.,8.7',2&%: ,,277. -80.22 ,2379 ()*+,. ,-./9 8-7177 ,.381
';*, ,,/7, 8,,0,7 ,23-- ()*+,7 ,-./- ,2,1992 ,.3/2
<1-,.1 .7.-/, 121821 ,73/9 ()*+,/ ,-.82 112287 ,2381
<=;,/> ..-110 -0/717 ,.3.. ()*+,9 ,-.87 1-,/01 ,7381
<=;,/? .,9.-/ ,20/2/2 ,7398 ()*+. ,-.88 -7,/-7 ,7321
<=;.8> ,.872 --8.22 ,73,7 ()*+.2 ,-.80 .0-2-7 ,.388
<=;.8? ,.87, ,,//./2 ,.391 ()*+., ./222 1.82.1 ,.308
<=;.8; ,.87. -/0821 ,7302 ()*+.. ,-.02 920,.2 ,238-
<=:+7 1.7-, ,./9.-7 ,.377 ()*+.7 ,2/97, 109./2 ,7322
<)=*, 01088 9.1717 ,2391 ()*+/ ,-.89 17/7/1 ,.398
<)=$*, ..1.-. ,.,7022 ,.3.. ()*+8 ,-.8- 997/.1 ,.3,1
<)=$*. 8./09 9/7821 ,/3,. ()*+1 7.2,7- -./791 ,/371
<)=$*@ 0-.1/ ,,,7922 -3/7 ()*+- 80.-/ 9-.2-7 ,,39.
A+>B;0 1.098 ,212/22 ,.32/ ()*5> ,-.0. ,2/91/1 ,7309
AC@@>5= 01,9, 187/87 ,737, ()*5? ,-.07 9702,7 ,23,2
AC$*, ,-.8. 1788/1 ,7387 ()*5; ,-.0/ ,2-8.92 ,.382
AC$*,2 07-87 ,28,717 ,.30/ ()*5D ,-.01 ,.2,9.1 ,.3-9
AC$*,, 1.,2. ,..9-21 ,.3/0 ()*56 ,-.09 -,9702 ,,31,
AC$*,. 92-,8 -79287 ,.3.- ()*5E ,-.12 89/-91 ,23-1
AC$*,7 .179- ,2-/901 ,2310 ()*5B ,-.1, 92--17 ,,39.
AC$*,/ 80/28 -79,.2 ,.300 ()*5: ,-.1. ,222,.2 ,73,-
AC$*,8 .8.90/ 0,1992 ,231. ()*5F ,-.1/ 1-77.2 ,.37-
AC$*,9 18.,- 92,287 ,.3., ()*5+ ,-.18 99-..1 ,.39.
AC$*,- 0929. 18/,.2 ,,3,. ()*5+. ,-.10 9.0102 ,.371
AC$*. ,7871 -2,.01 ,.3.0 ()*55 ,-.1- 1,2222 ,,37.
AC$*.. ,2878. ,./7-21 ,.3.- ()*5$ ,-.92 1.8-21 ,.370
AC$*.7 09//2 02,092 ,2378 ()*5) ,-.9, ,,.29/2 ,,3-2
AC$*.0 00-8- -,.,/1 ,/37, ()*5C ,-.17 ,22/,02 ,73//
AC$*.9 01//0 7,9287 ,.3.8 ()*5G ,7-./ 1//177 ,2311
AC$*7 1.7/- 0-7702 ,7311 &+E)) ./2,9 0,8791 -38/
AC$*/ 7,-8.2 1107.2 ,.380 H$I, .7,071 901.92 ,/3.2
AC$*8 ./201. ,222-02 ,730/ H$I. .71902 1-9022 ,23-1
AC$*0 01027 ,221,91 ,,31. H$I7 ./8981 1//9.1 ,2302
AC$*1 .7889/ 8899-7 ,,3.8 H$C1. 09--, 1-7201 ,23.7
AC$*9 ,9.,9 -28-/1 -390 H)JK 80.-, 1109.1 ,7307
AC$*- 188-2 ,2899.1 ,.320 LD+;, .2-27- 7/29,7 -310
M*F.> ,7987 977022 ,23.0 L%FF82 008.8 ,2-0,21 ,.31.
MJ>, ,/2/9 ,,1/..1 ,.3,9 N?@;*, 1-802 ,.,-777 ,.3.1
MJ>. ,/2/- 18.087 ,230.
MJ>7 ,/282 ,2.2-/1 ,.31-
4@:>* 01/// 08.0.1 ,.3/1
O>*.:, .07-8 ,,71702 ,73,,
O=*, 0199, 981.,7 ,/312
O)F, ,111. ,,979.1 ,73,0
O)F5, 8777. 81/.92 ,,3.9
O)F5,. .09197 -09-.2 ,23-1
O)F5. 11,,0 8-.022 ,/3.1
O)F57 1/72. -909.1 -3-0
O)F5/ ,121/- --.717 ,/32/
O)F50 .,-,78 101/22 ,2311
O)F51 8/79/ ,78--17 ,.30/
(I@** -9/7. 9-0,91 ,,3-2
(I*), 18/8/ 727-/1 ,23-9
(*D6. ,-2.7 /81-/1 93/-
(*F,? ,-2/7 -.09-7 ,.38-
(*F,= 879-. 9,22-7 ,.3/8
(*F,6 09020 80.102 ,,387
(*F,E ,/.29 19/0/2 ,7392
(*F,I 7,-/09 -/9/92 ,.3-,
(*F,B 1,991 1,8.22 ,238.
(*F,@ ./.297 917287 ,,3-0
(*F,F 01-28 1-8087 ,,312
(**,;> ,-2/8 8.1,02 ,73-2
(**,;? ,-2/0 8,2/22 ,.3.8
(**,;; ,-2/1 -78121 ,73.0
(**,5,.> ,1-7, .81.92 ,,3,7
(**,5,8? ,29-8/ -79877 ,.3,8
(**,57> ,/2/-, 9.-992 ,.312
(**.;> ,-28. ,,2..87 ,.372
(**.;? ,-287 9-72,7 ,2381
(**7;> ,-288 ,2--191 ,.39/
(**7;? ,-280 87,287 ,.309
(**7;; ,-281 0718/1 ,231.
(**75. ,-28- 0911/1 ,.38/
(**/; 80/.2 -8.2-7 ,,301
(**8; ,-202 1-,/,7 ,,32-
(**0; 01981 ,.18-21 ,/310
(*);1 7.21,1 012-17 ,,3/1
()D+ ,-.,, 0.0/-7 ,7388
()*/>, ,-./7 ,28/177 ,.3./
()*/>. ,-.// ,270721 ,23-,
()*/>7 ,-./8 ,2020/2 ,7372
()*=;, .,9.7. -/8//2 ,73.7
()*@> 72-07 -07.,7 ,2382
()*@? 12181 ,2,/./2 ,.312
()*F), 00/0, ,2,8022 ,737,  
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Supplementary Table 1.3e. siRNA screen (Deubiquitinases). 
 
!"#"$%&'" !"#"() *"++,-."/0!+1 +1234*5*6789$:2;'6<
!"#$%&!' 1252393 12.47
()*+ ,-.+. 1152920 8.69
'/01+ ..23.3 ,423,+ .56+-
789. .2--.3 4553:+ .56.-
7);;+ 5.2<33 .53355< .56<+
="9$3 534:+ 45,.4< ..64.
=>?@ <-5,3 ..2:.52 .-6<4
ABC. .+,+. 42-322 .+6+.
ABC.8 +4.:-- <+-:4< .56.3
ABC5 .+,+5 45+4:+ .56:,
D%*+* 3324, 355+<+ .26,:
D%*+E 34.+, .2:-2:+ .+6-.
FG,.+3 +3452+ .5-.-42 ..64.
H"$@. <-.,4 <-55.+ .56:<
H"$@5 33.5- .2-:43< ..6-3
H"$@+ <,+.3 <5.222 .56-5
I>$G. +52<.+ 443+52 .5634
J/BC. .2<532 .2<:+52 .56.3
J/BC5 34.-: .2:5<32 .+654
J/B@, ,-3-- 3+255< .26:-
J/B@3C <552. ,,+.32 .+6-3
K)9*4 .:5.,: +<3-5< 464,
K$G@.- ,:25: 4<+-< 36<.
K$G@< .<-3+ .422:+ <6<4
L/8GC9 <2,5< ..<-,-< .+6::
L/8GC9?. <33+2 .5,4-22 .+6<5
M;E?. 5555+ .5+-:52 .+645
M;E?+ ,2:++ .23:,52 ..634
M;E?- :+4-. :5.+32 .56-.
M;E?, ,352< .5<.:<+ .26:+
M$9. 5+2-4- ,<,,52 ..6.5
M$9.2 5555- <:4<-< .+62-
M$9.. 5+3<++ 45--5< ..65+
M$9.5 555.< 4-,<4< .-6:3
M$9.+ <532< :,-342 .5653
M$9.- ,:25, 4:3.++ .26<4
M$9., .--<: <2.:++ ..634
M$9.3 <-..5 :.-2:+ .56++
M$95 ,++<3 <<+.-< ..65,
M$952 <-5<2 <3,,++ .265-
M$95. +2:-. :.<342 ..6<,
M$955 5.345, <453,+ .565+
M$95- +5::24 3233-2 :6-:
M$953 4+,3+ ::+542 .26:5
M$95<0 ,-3,. ,<<+4< .-6+:
M$954 5+,+5+ .2,5<2< ..6-+
M$95: ,<<<, .:3542 .265:
M$9+ 5+,--. 3,-+<+ ..6..
M$9+2 .22<,3 .24-+2< .5643
M$9+. <3.<: .5-.342 .564-
M$9++ .<2455 44:<52 .56,,
M$9+3 <5+-- ..,5.++ .5642
M$9+< +.:3,. .5,,3-2 .+635
M$9+4 <-4-. .2<5,52 :6-3
M$9- 555,4 ,34542 .565<
M$9-5 <3422 .2,+-:+ .5652
M$9-+ 5.34+, :2,,<+ :654
M$9-- +5<<:: ..3,<4< .+62.
M$9-, <<,:+ .5-,2:+ ..6:,
M$9-3 3:<5< :5.3:+ .56+.
M$9-< <-::3 .2,+53< .+6<<
M$9-4 .<2<2< .2+2,++ .+6,3
M$9-: 55-4+3 433.-< :642
M$9, 5555, -4,<4< .+6-5
M$9,2 <,24+ 4,54-2 .264<
M$9,+ ::,53 <.+322 .+645
M$9,- <4<4< .2.5,2< .-62+
M$9< 5,54<2 :43<++ .26<-
M$94 4-2:5 3:<,-< .+6<<
M$9:0 5554- .5,,<52 .564+
M$9:> .2<434 .2++:<+ ..6,.
N;9%9. <23<, .22553< .+6.+
O"@. 553-.4 ..2++2< .56<4  
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Supplementary Table 1.4. ABCF1-interacting SILAC hits. 
 
!"#"$%&'" !"#"() *+,-./01 *+,-2/01 345&*6"$./0 345&*6"$2/0
!"#$% &&'('& &)*+& ,)-.( /)//01// /)//01//
234"& *(%+- %)/'+ /)*+& .)(%05/( ,)-/05/,
!67% %&//* /)*(& /)/+% ')''05/+ ')*/05/%
89:9#% *'%.' /).(/ /)&-. ,)'(05/- &).'05/%
;<"=>, &,.'+, /).+' %)&,+ ,).+05/- &)%,05/'
;">& &(,+. /).,( /)+%/ +)'&05/- -)%,05/&
?>#%=- &/-%' /).&( /)'+' ()(*05/- %)%+05/%
@74A& -',*+ /).&- /)'+/ ()*-05/- %)%*05/%
8$B> %.+'% /).%' /)(*, *).&05/- %)''05/&
C#=3% &&,&* /)(.- /)&*. %)+,05/' &)'+05/%
D9'( %+'&, /)((- /)*/% %)*(05/' -)**05/,
@74A% +/''/ /)(-, /)&(% &).,05/' &)(%05/%
&,%//%'2/%E7B (+''. /)(-% 5/)/%* &)*&05/' ,)*-05/%
?>$F* &,(..+ /)(', /).'/ ,),,05/' *)*(05/,
@GAH, %+''/ /)(&+ /),/% ')'(05/' &)',05/%
8>=&4'= %.(., /)(&/ /)/'& ')*,05/' ')+(05/%
;4GA &%.&& /)+*% /)'%+ ()(*05/' %)'.05/%
;=A& &%,-- /)+(& %)/-- %)/'05/, %)'-05/,
IJ=A% -/.+. /)+-& 5/)',( %)'/05/, +)&*05/&
K9L= %+.&. /)+'( %)%&' %)-,05/, ()&&05/'
@FGM, &&*-', /)+%- /)'(, &)'%05/, %)%%05/%
N"A& %''+* /)+/+ /).*, &)('05/, +)',05/,
N>M %'++/ /)+/& /)++. &)*&05/, ,)-'05/&
8HA$,% +.*.. /)+// /)'%* &)*(05/, %)'+05/%
;OJ% +.&(+ /)-'- /)&+/ +)&'05/, &).,05/%
P>B> ('-+. /)-&' 5/)/'( .)%(05/, ,)+&05/%
Q=MA -/*&( /)-&, /)&(- .)&-05/, &)+.05/%
R=:: %,%+, /)-%( /)./* .).,05/, %)&(05/&
@$7&/' %-*-% /)-%, /)'+% *)&.05/, %)%.05/%
!>9O= %%+(' /)'-. /).*% %)((05/& +)-+05/,
Q=G%/ *.*-+ /)'-( /).-/ %)./05/& *)%.05/,
K=M%> (+%,/ /)'', %)/.. &)%%05/& %)/-05/,
QO>* ('/,- /),*+ /).+/ ,)',05/& .)'+05/,
EA>. &+*+% /),*/ %)%,( ,)+-05/& +)&.05/'
?JG -+/.+ /),(- /).(. ')&+05/& (),/05/,
!FA,&= %%(,( /),+' /).'* ')(&05/& *)&.05/,
SLO9% &,'+.+ /),-/ %)%-, -),+05/& -),%05/'
EA>+ %**.. /),,* /).-/ -)*'05/& *)%+05/,
!H"A %%.,( /),&' /)*'- +)./05/& ')/.05/,
?=HG, -,.*/ /),/* /)..- ()(%05/& +)*/05/,
EA>( %**.* /)&*& /)**. .)*'05/& &)-/05/,
8J>A% (-&(, /)&', %),,( %),%05/% +),*05/-
E=F"A% %*,.- /)/%( %),,' ')+'05/% +)++05/-
;J:%/ &+*-,+ 5/)//( /)*&( ')*,05/% ')(*05/,
NJ37F- &%+(++ 5/)/&& %)%%' ')+-05/% .)//05/'
@$7,- (/%%/ 5/)/-% %)%++ ')%,05/% ')+%05/'
DMG$& %/./+& 5/)/+. %)*-( ,).,05/% -).*05/*
Q37 +'+.- 5/)/(% /)*+( ,)(*05/% ,),'05/,
8=HA% %%-'- 5/)%%/ %)&.& ,)%'05/% %)&-05/'
DT"-H, %/*(-' 5/)&%' %)%., %)+*05/% ,).'05/'
!H4><% &,'/&, 5/)&*. %)%,. .)**05/& +)&,05/'
K74, %+..& 5/),-' /)*/. -)-%05/& -)+-05/,
Q$% %./%- 5%),.( %)%-/ %)''05%/ -)-%05/'
DU$%*>& &''+(& 5%)+*% %)&/+ ()%%05%- &)*.05/'  
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Supplementary Table 1.5a. DNA ligands. 
 
!"#$ %$&'$()$*
!"# $%&'()(*(')'()'(*'*(')'('*()'*(')'*'()('*(')'()(&+%
$%&'*'(*(')('*'()(*(')(*')('(*(')()'(*'(*(')'*'(&+%
,!-./0/&122 $%&('**''*'(*)'*')))(('('''*')'()(*))'')'*('*')')'((((*())(**(''(()'*)*((')*'')'(*)')))'*)''()))('()'(&+%
$%&('(*'('***'((*)(***(*)'(*(()*('')*)(*''(('))'**')''''(*(*()(')(*((**)'*'(*()((('(''***()(*)'()(())('&+%
,"-32 $%&'((*()()*('*)*('((((')'*'''*'(((('''(''((***'()(((''*)))'(*)&+%
$%&*)'(***)(('''*'()))''(('(((''''()((()(*(''''(')*)(')*'*')''(&+%
$%&456758&!"# $%&456758&'()(*(')'()'(*'*(')'('*()'*(')'*'()('*(')'()(&+%
$%&'*'(*(')('*'()(*(')(*')('(*(')()'(*'(*(')'*'(&+%
$%&456758&!"#&(91 $%&:56758&'*((*')('*'*'*('(')()()'*)('*'**)'(*()'')('**&+%
$%&))('*((*')'(*))()('*)(*'*'*('(')()()('*()'')(&+%
$%&456758&!"#&0;7< $%&:56758&*'**)'))('))'**))')()'*'))())''))(*)(*('*'**(&+%
$%&'))()(')'*)'**((**'**()(*'*(**))(**('**(*))()&+%
$%&456758&/0/&122 $%&456758&('**''*'(*)'*')))(('('''*')'()(*))'')'*('*')')'((((*())(**(''(()'*)*((')*'')'(*)')))'*)''()))('()'(&+%
$%&('(*'('***'((*)(***(*)'(*(()*('')*)(*''(('))'**')''''(*(*()(')(*((**)'*'(*()((('(''***()(*)'()(())('&+%  
 
 
Supplementary Table 1.5b. siRNA sequences. 
 
!"#$%#& '#(# '#(#)* !#(&#+&#,-#($# ./0#&
!" #$%&' (()*)( +,-./-%"01234567!518!#9:;""< 23=>
!" #$%&' (()*)( ?@=#44##4ABBA4#BAB4###=C@ 23='
!" #$%&' (()*)( ?@=B4#:4#:#4:4#:4#4#4#=C@ 23=(
!" D9EC ?)'C' ?@=B44#B##4BAA4A4##44#=C@
!" BF%C* '(?CG ?@=4B4BB##4BA4B4##A#4#=C@
!" HI;0' 'G()J ?@=4#BB#B#4AB44#AA###A=C@
!" :3;-.; GGG(G ?@=4###B#AB#B#BB4A#AA4=C@
!" !F;' J*KK' ?@=##B4AA##BAB##44#AA#=C@
!" H;;J% J*K?* ?@=4B#B4##44BA#A##4AAA=C@
!" #2$'C ')(JKK ?@=A#4#4###4AB4BB##4AA=C@
!" :.3/?J CK)C>G ?@=4##4BB##BAA4B4BABA4=C@
!" A2;)G (()KCJ ?@=4#BBA4##4AA4BA4#4##=C@
!" 9LL;) *(?)G ?@=4#A4#ABA4AB4BBA44A#=C@
!" #0;C(- ''*C* ?@=B##:#4#4BB4B:4##4##=C@
!" BM$?.C '>G*?) ?@=BB##A444BA#BA44ABA#=C@
!" 6N/-' '>'*>J ?@=44#B44BB#AABABA#4A#=C@
!" 8LI ?J>KJ ?@=44##4#:#::4#:4##4##=C@
!" OF.** *>)J? ?@=444A4AB#BA#4#BA44A#=C@
!" #2&'- JJ)>C ?@=##ABA#B#4ABBBAABAAA=C@
!" :PQ' ?J)K> ?@=B#4#BA#4BAA#A##A4##=C@
!" !I/.C *)C>( ?@=444##4#44A4BBA4BA#A=C@
!" 8I30R *(?'( ?@=44#ABB4##A4AAB##AB#=C@
!" 9D4=D (C>>*C +,-./-%"0176=:#945:;<N218!#9:;""<
!" D&0-.' '?G*? +,-./-%"01234567!518!#9:;""<
!" S-T' 'J)?' +,-./-%"01234567!518!#9:;""<  
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Supplementary Table 1.5c. cDNA primers. 
 
!"#$%&''&()*+$,-).#-/$(#-#$0/#1$%&-$2'&*)*+$)*3&$,4567189:;<=$
!"#$%&$'()*(+ ,-./!0/!01/0!1/1//1//!//!01//1!!1110///!!1.2-
!"#$%&(343(53 ,-.!01!01!//1100/!!0///1!11!/11001!/.2-
!"#$%.6!&(343(53 ,-.!01!01!//1100/!01/10!!0/!11/!/!0/10!!1110!01/!0///1!11!/11001!//!.2-
!"#$%&(35#73&$'()*(+ ,-./!!!!1!110100!!/!/10!!!/!1/!1!!101//1!/1.2-
!"#$%&(35#73&(343(53 ,-.1/01000!/10100!!/!//0/000010001/0000//1/001/001.2-
8($2&$'()*(+ ,-./!0/!01/0!1/1//1//!//!011!!!////1!!!//1/11!.2-
8($2&(343(53 ,-.!01!01!//1100/!1!0!000//!1011//011!!10.2-
8($2&(35#73&$'()*(+ ,-.0/01!/01!0!!!00110/!!!1!10!/101111/!1101/.2-
8($2&(35#73&(343(53 ,-./!/10!/0/0001!//!!000!0/!10/!1!!!////0/!11!0/1.2-9
:3;<==*&$'()*(+ ,-./!0/!01/0!1/1//1//!//!01!/00/1!!!1000!01!0//!1!!/!!!11!.2-
:3;<==*.6!&(343(53 ,-.!01!01!//1100/!01/10!!0/!11/!/!0/10!!1110!01/00100/!000001!1!!/0/1/0/!!/1!!/.2-
!"#$%&''&()*+$,-).#-/$(#-#$0/#1$%&-$2'&*)*+$)*3&$,>?@AB=$
!"#$%&$'()*(+ ,-./!0/!01!!00/1//1//!//!01//1!!1110///!!1.2-
!"#$%&(343(53 ,-.!01!01/0/1!10/!!0///1!11!/11001!/.2-
!"#$%.6!&(343(53 ,-.!01!01/0/1!10/!01/10!!0/!11/!/!0/10!!1110!01/!0///1!11!/11001!//!.2-
>?<;@&$'()*(+ ,-./!0/!01!!00/@##1//!//*?@//!0!/0//!!//01/!0/.2-
>?<;@.6!&(343(53 ,-.!01!01/0/1!1?#*01/10!!0/!11/!/!0/10!!1110!01/1!01!110/!101/11!.2-  
 
 
Supplementary Table 1.5d. qPCR primers. 
 
!"#$%#& '#(# '#(#)* +,-./-0 1#2#-&#
!" #$%&' ())** +,-##.///00.//.##././#0-*, +,-/#/0##0#/0###.00...-*,
!" 1234( (+566 +,-.0##.00../0./0#//.//-*, +,-/#/###.0#0##0##/#//-*,
!" .789(: (+5)+ +,-..//#0#.0#..#0./0000.-*, +,-##.0.#./###/0#/000.//-*,
!" /482( ;;)6); +,-/#///#...#/#00#0#000#-*, +,-#.....00#0/#0.#00#/0#-*,
!" <1#-1 ;*::6* +,-/.00###0/.//./00#.#/#-*, +,-#00././/#//0.0####0#0.-*,
!" 12=>( (+5+6 +,-.0#/#/0#0./.00././0##//-*, +,-#0#./0....//0###00.0-*,
!" !7( (6?+6 +,-#/../0/####0.00#/..//-*, +,-/#/.00#.0.000.0#////#..-*,
!" 12='( 6(+?@ +,-/#/0.//./..0#0##0//./..-*, +,-.0.0/###..0../.#//./-*,
!" 1A@ (@(5* +,-0/#0..00..0/....//000..-*, +,-00##0..00/#../.0..00.-*,
!" 1B26 +)(;* +,-#/#/.0##.0/00#####/#-*, +,-#/..#///0#.00../###-*,
!" C'7+? ?:?@( +,-##//#0#/0.00/..0#.0.0##-*, +,-00#..0.0#0.0/..#0.0.0-*,
!" 1DE(+ (:::*???; +,-##0#0..#0#/.0//.0../0-*, +,-0##///###0//#/..#0..0-*,
!" 12=)) 55?55 +,-//.0#/.0#.0.#.//0//0#0-*, +,-#0//././#.//0#..0.00#0-*,
!" F>$>( ;:?)@ +,-0././#0##00.#/#.00./#-*, +,-#.///.#/#/./0./0/##./-*,
!" .89+ ;:*:) +,-#.0#.000#..0/..0.0..-*, +,-0.#/#0#/.///./.#/.0#.-*,
!" G>%3( (5;)@ +,-##//.0###.##.0/000/..-*, +,-.////###.0#/./0.0.##0-*,
!" 0=%$B% 555;5 +,-#../#/.0#0#0/#0/./#..-*, +,-###00../#00...//0.0000-*,
!" G%%@8 @6?+6 +,-..#.0##/0.0##/.//#0/0-*, +,-/./.0##.0#//./00.#/.0-*,
!" !&%( @6??( +,-00#/0.0##/00/./.#.0.0##-*, +,-../0.#.0#.0.00#0##//0-*,
!" /D4(* ();@?? +,-0..0###/#/0#0###000.0-*, +,-//####0#0#/0.#/#0../-*,
!" 0B=H+@ *?)*:5 +,-//#/.0..0....//.0.0#-*, +,-##.//0/##0/0#0/##./0##-*,
!" ID%)5 ;;)?*@ +,-/#00..###//0#000..0#/-*, +,-.0..00/.0#/.//.0.0#.#-*,
!" <JJ%) 6;+)5 +,-#..0##0/#0#.0./0/000##-*, +,-#../0#//#/0.#.///#/.//-*,
!" .K4+B* (:56+) +,-./###.00.#0#//0#/##/#-*, +,-0../././0./#0/0./#.##-*,
!" LMH$( (:(6:@ +,-...//###/##//0/#.00.0-*, +,-.0.0#.#/0#.##00..//-*,
!" N&B66 6:)@+ +,-.00#.0#0#.0##/00.//#.-*, +,-.//.0#0##0//#//###/#0#-*,
!" 1B2* +)(*( +,-#/#/#..#//.#/##00./#-*, +,-.00../##00#/./.#0..#-*,
!" /D2($ @@):* +,-#0##0#.0##/0//...#0.-*, +,-###/.../.0////./#/#0.0/-*,
!" 04O( +@)?: +,-/.0##0#/0.0.0/0#.0#0./-*, +,-00.0##//#0../0/.#./00#-*,
!" !>HB* 6)*:; +,-/0#/.0.#00##.0/..0#/.-*, +,-#//..##//..00.0##00/.-*,
!" F>=3E 6;+(; +,-##0./..#.0..///0/0#0/#-*, +,-./#0/#0..//#00.#0#.#/-*,
!" .&8*6 (;+*5 +,-#/.0/./#.#000###/0./.-*, +,-....##0../#00..0.00-*,  
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Appendix B: Supporting information for Chapter 2 
 
Supplementary Figure 2.1. A robust system to quantitatively assess innate immune responses in 
humans. (a) Time course and titration curves of MoDCs pooled from 5 donors and stimulated with LPS 
or infected with influenza virus. Lysates were run on a pilot Nanostring codeset. (b) Time course of 
MoDCs pooled from 13 donors and stimulated with LPS or infected with influenza virus. Global gene-
expression was measured by microarray, and heatmap of selected genes is shown. (c) To estimate the 
technical reproducibility of the assay, PBMCs were divided into two samples and the assay was run in 
parallel. Monocytes from the two samples were isolated, differentiated into MoDCs, and stimulated with 
LPS; lysates were then run on Nanostring. R2 = 0.98. (d) To estimate the technical reproducibility of steps 
following monocyte isolation, monocytes were divided into two samples and the assay was run in parallel 
as above. R2 = 0.99.  
